var title_f38_8_39040="Sulfacetamide: Patient drug information";
var content_f38_8_39040=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"22\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Sulfacetamide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block note\" id=\"F12804726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12804727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?17/55/18292?source=see_link\">",
"       Sulfacetamide (ophthalmic): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/37/40531?source=see_link\">",
"       Sulfacetamide (topical): Patient drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11058 Version 25.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-122.72.76.133-33CB703E27-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_8_39040=[""].join("\n");
var outline_f38_8_39040=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?17/55/18292?source=related_link\">",
"      Sulfacetamide (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/37/40531?source=related_link\">",
"      Sulfacetamide (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_8_39041="Vaginoscopy of a child";
var content_f38_8_39041=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F79212&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F79212&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Initiating vaginoscopy in a child",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 336px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    After carefully placing the irrigating endoscope approximately 3 to 4 cm into the vagina, the vulvar tissues are gently pressed against the endoscope, trapping the irrigating fluid in the vagina. At this point, the endoscope is withdrawn to approximately 1 cm from the introitus for full visualization of the vaginal canal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_8_39041=[""].join("\n");
var outline_f38_8_39041=null;
var title_f38_8_39042="Melanoma treatment; advanced or metastatic melanoma";
var content_f38_8_39042=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Melanoma treatment; advanced or metastatic melanoma (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?38/8/39042/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/8/39042/contributors\" id=\"au7457\">",
"       Jeffrey A Sosman, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?38/8/39042/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/8/39042/contributors\" id=\"se4430\">",
"       Michael B Atkins, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?38/8/39042/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/8/39042/contributors\" id=\"de7369\">",
"       Michael E Ross, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?38/8/39042?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      MELANOMA OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Melanoma is a serious form of skin cancer that develops in the cells (melanocytes) that make our skin color. Melanoma is the sixth most common cancer in the United States, and the number of melanoma cases diagnosed annually is increasing faster than for any other cancer.",
"    </p>",
"    <p>",
"     After melanoma is diagnosed, the next step is to determine the cancer's stage, which is based upon the thickness of the tumor, the extent of its spread, and its aggressiveness. Staging is important to determine the most appropriate treatment.",
"    </p>",
"    <p>",
"     Melanoma generally starts as a single tumor or lesion. Cancer cells can then spread to nearby lymph nodes",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     distant sites throughout the body. Once melanoma spreads to distant locations, it is called advanced or metastatic.",
"    </p>",
"    <p>",
"     This article discusses the treatment of stage IV (advanced or metastatic) melanoma. The diagnosis and treatment of localized melanoma is discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/6/28772?source=see_link\">",
"      \"Patient information: Melanoma treatment; localized melanoma (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      MELANOMA STAGING",
"     </span>",
"    </p>",
"    <p>",
"     For people with stage IV disease, the melanoma has spread beyond the local area into other parts of the body or internal organs. The most common sites of such spread (metastases) are under the skin (subcutaneous tissue), lymph nodes away from the original tumor, the lungs, liver, brain, and bone. However, metastasis to other sites in the body (such as the adrenal glands, spleen, gastrointestinal tract, and heart) can also occur.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      MELANOMA TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Treatment of metastatic melanoma focuses on:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Prolonging survival",
"      </li>",
"      <li>",
"       Shrinking or stopping the growth of known metastases",
"      </li>",
"      <li>",
"       Preventing the development of new sites of disease",
"      </li>",
"      <li>",
"       Providing comfort",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     In most cases, it is not possible to completely eliminate or cure the cancer. Depending upon where and how big the metastases are, treatment may involve drug treatments, surgery,",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     radiation therapy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1267798\">",
"     <span class=\"h2\">",
"      Drug treatments",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are three main categories of drug treatments:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Immunotherapy &ndash; drugs that work with your immune system to stop or slow the growth of cancer cells",
"      </li>",
"      <li>",
"       Targeted therapy- drugs that inhibit specific enzymes or molecules important to the cancer cells",
"      </li>",
"      <li>",
"       Chemotherapy &ndash; drugs that stop or slow the growth of cancer cells by interfering with their ability to divide or reproduce themselves",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Advances in the use of immunotherapy and targeted therapy have been shown to potentially improve survival and have become the preferred approaches for most patients with metastatic melanoma. Although chemotherapy was widely used in the past, it now has a secondary role for patients whose disease can no longer be controlled with either immunotherapy or targeted therapy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h3\">",
"      Immunotherapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Two different types of immunotherapy have been developed, high dose interleukin-2 (IL-2) and ipilimumab. Both of these have important benefits in some patients, although each can cause significant side effects.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h4\">",
"      Interleukin-2 (IL-2)",
"     </span>",
"     &nbsp;&mdash;&nbsp;IL-2 is a form of immunotherapy that has been found to help some people with metastatic melanoma when given in high doses. In some people treated with high dose IL-2, the disease may disappear completely or stop growing for a prolonged period in excess of five years. IL-2 is usually given into a vein three times per day for five days twice per month. Treatment is usually completed while you are in the hospital.",
"    </p>",
"    <p>",
"     However, high dose IL-2 can cause serious side effects, including low blood pressure, irregular heart rhythms, accumulation of fluid in the lungs, fever, and rarely death. Because of this, treatment with high dose IL-2 is generally reserved for younger patients who are otherwise healthy and have good heart and lung function.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H855860657\">",
"     <span class=\"h4\">",
"      Ipilimumab",
"     </span>",
"     &nbsp;&mdash;&nbsp;Ipilimumab (Yervoy) is a drug that stimulates the body&rsquo;s immune system to react against the melanoma. Ipilimumab is given once every three weeks for a total of four doses. Treatment with ipilimumab may decrease the extent of your melanoma and help you live longer.",
"    </p>",
"    <p>",
"     However, ipilimumab can also cause the body to develop an immune reaction against its own tissues. This can result in a wide range of side effects that may be severe or life threatening. The most important of these include colitis (causing diarrhea, bleeding, or more serious complications), hepatitis, rash or inflammation of the skin, and inflammation of endocrine organs (pituitary, thyroid, or adrenal) leading to diminished hormone production. If this occurs, you might have to stop the ipilimumab and receive additional treatment for the complications. &nbsp;",
"    </p>",
"    <p>",
"     If one takes this drug, it is important to tell their doctor about any side effects they experience, even mild ones. This will help to avoid more serious complications.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H877080\">",
"     <span class=\"h3\">",
"      Targeted therapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;About one-half of metastatic melanomas contain a specific mutation in one gene (BRAF) that causes the cell to make a particular protein that drives the growth of cancer cells. The melanoma actually becomes addicted to the actions of this protein (oncogene addiction).",
"    </p>",
"    <p>",
"     Vemurafenib (Zerlboraf) blocks this protein and causes tumors with this specific mutation in BRAF to shrink. Vemurafenib thus prolongs the time until there is disease growth and extends overall survival in patients with BRAF mutant melanoma. However, tumors eventually start to grow again despite continuation of treatment with this targeted therapy. The most significant side effects are the development of other kinds of skin cancers (non-melanoma), which can be managed with routine skin cancer care and do not require interruption of vemurafenib treatment, skin photosensitivity, joint pain, and fatigue.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H855860636\">",
"     <span class=\"h3\">",
"      Chemotherapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Chemotherapy uses medicines such as dacarbazine or temozolomide to stop or slow the growth of cancer cells by interfering with the ability of cancer cells to divide or reproduce. Because most of an adult's normal cells are not actively growing, they are not affected by chemotherapy, with the exception of bone marrow (where the blood cells are produced), the hair, and the lining of the gastrointestinal (GI) tract. Effects of chemotherapy on these and other normal tissues result in side effects during treatment.",
"    </p>",
"    <p>",
"     Chemotherapy is less effective than immunotherapy with ipilimumab and targeted therapy with vemurafenib, and it generally is not used as the initial treatment for patients with advanced disease.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Surgery",
"     </span>",
"     &nbsp;&mdash;&nbsp;Surgery may be recommended if melanoma has spread to one or a very limited number of sites. Surgery may prolong survival or relieve symptoms caused by the melanoma. However, surgery is rarely curative because metastatic melanoma usually spreads to many different places throughout the body. Surgery can also help to relieve pain caused by a metastatic tumor, such as in the lung or brain.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Radiation therapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Melanoma frequently spreads to the brain. If the spread is limited to one or a very limited number of spots within the brain, surgery may be indicated to remove the tumor. However, if the tumor is in a location in the brain that cannot be easily removed, or if there are several tumors, radiation therapy may be useful to shrink the tumors and prevent the development of additional tumors.",
"    </p>",
"    <p>",
"     Radiation therapy may be given to only the parts of the brain containing tumor, using a technique called radiosurgery (or stereotactic radiation therapy). Alternatively, if more extensive disease is present in the brain, a technique called &ldquo;whole brain&rdquo; radiation therapy may be useful. Radiation therapy may also be used in some cases following surgery to destroy any cancer cells that remain in the brain.",
"    </p>",
"    <p>",
"     Radiation therapy may also have a role in controlling symptoms from a particular site of metastasis, such as bone.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      END OF LIFE CARE",
"     </span>",
"    </p>",
"    <p>",
"     In some people with metastatic melanoma, the disease cannot be cured. Deciding when to stop treating the melanoma can be difficult, and this decision should involve the patient, family, friends, and the healthcare team.",
"    </p>",
"    <p>",
"     Ending treatment does not mean ending care for the patient. Hospice care is frequently recommended when a person is unlikely to live longer than six months. Hospice care involves treatment of all aspects of a patient and family's needs, including the physical (eg, pain relief), psychological, social, and spiritual aspects of suffering. This care may be given at home or in a nursing home or hospice facility, and usually involves multiple people, including a physician, registered nurse, nursing aide, a chaplain or religious leader, a social worker, and volunteers.",
"    </p>",
"    <p>",
"     These providers work together to meet the patient and family's needs and significantly reduce their suffering. For more information about hospice, see",
"     <a class=\"external\" href=\"file://www.hospicenet.org/\">",
"      www.hospicenet.org",
"     </a>",
"     . (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/16/32008?source=see_link\">",
"      \"Hospice: Philosophy of care and appropriate utilization in the United States\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      MELANOMA SURVIVAL",
"     </span>",
"    </p>",
"    <p>",
"     Significant progress has been made in the treatment of metastatic melanoma over the past decade. Two drugs that stimulate the immune system, high dose interleukin-2 (IL-2) and ipilimumab, and the targeted drug vemurafenib are often effective for controlling metastatic melanoma and prolong life in some people. However, both forms of immunotherapy (IL-2 and ipilimumab) can be associated with severe side effects, and the duration of benefits is not certain. Targeted therapy with vemurafenib has also improved overall survival in some melanoma patients. This may be surprising, but it is exciting to finally achieve this progress towards making lives of melanoma patients better.",
"    </p>",
"    <p>",
"     In deciding what treatment is right for you, you and your family must consider the risks and benefits of each option according to your values and preferences.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      CLINICAL TRIALS",
"     </span>",
"    </p>",
"    <p>",
"     Progress in treating cancer requires that better treatments be identified through clinical trials, which are conducted all over the world. A clinical trial is a carefully controlled way to study the effectiveness of new treatments or new combinations of known therapies. Ask for more information about clinical trials, or read about clinical trials at:",
"    </p>",
"    <p>",
"     <a class=\"external\" href=\"file://www.cancer.gov/clinicaltrials/learning/\">",
"      www.cancer.gov/clinicaltrials/learning/",
"     </a>",
"    </p>",
"    <p>",
"     <a class=\"external\" href=\"file://www.cancer.gov/clinicaltrials\">",
"      www.cancer.gov/clinicaltrials/",
"     </a>",
"    </p>",
"    <p>",
"     <a class=\"external\" href=\"file://clinicaltrials.gov/\">",
"      file://clinicaltrials.gov/",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1785020547\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5514311\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?41/46/42722?source=see_link\">",
"      Patient information: Melanoma skin cancer (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5514319\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/6/28772?source=see_link\">",
"      Patient information: Melanoma treatment; localized melanoma (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/2/26664?source=see_link\">",
"      Evaluation and treatment of regional lymph nodes in melanoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/5/15450?source=see_link\">",
"      Imaging studies in melanoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/61/26585?source=see_link\">",
"      Initial surgical management of melanoma of the skin and unusual sites",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/63/39927?source=see_link\">",
"      Management of brain metastases in melanoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/13/34007?source=see_link\">",
"      Cutaneous melanoma: Management of local recurrence",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/28/27081?source=see_link\">",
"      Cutaneous melanoma: Management of in transit metastases",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/31/22009?source=see_link\">",
"      Pathologic characteristics of melanoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/32/8713?source=see_link\">",
"      Role of radiation therapy in the management of melanoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/15/35065?source=see_link\">",
"      Staging work-up and surveillance after treatment of melanoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/28/7625?source=see_link\">",
"      Interleukin-2 and other immunotherapies for advanced melanoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/30/19944?source=see_link\">",
"      Molecularly targeted therapy for metastatic melanoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/28/2506?source=see_link\">",
"      Advanced melanoma: anti-CTLA-4 antibodies and other immune checkpoint strategies",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/8/8328?source=see_link\">",
"      Cytotoxic chemotherapy for metastatic melanoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/8/2183?source=see_link\">",
"      Surgical management of metastatic melanoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/16/32008?source=see_link\">",
"      Hospice: Philosophy of care and appropriate utilization in the United States",
"     </a>",
"    </p>",
"    <p>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Cancer Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; 1-800-4-CANCER",
"     <br/>",
"     &nbsp; &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.cancer.gov/\">",
"      www.cancer.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The American Society of Clinical Oncology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.net/portal/site/patient\">",
"      www.cancer.net/portal/site/patient",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Comprehensive Cancer Network",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nccn.com/\">",
"      www.nccn.com",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Cancer Society",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; 1-800-ACS-2345",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.org/\">",
"      www.cancer.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Melanoma Center, University of Pittsburgh Cancer Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.melanomacenter.org/\">",
"      www.melanomacenter.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Melanoma Research Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.melanoma.org/\">",
"      www.melanoma.org",
"     </a>",
"     )",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Patient support",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are a number of online forums where patients can find information and support from other people with similar conditions:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://about.com/\">",
"        About.com",
"       </a>",
"       Cancer Forum",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://cancer.about.com/forum\">",
"      file://cancer.about.com/forum",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?38/8/39042/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 29, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?38/8/39042?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39042/abstract/1\">",
"      Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17:2105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39042/abstract/2\">",
"      Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 2000; 6 Suppl 1:S11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39042/abstract/3\">",
"      Tarhini AA, Kirkwood JM, Gooding WE, et al. Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy. J Clin Oncol 2007; 25:3802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39042/abstract/4\">",
"      Elwood JM, Jopson J. Melanoma and sun exposure: an overview of published studies. Int J Cancer 1997; 73:198.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f38_8_39042=[""].join("\n");
var outline_f38_8_39042=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           MELANOMA OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           MELANOMA STAGING",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           MELANOMA TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           END OF LIFE CARE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           MELANOMA SURVIVAL",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           CLINICAL TRIALS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f38_8_39043="Choledocholithiasis EBD ERCP";
var content_f38_8_39043=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F81600&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F81600&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endoscopic removal of bile duct stones after endoscopic balloon dilation of the biliary sphincter",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 364px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left: EN = endoscope positioned in descending duodenum; BD = bile duct filled with contrast, two bile duct stones visible; DB = dilation balloon placed in bile duct opening after passage over a guidewire (white arrow) and inflated with dilute contrast - biliary sphincter is seen as a \"waist\" in the balloon (black arrows). Middle: biliary sphincter adequately dilated if \"waist\" in balloon has completely disappeared. Right: after removal of bile duct stones.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission&nbsp;from: Bergman JJ, et al. Lancet 1997; 349:1124. Photo courtesy of Jacques Bergman and Kees Huibregtse.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_8_39043=[""].join("\n");
var outline_f38_8_39043=null;
var title_f38_8_39044="Precut fistulotomy 1";
var content_f38_8_39044=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F76007&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F76007&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Precut fistulotomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 423px; height: 505px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Martin L Freeman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_8_39044=[""].join("\n");
var outline_f38_8_39044=null;
var title_f38_8_39045="Eyelid lacerations";
var content_f38_8_39045=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Eyelid lacerations",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/8/39045/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/8/39045/contributors\">",
"     Matthew F Gardiner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/8/39045/contributors\">",
"     Carolyn E Kloek, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/8/39045/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/8/39045/contributors\">",
"     Richard G Bachur, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/8/39045/contributors\">",
"     Maria E Moreira, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/8/39045/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/8/39045/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/8/39045/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H6664550\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proper management of eyelid lacerations requires thorough knowledge of the anatomy of the eyelids and periorbital structures, careful examination for associated ocular injury, and prompt referral to a subspecialist when complicated lacerations are encountered. (See",
"    <a class=\"local\" href=\"#H20931378\">",
"     'Indications for surgical subspecialty consultation or referral'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The evaluation and management of eyelid lacerations will be reviewed here. Closure of simple lacerations in other parts of the body is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/7/18553?source=see_link\">",
"     \"Closure of skin wounds with sutures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6664558\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eyelid lacerations are an important subtype of facial trauma. In children, dog bites, handlebar injuries, and collisions with sharp objects while running (eg, sticks, thorns, retail display hooks, protruding nail) comprise the most common etiologies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39045/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. In adolescents and adults, blunt trauma (eg, motor vehicle collision, fist fight, eye gouging, ball sports) is most frequent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39045/abstract/4\">",
"     4",
"    </a>",
"    ]. Males are affected more commonly than females.",
"   </p>",
"   <p>",
"    Ocular injury (eg, open globe, traumatic hyphema, corneal abrasion) may accompany eyelid laceration in up to two-thirds of cases; about one quarter of patients with open globe injures have associated eyelid or periorbital lacerations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39045/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6664565\">",
"    <span class=\"h1\">",
"     PERTINENT ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proper management and repair of eyelid lacerations requires a basic understanding of the anatomy of the eyelid and its surrounding structures (",
"    <a class=\"graphic graphic_figure graphicRef69153 \" href=\"mobipreview.htm?21/39/22135\">",
"     figure 1",
"    </a>",
"    ). The outermost layer of the eyelid is skin. Beneath skin is the orbicularis muscle, the contraction of which closes the eyelid. The orbital septum is a fibrous sheet that lies beneath the orbicularis muscle. This important structure acts as a barrier between superficial preseptal tissues and postseptal orbital anatomy. More posteriorly, orbital fat separates the orbital septum from the levator muscle which is the main retractor of the eyelid. Mueller's muscle also aids the levator in elevation of the eyelid. The conjunctiva lines the inner aspect of the eyelid and contacts the ocular surface.",
"   </p>",
"   <p>",
"    The eyelid margin refers to the mucocutaneous junction of the eyelid. The anterior portion of the eyelid margin consists of skin and orbicularis muscle; the posterior portion of the eyelid margin consists of tarsus, a fibrovascular tissue that provides rigidity to the eyelids, and conjunctiva. The levator muscle inserts on the inferior, anterior edge of the tarsal plate, while Mueller's muscle attaches more superiorly along the upper margin of the tarsus.",
"   </p>",
"   <p>",
"    The anatomy of the lacrimal system, also known as the tear drainage system, is an important consideration when evaluating a laceration of the periorbital tissues, especially when they involve the medial aspect of the eye (",
"    <a class=\"graphic graphic_figure graphicRef68267 \" href=\"mobipreview.htm?3/40/3717\">",
"     figure 2",
"    </a>",
"    ). Tears drain through two small openings on the medial aspect of the eyelids called puncta: one on each of the upper and lower eyelids. Tears pass through the upper and lower puncta and enter small tubular structures called canaliculi. Again, there is one in each of the upper and lower eyelids. The upper and lower canaliculi join to form one common canaliculus which then drains into the lacrimal sac on the medial aspect of the orbit (lateral aspect of the nose). The lacrimal sac empties into the nasolacrimal duct which drains into the nose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6664572\">",
"    <span class=\"h1\">",
"     PRIMARY EVALUATION AND MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standard trauma evaluation should be followed to evaluate for life-threatening injuries in multiple trauma patients before attention is focused on the eye. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/16/29962?source=see_link\">",
"     \"Trauma management: Approach to the unstable child\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/11/35002?source=see_link\">",
"     \"Initial management of trauma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The key to appropriate care of eyelid lacerations is rapid recognition of serious associated ocular injuries and differentiation of simple eyelid lacerations from complicated lacerations requiring surgical subspecialty evaluation and repair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39045/abstract/7\">",
"     7",
"    </a>",
"    ]. The clinician should have a high suspicion for an open globe injury or traumatic hyphema in any patient who has sustained an eyelid laceration. The clinical features and initial management of patients with these ocular injuries are summarized in the rapid overviews (",
"    <a class=\"graphic graphic_table graphicRef50022 \" href=\"mobipreview.htm?16/28/16845\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef74146 \" href=\"mobipreview.htm?28/28/29133\">",
"     table 2",
"    </a>",
"    ) and are discussed in detail separately (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/10/38057?source=see_link&amp;anchor=H12#H12\">",
"     \"Traumatic hyphema: Clinical features and management\", section on 'Initial emergency assessment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/34/8745?source=see_link&amp;anchor=H22#H22\">",
"     \"Open globe injuries: Emergent evaluation and initial management\", section on 'Initial emergency assessment and treatment'",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Corneal abrasions and foreign bodies are also frequently associated with eyelid lacerations and are evaluated using slit lamp and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    examination. However, the clinician should not place eye drops or fluorescein in the eye if an open globe is obvious or highly likely. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34600?source=see_link\">",
"     \"Corneal abrasions and corneal foreign bodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At times, the extent of damage to surrounding structures in a child with an eyelid laceration cannot be determined because the patient is unable to cooperative with the examination. In these situations, if an open globe is likely, the child should have an eye shield placed and arrangements be made for examination by an ophthalmologist under procedural sedation in the emergency department or general anesthesia in the operating room.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6664579\">",
"    <span class=\"h2\">",
"     Simple eyelid lacerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following precautions are essential before closing an eyelid laceration:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Do not initiate closure of an eyelid laceration prior to excluding injury to the globe. Pressure exerted on the eyelids and globe during wound closure can cause expulsion of intraocular contents if an open globe is present (",
"      <a class=\"graphic graphic_table graphicRef50022 \" href=\"mobipreview.htm?16/28/16845\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Have a low threshold to obtain computed tomography of the orbits if there is suspected open globe injury, significant periorbital edema, marked ecchymosis, a projectile injury to the orbit, or a suspected orbital foreign body. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/34/8745?source=see_link&amp;anchor=H13#H13\">",
"       \"Open globe injuries: Emergent evaluation and initial management\", section on 'Clinical features'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/34/8745?source=see_link&amp;anchor=H24#H24\">",
"       \"Open globe injuries: Emergent evaluation and initial management\", section on 'Imaging'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Do not attempt to close complicated lid lacerations (eg, full-thickness lid lacerations, lacerations with orbital fat prolapse, suspected injury to the tear drainage system) prior to obtaining consultation with ophthalmology or plastic surgery. Permanent problems with scarring, eyelid malposition, and tearing could result. (See",
"      <a class=\"local\" href=\"#H20931378\">",
"       'Indications for surgical subspecialty consultation or referral'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Superficial, simple lacerations that are horizontal and follow the skin lines and that involve less than 25 percent of the lid will usually heal well without suturing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39045/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. The clinician may dress these with a triple antibiotic ointment (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/20/6469?source=see_link\">",
"     Bacitracin",
"    </a>",
"    &trade;).",
"   </p>",
"   <p>",
"    Uncomplicated lid lacerations of a greater extent are repaired with simple interrupted or running sutures placed in similar fashion as for other anatomic locations. Lacerations to the eyelid should be repaired within 24 hours of injury to prevent scarring and promote appropriate alignment of the eyelid tissues (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/7/18553?source=see_link\">",
"     \"Closure of skin wounds with sutures\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prep and drape the operative area in a sterile fashion using Betadine.",
"     </li>",
"     <li>",
"      Apply local anesthesia to the affected area. Provide procedural sedation to uncooperative patients (eg, young children).",
"     </li>",
"     <li>",
"      Irrigate lacerations with normal saline, and carefully explore them prior to repair to delineate their full extent and to search for possible retained foreign bodies. &nbsp;",
"     </li>",
"     <li>",
"      Close the laceration using either absorbable or permanent sutures, depending on personal preference. Acceptable suture choices for skin closure of eyelid lacerations include 6-0 or 7-0 nylon if permanent sutures are desired, or 6-0 fast absorbing plain gut if absorbable sutures are desired (eg, pediatric lacerations to avoid the need for suture removal). Care should be taken to avoid penetration of the lid with suture needle and to anatomically realign the wound edges with sufficient tension to appose the tissue and slightly evert the wound edges [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/8/39045/abstract/7,10\">",
"       7,10",
"      </a>",
"      ]. If the wound is deep, layered closure may be necessary. Deep layers can be closed with either 5-0 or 6-0 vicryl sutures. Wounds with protruding fat indicate that the tarsal plate has been violated and warrant ophthalmologic consultation.",
"     </li>",
"     <li>",
"      Provide tetanus prophylaxis as needed (",
"      <a class=\"graphic graphic_table graphicRef61087 \" href=\"mobipreview.htm?7/52/8013\">",
"       table 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Arrange for wound recheck and suture removal (if nonabsorbable sutures placed) in five to seven days.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1118998\">",
"    <span class=\"h2\">",
"     Lid lacerations in children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although most superficial lid wounds can be managed primarily by the emergency clinician, eyelid lacerations in children should be approached with particular care given that the clinical exam is often limited by patient cooperation. If trauma to the globe or complicated lid laceration is suspected, an ophthalmologist should be consulted to perform an exam under sedation or anesthesia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39045/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1119038\">",
"    <span class=\"h2\">",
"     Animal bites",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eyelid lacerations from animal bites cause a combination of lacerating and blunt injury to the affected tissue. Dog bites are most common and have a predisposition for injury to the medial aspect of the eyelids and the canalicular system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39045/abstract/12\">",
"     12",
"    </a>",
"    ]. Animal bites are often contaminated with polymicrobial pathogens from the animal's saliva, requiring thorough wound irrigation prior to closure, antibiotic prophylaxis, and careful monitoring for infection. Rabies prophylaxis should be considered if the attacking animal has signs of rabies or cannot be located. The management of animal bites is discussed in greater detail separately (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/57/20377?source=see_link\">",
"     \"Initial management of animal and human bites\"",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20931378\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR SURGICAL SUBSPECIALTY CONSULTATION OR REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following injuries warrant care by an ophthalmologist or surgeon with special expertise in cosmetic repair of the eyelid (eg, plastic surgeon, oromaxillofacial surgeon):",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6247431\">",
"    <span class=\"h2\">",
"     Full-thickness lid lacerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;A high threshold of suspicion for penetrating injury to the globe must be maintained in the setting of lacerations extending through the full-thickness of the eyelid. Subconjunctival hemorrhage, chemosis, or other changes to the ocular surface beneath a full-thickness laceration to the eyelid are particularly suggestive of possible trauma to the globe and merit urgent ophthalmologic evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6247439\">",
"    <span class=\"h2\">",
"     Lacerations with orbital fat prolapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of fat in an eyelid laceration suggests that the orbital septum has been violated, allowing the underlying orbital fat to prolapse through the laceration (",
"    <a class=\"graphic graphic_picture graphicRef70698 \" href=\"mobipreview.htm?17/23/17779\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef69153 \" href=\"mobipreview.htm?21/39/22135\">",
"     figure 1",
"    </a>",
"    ). Penetration of the orbital septum is a concerning finding in eyelid lacerations, since the laceration may have damaged the levator muscle, penetrated the orbital space, or both. Limitation of elevation of the upper eyelid would confirm suspected damage to the levator muscle. Computed tomography of the orbit should be performed in the setting of fat prolapse to assess the extent of orbital injury, and surgical repair should be performed by a subspecialty service (eg, ophthalmology or plastic surgery) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39045/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6247447\">",
"    <span class=\"h2\">",
"     Lacerations through the lid margin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repair of lacerations through the margin of the eyelid should also be deferred to a subspecialty service (",
"    <a class=\"graphic graphic_picture graphicRef50739 \" href=\"mobipreview.htm?31/40/32387\">",
"     picture 2",
"    </a>",
"    ). Meticulous realignment of the anatomic layers of the eyelid and the eyelid margin is essential in order to prevent scarring and notching of the eyelid margin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39045/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6247455\">",
"    <span class=\"h2\">",
"     Lacerations involving the tear drainage system",
"    </span>",
"    &nbsp;&mdash;&nbsp;If not repaired appropriately, a lacerating injury to the tear drainage system can result in permanent tearing. Lacerations involving the medial aspect of the eyelids mandate particularly close inspection to exclude damage to the lacrimal system. The canaliculi are essential components of the tear drainage system of the eye that extend medially from the puncta on the nasal aspect of the upper and lower eyelids (",
"    <a class=\"graphic graphic_figure graphicRef68267 \" href=\"mobipreview.htm?3/40/3717\">",
"     figure 2",
"    </a>",
"    ). Thus, trauma to the canalicular system should be suspected when a laceration occurs medially to the punctum on the upper or lower eyelid. Definitive determination of canalicular involvement requires ophthalmologic consultation. The ophthalmologist may use special instruments to probe and irrigate the laceration in order to establish whether the laceration involves the tear drainage system. Lacerations involving the canaliculi require placement of silicone tubes to maintain patency of the drainage system while the laceration heals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39045/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6247463\">",
"    <span class=\"h2\">",
"     Orbital injury or foreign body",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the full extent and depth of an eyelid laceration cannot be determined, particularly in the setting of a puncture wound or when the history suggests projectile injury with a possible intraocular or intraorbital foreign body, computed tomography of the orbit and ophthalmologic consultation are warranted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39045/abstract/13\">",
"     13",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6247471\">",
"    <span class=\"h2\">",
"     Laceration with poor alignment and/or avulsion",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the wound edges do not align well",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tissue loss is suspected, repair of the laceration should be referred to a subspecialty surgery service (eg, ophthalmology or plastic surgery). Excessive tension on the wound margins after repair can lead to scarring and traction on the eyelid, causing malposition and distortion of the native lid anatomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6664667\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;If eyelid lacerations are repaired appropriately, most patients will achieve a successful cosmetic and functional outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6664674\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Eyelid lacerations are an important subtype of facial trauma. Ocular injury (eg, open globe, traumatic hyphema, corneal abrasion) may accompany eyelid laceration in up to two-thirds of cases. (See",
"      <a class=\"local\" href=\"#H6664558\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Proper management and repair of eyelid lacerations requires a basic understanding of the anatomy of the eyelid and its surrounding structures (",
"      <a class=\"graphic graphic_figure graphicRef69153 \" href=\"mobipreview.htm?21/39/22135\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The clinician should have a high suspicion for an open globe injury or other ocular injuries in any patient who has sustained an eyelid laceration. The clinical features and initial management of patients with these ocular injuries is summarized in the rapid overviews (",
"      <a class=\"graphic graphic_table graphicRef50022 \" href=\"mobipreview.htm?16/28/16845\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef74146 \" href=\"mobipreview.htm?28/28/29133\">",
"       table 2",
"      </a>",
"      ) and are discussed in detail separately. (See",
"      <a class=\"local\" href=\"#H6664572\">",
"       'Primary evaluation and management'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/34/8745?source=see_link&amp;anchor=H22#H22\">",
"       \"Open globe injuries: Emergent evaluation and initial management\", section on 'Initial emergency assessment and treatment'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/10/38057?source=see_link&amp;anchor=H12#H12\">",
"       \"Traumatic hyphema: Clinical features and management\", section on 'Initial emergency assessment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The following injuries warrant prompt consultation with an ophthalmologist or surgeon with special expertise in cosmetic repair of the eyelid (eg, plastic surgeon, oromaxillofacial surgeon) (see",
"      <a class=\"local\" href=\"#H20931378\">",
"       'Indications for surgical subspecialty consultation or referral'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Suspected open globe or intraocular foreign body (",
"      <a class=\"graphic graphic_table graphicRef50022 \" href=\"mobipreview.htm?16/28/16845\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Laceration through the full-thickness of the eyelid",
"     </li>",
"     <li>",
"      Lacerations with orbital fat prolapse (",
"      <a class=\"graphic graphic_picture graphicRef70698 \" href=\"mobipreview.htm?17/23/17779\">",
"       picture 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Lacerations through the lid margin (",
"      <a class=\"graphic graphic_picture graphicRef50739 \" href=\"mobipreview.htm?31/40/32387\">",
"       picture 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Lacerations involving the tear drainage system (",
"      <a class=\"graphic graphic_figure graphicRef68267 \" href=\"mobipreview.htm?3/40/3717\">",
"       figure 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Lacerations with poor alignment",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      avulsion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Once serious ocular injuries and complicated lacerations are excluded, superficial eyelid lacerations that comprise less than 25 percent of the lid may be managed with local wound care and healing by secondary intention alone. Uncomplicated lid lacerations of a greater extent are repaired with simple interrupted sutures (6-0 or 7-0 nonabsorbable nylon or 6-0 absorbable fast gut) placed in similar fashion as for other anatomic locations. Absorbable sutures are preferred for children. (See",
"      <a class=\"local\" href=\"#H6664579\">",
"       'Simple eyelid lacerations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39045/abstract/1\">",
"      Kennedy RH, May J, Dailey J, Flanagan JC. Canalicular laceration. An 11-year epidemiologic and clinical study. Ophthal Plast Reconstr Surg 1990; 6:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39045/abstract/2\">",
"      Reifler DM. Management of canalicular laceration. Surv Ophthalmol 1991; 36:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39045/abstract/3\">",
"      Fannin LA, Fitch CP, Raymond WR, et al. Eye injuries from merchandise display hooks. Am J Ophthalmol 1995; 120:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39045/abstract/4\">",
"      Zagelbaum BM, Starkey C, Hersh PS, et al. The National Basketball Association eye injury study. Arch Ophthalmol 1995; 113:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39045/abstract/5\">",
"      Hatton MP, Thakker MM, Ray S. Orbital and adnexal trauma associated with open-globe injuries. Ophthal Plast Reconstr Surg 2002; 18:458.",
"     </a>",
"    </li>",
"    <li>",
"     Long, JA, Tann, TA. Eyelid and Lacrimal System Trauma. In: Ocular Trauma: The Essentials, Kuhn, F, Pieramici, D (Eds), Thieme, New York 2001. p.373.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39045/abstract/7\">",
"      Nelson CC. Management of eyelid trauma. Aust N Z J Ophthalmol 1991; 19:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39045/abstract/8\">",
"      Chandler DB, Gausas RE. Lower eyelid reconstruction. Otolaryngol Clin North Am 2005; 38:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39045/abstract/9\">",
"      Brown DJ, Jaffe JE, Henson JK. Advanced laceration management. Emerg Med Clin North Am 2007; 25:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39045/abstract/10\">",
"      Chang EL, Rubin PA. Management of complex eyelid lacerations. Int Ophthalmol Clin 2002; 42:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39045/abstract/11\">",
"      Levine LM. Pediatric ocular trauma and shaken infant syndrome. Pediatr Clin North Am 2003; 50:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39045/abstract/12\">",
"      Gonnering RS. Ocular adnexal injury and complications in orbital dog bites. Ophthal Plast Reconstr Surg 1987; 3:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39045/abstract/13\">",
"      Mutlukan E, Fleck BW, Cullen JF, Whittle IR. Case of penetrating orbitocranial injury caused by wood. Br J Ophthalmol 1991; 75:374.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13905 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-219.243.220.100-537ACF1ECA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_8_39045=[""].join("\n");
var outline_f38_8_39045=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6664674\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6664550\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6664558\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6664565\">",
"      PERTINENT ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6664572\">",
"      PRIMARY EVALUATION AND MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6664579\">",
"      Simple eyelid lacerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1118998\">",
"      Lid lacerations in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1119038\">",
"      Animal bites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20931378\">",
"      INDICATIONS FOR SURGICAL SUBSPECIALTY CONSULTATION OR REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6247431\">",
"      Full-thickness lid lacerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6247439\">",
"      Lacerations with orbital fat prolapse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6247447\">",
"      Lacerations through the lid margin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6247455\">",
"      Lacerations involving the tear drainage system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6247463\">",
"      Orbital injury or foreign body",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6247471\">",
"      Laceration with poor alignment and/or avulsion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6664667\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6664674\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/13905\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13905|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?21/39/22135\" title=\"figure 1\">",
"      Eyelid anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/40/3717\" title=\"figure 2\">",
"      Eye structures lacerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13905|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/23/17779\" title=\"picture 1\">",
"      Eyelid laceration with orbital fat prolapse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/40/32387\" title=\"picture 2\">",
"      Laceration through the eyelid margin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13905|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/28/16845\" title=\"table 1\">",
"      Open globe rapid overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/28/29133\" title=\"table 2\">",
"      Hyphema rapid overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/52/8013\" title=\"table 3\">",
"      Tetanus prophylaxis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/7/18553?source=related_link\">",
"      Closure of skin wounds with sutures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34600?source=related_link\">",
"      Corneal abrasions and corneal foreign bodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/57/20377?source=related_link\">",
"      Initial management of animal and human bites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/11/35002?source=related_link\">",
"      Initial management of trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/34/8745?source=related_link\">",
"      Open globe injuries: Emergent evaluation and initial management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/16/29962?source=related_link\">",
"      Trauma management: Approach to the unstable child",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/10/38057?source=related_link\">",
"      Traumatic hyphema: Clinical features and management",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_8_39046="Fetal development weeks 3-5";
var content_f38_8_39046=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57342&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57342&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Umbilical cord development 3rd to 5th week gestation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 562px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_8_39046=[""].join("\n");
var outline_f38_8_39046=null;
var title_f38_8_39047="Preparing an office practice for pediatric emergencies";
var content_f38_8_39047=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Preparing an office practice for pediatric emergencies",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/8/39047/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/8/39047/contributors\">",
"     Karen S Frush, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/8/39047/contributors\">",
"     William C Bordley, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/8/39047/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/8/39047/contributors\">",
"     Richard D Zane, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/8/39047/contributors\">",
"     George A Woodward, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/8/39047/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/8/39047/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/8/39047/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H19564731\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pediatric providers deliver a variety of services to children and their families, including, on occasion, triage and treatment of childhood emergencies. Infants and children with potentially life-threatening illnesses and injuries are sometimes taken to primary care offices by parents or caregivers who are seeking help from healthcare professionals they know and trust. When this occurs, the office and staff need to be prepared to provide initial stabilization and when necessary, life-saving care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39047/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies have shown that office visits by children requiring emergency care are common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39047/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Thus, it is essential that pediatric primary care offices are equipped with devices, medications, communication systems, and trained personnel to manage the most frequent types of pediatric office emergencies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39047/abstract/4\">",
"     4",
"    </a>",
"    ]. The consequences of being unprepared are serious; initial treatment provided in the office may mean the difference between life and death. Appropriate stabilization of pediatric emergencies and timely transfer to an appropriate facility for definitive care are important responsibilities of every medical provider who cares for children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19564737\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emergency conditions in infants and children coming to medical office settings are relatively frequent, but the actual number varies significantly depending upon practice characteristics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39047/abstract/4\">",
"     4",
"    </a>",
"    ]. As an example, more than 2400 life-threatening pediatric emergencies per year were reported in a telephone survey of 51 pediatric offices in one suburban county of Connecticut (an average of 24 emergencies per office per year) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39047/abstract/3\">",
"     3",
"    </a>",
"    ]. In a survey of pediatricians and family medicine providers who practice in an urban setting, almost two-thirds of those who responded reported that they cared for at least one child who required hospitalization or urgent care each week, and 80 percent had cared for at least one severely ill patient in the past three months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39047/abstract/2\">",
"     2",
"    </a>",
"    ] In a separate survey of pediatricians, 73 percent reported one or more emergencies per week [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39047/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several studies have been conducted to identify the types of pediatric emergencies that are most often encountered in the office setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39047/abstract/2,3,5,6\">",
"     2,3,5,6",
"    </a>",
"    ]. Respiratory emergencies, seizures, infections (especially in young infants), and",
"    <span class=\"nowrap\">",
"     shock/dehydration",
"    </span>",
"    are reported most often, and serious traumatic injuries have also been noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39047/abstract/2,5,6\">",
"     2,5,6",
"    </a>",
"    ]. In a nationwide survey of 1000 randomly selected, nonhospital based pediatricians, the percentage of pediatricians who had encountered children with the following conditions in the office setting in the previous year was as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39047/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Meningitis: 71 percent",
"     </li>",
"     <li>",
"      Severe asthma: 66 percent",
"     </li>",
"     <li>",
"      Severe hypovolemia: 58 percent",
"     </li>",
"     <li>",
"      Ongoing seizure activity: 45 percent",
"     </li>",
"     <li>",
"      Head trauma: 40 percent",
"     </li>",
"     <li>",
"      Anaphylaxis: 14 percent",
"     </li>",
"     <li>",
"      Cardiopulmonary arrest: 8 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the type of pediatric emergencies encountered in a given office will vary significantly depending on prevalence of disease within a given geographical area, the proximity of the practice to a facility with pediatric resuscitation capability, the numbers and types of chronic medical conditions cared for by the practice, the practice culture with respect to evaluating children with acute illness in the office, and the severity of disease within individual patients.",
"   </p>",
"   <p>",
"    Because of the frequency of emergent conditions in children coming to office-based settings, pediatric care providers need to ensure that pediatric specific resources are available to provide initial resuscitation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19564743\">",
"    <span class=\"h1\">",
"     OFFICE PREPAREDNESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The steps to prepare an office for handling a pediatric emergency involves office-based self assessment, development of a written response plan, training for all office staff, effective surveillance and triage for critically ill or injured children who come to the office, immediate availability of appropriate pediatric resuscitation equipment and medications, effective communication with emergency medical services, and assurance of safe transport to a higher level of pediatric care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39047/abstract/1\">",
"     1",
"    </a>",
"    ]. In office practices in close proximity to facilities with pediatric resuscitation capability, the focus should be on brief stabilization of life-threatening conditions and rapid transfer. In practices that are remote to definitive care and with only basic emergency medical services, the office staff need to be able to provide extended resuscitation care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5170310\">",
"    <span class=\"h2\">",
"     Office-based self assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;An office-based self assessment provides practitioners with information necessary to optimize readiness for pediatric emergencies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39047/abstract/7\">",
"     7",
"    </a>",
"    ]. The goal of the assessment is to determine the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The types of pediatric emergencies most likely to be encountered in the office given the provider&rsquo;s patient population and past experience",
"     </li>",
"     <li>",
"      Office resources available to respond to pediatric emergencies on site",
"     </li>",
"     <li>",
"      Emergency medical services capability (basic life support, advanced life support, or both) and response time to the practice",
"     </li>",
"     <li>",
"      The closest facility that can provide a higher level of pediatric resuscitation (eg, closest general emergency department) along with the best means of communication with that facility and expected transport time",
"     </li>",
"     <li>",
"      The closest facility that can provide definitive pediatric care (eg, free-standing children&rsquo;s hospital) along with the best means of communication with that facility and expected transport time",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The table provides sample questions that may be useful when performing an office-based self assessment (",
"    <a class=\"graphic graphic_table graphicRef64973 \" href=\"mobipreview.htm?39/12/40141\">",
"     table 1",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18522168\">",
"    <span class=\"h2\">",
"     Response plan",
"    </span>",
"    &nbsp;&mdash;&nbsp;The practice should develop a written response plan and obtain appropriate pediatric training, equipment, and medications to support effective office-based stabilization and transfer of the critically ill or injured child. The response plan is best developed by convening representative members of the office team and discussing each step that is required to assure appropriate management of an office emergency. Roles are assigned to each team member in advance of the event (these should not exceed a standard scope of practice). The response plan should also cover times when the office is open, but staffing is limited to ensure that patient stabilization occurs while external assistance is sought [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39047/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A comprehensive response plan should address the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Recognition and triage of a pediatric emergency",
"      </strong>",
"      &ndash; Nonclinical personnel (eg, the receptionist) are often the first office staff to assess the patient. They should receive basic training regarding signs and symptoms of common pediatric emergencies, including those associated with respiratory distress, shock, seizures, and altered mental status. (See",
"      <a class=\"local\" href=\"#H19564755\">",
"       'Triage'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      Periodic surveillance of children in the waiting room and examination rooms by clinical personnel, such as the head nurse, is also advisable.",
"     </li>",
"     <li>",
"      <strong>",
"       Internal notification",
"      </strong>",
"      &ndash; The practice should establish a system to rapidly notify appropriate office staff, especially clinical personnel, of an emergency.",
"     </li>",
"     <li>",
"      <strong>",
"       EMS activation",
"      </strong>",
"      &ndash; A staff member should expeditiously access the local emergency medical services (EMS) system when an emergency is recognized. Staff who are given this role need to know the phone number to access EMS and have a clear understanding of the capability of their local emergency medical service agency. (See",
"      <a class=\"local\" href=\"#H5170310\">",
"       'Office-based self assessment'",
"      </a>",
"      above.) They should also provide the following information to the EMS dispatcher [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/8/39047/abstract/1,7,9\">",
"       1,7,9",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Office address and practice location within the building",
"     </li>",
"     <li>",
"      Where to access the building",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      meet personnel (eg, security) who will escort them to the patient, including where to park the ambulance",
"     </li>",
"     <li>",
"      Child&rsquo;s age, medical condition, and if available, vital signs",
"     </li>",
"     <li>",
"      Type of EMS provider needed (basic life support or advanced life support)",
"     </li>",
"     <li>",
"      The caller should",
"      <strong>",
"       not",
"      </strong>",
"      hang up until the EMS dispatcher has all of the above information, has had the opportunity to ask follow up questions, and has hung up",
"      <strong>",
"       first",
"      </strong>",
"      .",
"      <br/>",
"      <br/>",
"      Posting of scripted instructions near telephones can give prompts that encourage clear and informative communication with the EMS dispatcher. (See",
"      <a class=\"local\" href=\"#H5170302\">",
"       'Additional resources'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Office resuscitation",
"      </strong>",
"      &mdash; Staff should decide where the child should be resuscitated (eg, designated examination room, ideally with wide enough access for an EMS stretcher), how resuscitation equipment and medications are organized, and who is responsible for bringing them to the patient. (See",
"      <a class=\"local\" href=\"#H19564761\">",
"       'Emergency equipment and medications'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      Resuscitation roles should be outlined in the response plan [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/8/39047/abstract/1\">",
"       1",
"      </a>",
"      ]. As an example, a practice may decide to use an approach such as:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The receptionist notifies the local EMS system, then provides support to family members.",
"     </li>",
"     <li>",
"      The physician directs resuscitation efforts and controls the airway.",
"     </li>",
"     <li>",
"      One nurse is responsible for intravenous access and drug administration and another nurse or medical assistant is designated to provide chest compressions; and a nursing assistant records events and interventions (eg, medications given) as they occur.",
"     </li>",
"     <li>",
"      Each member of the team needs to have the training to ensure that they can perform their assigned clinical duties.",
"      <br/>",
"      The response plan should also address who is in charge of the resuscitation if there are times in which there is no physician in the office.",
"      <br/>",
"      <br/>",
"      Use of a code documentation sheet can assist in rapidly capturing key information about the resuscitation, such as clinical personnel involved, all interventions performed, timing of interventions, time that EMS was called, time that EMS arrived, time that EMS departed, and equipment used. A copy of the code documentation sheet is an efficient method of supplementing the documentation that should go with the patient when they are transferred to definitive care. (See",
"      <a class=\"local\" href=\"#H19564773\">",
"       'Documentation'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H5170302\">",
"       'Additional resources'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Patient transfer",
"    </strong>",
"    &mdash; The response plan should identify the preferred EMS provider and the preferred destination facility for EMS transport. In some situations (eg, child with severe trauma), regional EMS protocols will mandate the facility that should receive the patient. Important telephone numbers (eg, EMS provider, receiving hospital emergency departments) should be posted prominently to facilitate verbal communication. The plan should reinforce that a written patient care record should be generated during the resuscitation and accompany the patient as part of the transfer process. (See",
"    <a class=\"local\" href=\"#H19564773\">",
"     'Documentation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H462165932\">",
"    <span class=\"h3\">",
"     Mock resuscitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testing of the response plan through periodic mock resuscitations maintains readiness for pediatric emergencies and permits updating of the response plan based upon team performance. Low fidelity simulations (eg, role play, use of a baby doll as a patient, live child volunteer) are as effective as high fidelity exercises in teaching nontechnical teamwork skills and role clarity and are easy to implement in any office setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39047/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Performing mock resuscitations in conjunction with emergency providers and local EMS teams is also a proven method for enhancing office readiness for pediatric emergencies:",
"    <br/>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized, controlled trial in which unannounced mock resuscitations were performed by emergency providers (physician or nurse) in the intervention group and participating practices were expected to respond with existing office resources and their local EMS team [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/8/39047/abstract/11\">",
"       11",
"      </a>",
"      ]. After the exercise, the emergency medicine providers and local EMS team members provided constructive feedback, reviewed the available pediatric office equipment, and left a resource manual. Mock resuscitations were not performed in the control group. At follow-up three to six months later, a greater proportion of intervention practices had developed written protocols (60 versus 21 percent) and a greater number of intervention staff had received additional training in basic life support, advanced life support,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pediatric advanced life support (118 versus 54); the practices did not differ in the purchase of new equipment or medications.",
"     </li>",
"     <li>",
"      In an observational study of 97 physicians and other medical providers one hour of didactic teaching and participation in one mock code exercise was significantly associated with increased confidence and decreased anxiety with specific skills used in pediatric resuscitation (eg, oxygen administration, airway suctioning, bag-mask ventilation, or intraosseous needle placement) 12 months after the intervention [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/8/39047/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19564749\">",
"    <span class=\"h2\">",
"     Training",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effective management of a seriously ill or injured child requires training of the pediatric office staff in the proper use of emergency equipment and medication. A list of training courses and representative training costs are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef66777 \" href=\"mobipreview.htm?16/44/17099\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The American Academy of Pediatrics recommends that all certified pediatric providers (eg, physicians, nurse practitioners, physician assistants, nurses) at a minimum have training in basic life support (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/43/7864?source=see_link\">",
"     \"Basic life support in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/22/29030?source=see_link\">",
"     \"Basic airway management in children\"",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39047/abstract/1\">",
"     1",
"    </a>",
"    ]. Furthermore, a more advanced level of training (eg, The Pediatric Advanced Life Support Course or Advanced Pediatric Life Support) is strongly encouraged for staff who work in offices that do not have ready access to advanced life support courses through their local emergency medical services system. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/16/20746?source=see_link\">",
"     \"Guidelines for pediatric advanced life support\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    EMS providers and office staff can create opportunities to improve communication and develop teamwork skills that will facilitate the transfer of care at the time of a true emergency. Some practices also find it helpful to review actual cases, to invite local EMS providers to participate in simulated drills, and to provide continuing education addressing the most common problems seen in their offices",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19564755\">",
"    <span class=\"h2\">",
"     Triage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Triage in pediatric practices consists of two scenarios:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Children already in the office",
"      </strong>",
"      &ndash; A seriously ill or injured child, or one whose condition is deteriorating in the office, needs to be evaluated, treated, and transferred emergently rather than waiting his or her turn. All office staff, both clinical and nonclinical, should know signs and symptoms of respiratory distress, shock, seizures, and altered mental status and know how to initiate the office response plan [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/8/39047/abstract/1\">",
"       1",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H18522168\">",
"       'Response plan'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Periodic surveillance by experienced clinical personnel (eg, head nurse) of children who are in the waiting area or examination rooms provides additional opportunity to recognize and respond to an office emergency [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/8/39047/abstract/1,9\">",
"       1,9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Telephone triage",
"      </strong>",
"      &ndash; Each practice should have a specific set of formal guidelines for telephone communication that allows users to determine the degree of illness of the child and the appropriate disposition (care at home, office evaluation, emergency department evaluation). Commercial telephone triage algorithms are available with a series of specific and directed questions for each chief complaint or set of presenting symptoms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/8/39047/abstract/13\">",
"       13",
"      </a>",
"      ]. Every staff member who is responsible for fielding parent telephone calls should be trained in the use of such a protocol, with clear instructions for when to refer the call to the physician. All telephone calls should be documented and any advice given to the family included in the patient's chart. Many pediatric providers subscribe to call centers that provide after hours telephone advice and triage. The American Academy of Pediatrics has provided guidance on the safe operation of these centers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/8/39047/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19564761\">",
"    <span class=\"h2\">",
"     Emergency equipment and medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Committee on Pediatric Emergency Medicine for the American Academy of Pediatrics have provided lists that delineate the essential and strongly suggested emergency equipment and medications that should be available in offices that care for children (",
"    <a class=\"graphic graphic_table graphicRef53154 \" href=\"mobipreview.htm?12/32/12814\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39047/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Essential equipment (eg, oxygen delivery system and masks, bag-valve mask, suction, pulse oximeter,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/19/37168?source=see_link\">",
"     epinephrine",
"    </a>",
"    [1",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    or 1:1000]) should be available in all pediatric practices. Strongly suggested supplies (eg, equipment for endotracheal intubation, equipment to establish vascular access, intravenous medications, automated external defibrillator with pediatric capabilities) are considered essential if response time for an advanced life support ambulance is &gt;10 minutes. Pediatric providers may obtain prepackaged emergency kits from commercial medical suppliers (eg, Armstrong Medical Industries Inc, Banyan International Corporation). An emergency medical services equipment provider or a pediatric hospital may also be able to help with procurement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39047/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Utilizing a system that helps clinical staff rapidly determine the appropriate equipment size and emergency medication dosing for children during emergency care is strongly encouraged. The Broselow&reg; Pediatric Emergency Tape and the Broselow&trade; Pediatric Resuscitation System are widely used in the United States. Trials of physician use during simulated pediatric resuscitations suggest that these clinical tools significantly reduce medication and equipment sizing errors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39047/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Web-based education on the proper use of the Broselow tape further decreases the frequency of medication dosing errors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39047/abstract/11\">",
"     11",
"    </a>",
"    ]. Although evidence is limited, charts or manuals with equipment size and medication dosing (including dose in",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    drug formulation, and volume to administer) organized by patient weight are alternative resources that may be useful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39047/abstract/17\">",
"     17",
"    </a>",
"    ]. Local emergency departments may provide guidance on available systems and assist with ordering materials.",
"   </p>",
"   <p>",
"    Regardless of how resuscitation supplies are organized, it is essential that all clinical staff have a working knowledge of the system in use. Mock resuscitations provide a low stakes environment to test the effectiveness of the storage system and resuscitation resources for quickly guiding clinicians to the appropriately sized equipment and proper medication doses. (See",
"    <a class=\"local\" href=\"#H462165932\">",
"     'Mock resuscitation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Organization of pediatric resuscitation supplies should be individualized based on the practice&rsquo;s response plan. (See",
"    <a class=\"local\" href=\"#H18522168\">",
"     'Response plan'",
"    </a>",
"    above.) Options include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39047/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stocked resuscitation room",
"     </li>",
"     <li>",
"      Portable resuscitation pack that utilizes a backpack, toolbox, or tackle box",
"     </li>",
"     <li>",
"      Portable resuscitation cart",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A designated member of the office staff should regularly and frequently inspect the pediatric resuscitation supplies and ensure that they are complete, medications are not expired, and equipment is functioning properly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39047/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. Hospital pharmacies in the region may permit exchange of medications that are within six months of expiration to help reduce the cost of restocking resuscitation medications in the office.",
"   </p>",
"   <p>",
"    Securing the resuscitation supplies with a plastic lock or other rapidly removable device helps ensure availability of necessary materials during a resuscitation by avoiding use of contents for routine patient care and by reminding staff to restock and check expiration dates on medications and equipment after an emergency response has occurred.",
"   </p>",
"   <p>",
"    In addition to procuring, organizing, and maintaining these supplies, practice leadership must ensure that personnel are properly trained in their use within the office setting. (See",
"    <a class=\"local\" href=\"#H18522168\">",
"     'Response plan'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H19564749\">",
"     'Training'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19564767\">",
"    <span class=\"h2\">",
"     Transport of the critically ill child",
"    </span>",
"    &nbsp;&mdash;&nbsp;Safe transport of a critically ill or injured child involves moving the patient to a higher level of care, in as stable a condition as possible, with personnel in attendance who can provide care if the condition of the patient should deteriorate during transport. A clear understanding of the different types of EMS transport personnel and their scope of practice is essential when deciding the best mode of transport for a child with an office emergency (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/59/26553?source=see_link&amp;anchor=H11#H11\">",
"     \"Prehospital pediatrics and emergency medical services (EMS)\", section on 'Scope of practice'",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In general, an advanced life support response is required if the child has a life-threatening problem, alteration of consciousness, or respiratory distress, or potentially requires airway management or vascular access. A basic life support response may be more appropriate and expeditious for limb-threatening problems and those requiring first-aid, immobilization, oxygen&nbsp;administration, and immediate transport (eg, \"load and go\"). In some instances, the pediatric provider may choose to accompany the child during transport. However, he or she should only do so with the support of appropriate personnel (eg, paramedic, nurse) and in an ambulance that allows for the provision of emergency care.",
"   </p>",
"   <p>",
"    Unless an advanced pediatric facility is nearby, initial transfer to a local hospital emergency department by emergency medical services is usually preferred. Once stabilized, the child can then undergo transport to an advanced pediatric center via a pediatric interfacility transport team [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39047/abstract/21\">",
"     21",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    <br/>",
"    Telephone contact between the pediatric provider and the physician at the receiving facility is essential and should include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Data identifying the child (name, age, sex)",
"     </li>",
"     <li>",
"      A brief history of the illness and relevant past medical history",
"     </li>",
"     <li>",
"      Clinical findings, including serial vital signs",
"     </li>",
"     <li>",
"      Any interventions performed by office staff and the response to therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A written record should accompany the patient and should include all of the above information as well as the name and phone number of the referring medical provider [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39047/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H19564773\">",
"     'Documentation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Safe transport of the critically ill or injured patient does not include the parents&rsquo; car, a taxi cab, bus, or other transit vehicle without medical supervision and equipment. In a 1991 survey of pediatricians and family practice physicians, 54 percent reported that they used the family car most often as the means to transport seriously ill children (eg, anaphylaxis, seizure, asthma, meningitis, foreign body aspiration, sepsis, and epiglottitis), even though 93 percent had access to EMS, and 9.5 percent had a standing contract with a specific ambulance company for patient transport [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39047/abstract/23\">",
"     23",
"    </a>",
"    ]. The reasons they gave for this choice included a perception of increased efficiency of the family car, the expense of an EMS response, and failure to consider the option of ambulance transport. However, deterioration or death of the patient during transport without adequate equipment and personnel is the responsibility of the sending physician when nonmedical means of transportation are used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39047/abstract/24\">",
"     24",
"    </a>",
"    ], and the benefit of trained personnel and proper equipment during transport outweighs the risk of waiting for emergency medical services personnel to arrive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39047/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19564773\">",
"    <span class=\"h2\">",
"     Documentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A patient care record should be generated during the resuscitation. This record should be clear and legible. Use of a preformatted code documentation sheet can assist in rapidly capturing key information about the resuscitation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39047/abstract/1\">",
"     1",
"    </a>",
"    ]. Important components include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical personnel involved (including names of the emergency medical services (EMS) personnel and ambulance company)",
"     </li>",
"     <li>",
"      Initial patient condition",
"     </li>",
"     <li>",
"      Patient assessment with serial vital signs and presumptive diagnosis",
"     </li>",
"     <li>",
"      All interventions performed, including medication doses and size of equipment used",
"     </li>",
"     <li>",
"      Timing of interventions",
"     </li>",
"     <li>",
"      Patient response to treatment and interventions",
"     </li>",
"     <li>",
"      Patient condition upon departure",
"     </li>",
"     <li>",
"      Time that EMS was called, time that EMS arrived, and time that EMS departed",
"     </li>",
"     <li>",
"      Time of call to receiving facility, name of receiving physician, and content of discussion",
"     </li>",
"     <li>",
"      Communication with the family",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A copy of the code documentation sheet is an efficient method of supplementing the documentation that should go with the patient when they are transferred to definitive care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5170302\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following resources are available as appendices to the American Academy of Pediatrics Policy Statement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39047/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Office-based self assessment tool",
"     </li>",
"     <li>",
"      Reception desk emergency card",
"     </li>",
"     <li>",
"      Calling EMS for an office emergency",
"     </li>",
"     <li>",
"      Important emergency telephone numbers",
"     </li>",
"     <li>",
"      Mock resuscitation evaluation forms",
"     </li>",
"     <li>",
"      Mock resuscitation sample scenarios",
"     </li>",
"     <li>",
"      Resuscitation documentation form",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An online &ldquo;user&rsquo;s guide&rdquo; is available to teach the appropriate use of the Broselow&reg; pediatric resuscitation tape [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39047/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rapid overviews and algorithms provide guidance for office-based, disease-specific treatment plans, including anaphylaxis (",
"    <a class=\"graphic graphic_table graphicRef74242 \" href=\"mobipreview.htm?17/50/18221\">",
"     table 4",
"    </a>",
"    ), status asthmaticus (",
"    <a class=\"graphic graphic_algorithm graphicRef76087 \" href=\"mobipreview.htm?16/52/17230\">",
"     algorithm 1",
"    </a>",
"    ) , status epilepticus (",
"    <a class=\"graphic graphic_table graphicRef55368 \" href=\"mobipreview.htm?29/20/30029\">",
"     table 5",
"    </a>",
"    ), shock (",
"    <a class=\"graphic graphic_algorithm graphicRef77079 \" href=\"mobipreview.htm?41/12/42178\">",
"     algorithm 2",
"    </a>",
"    ), and basic and advanced life support (",
"    <a class=\"graphic graphic_algorithm graphicRef66803 \" href=\"mobipreview.htm?17/38/18018\">",
"     algorithm 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef67438 \" href=\"mobipreview.htm?11/37/11860\">",
"     algorithm 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef80003 \" href=\"mobipreview.htm?41/30/42470\">",
"     algorithm 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef52446 \" href=\"mobipreview.htm?20/4/20545\">",
"     algorithm 6",
"    </a>",
"    ). Pediatric assessment and management of respiratory distress, failure, shock, cardiac arrhythmias, and hypoglycemia are also discussed separately (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/16/20746?source=see_link\">",
"     \"Guidelines for pediatric advanced life support\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/0/8201?source=see_link&amp;anchor=H8#H8\">",
"     \"Approach to hypoglycemia in infants and children\", section on 'Immediate management'",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19564779\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Office visits by children requiring emergency care are common. (See",
"      <a class=\"local\" href=\"#H19564737\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An office-based self assessment and development of an emergency response plan comprise essential steps for preparing a practice for a pediatric emergency. (See",
"      <a class=\"local\" href=\"#H5170310\">",
"       'Office-based self assessment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18522168\">",
"       'Response plan'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Periodic mock codes performed in primary care offices are an effective method to increase resuscitation skills and decrease staff anxiety around managing critically ill children until EMS arrives. (See",
"      <a class=\"local\" href=\"#H462165932\">",
"       'Mock resuscitation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nonclinical personnel (eg, the receptionist) are often the first office staff to assess the patient. They should receive basic training regarding signs and symptoms of common pediatric emergencies, including those associated with respiratory distress, shock, seizures, and altered mental status. (See",
"      <a class=\"local\" href=\"#H18522168\">",
"       'Response plan'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to obtaining, organizing, and maintaining appropriate emergency equipment and medications (",
"      <a class=\"graphic graphic_table graphicRef53154 \" href=\"mobipreview.htm?12/32/12814\">",
"       table 3",
"      </a>",
"      ), the effective preparation for office management of seriously ill or injured children requires training of the pediatric office staff in their proper use. (See",
"      <a class=\"local\" href=\"#H19564749\">",
"       'Training'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H462165932\">",
"       'Mock resuscitation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19564761\">",
"       'Emergency equipment and medications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Periodic surveillance by experienced clinical personnel (eg, head nurse) of children who are in the waiting area or examination rooms provides additional opportunity to recognize and respond to an office emergency. (See",
"      <a class=\"local\" href=\"#H19564755\">",
"       'Triage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After providing emergency stabilization, the pediatric provider is responsible for assuring safe transport of the critically ill or injured child to a higher level of pediatric care, communicating with the receiving physician, and providing complete documentation. (See",
"      <a class=\"local\" href=\"#H19564767\">",
"       'Transport of the critically ill child'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19564773\">",
"       'Documentation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39047/abstract/1\">",
"      American Academy of Pediatrics Committee on Pediatric Emergency Medicine, Frush K. Preparation for emergencies in the offices of pediatricians and pediatric primary care providers. Pediatrics 2007; 120:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39047/abstract/2\">",
"      Fuchs S, Jaffe DM, Christoffel KK. Pediatric emergencies in office practices: prevalence and office preparedness. Pediatrics 1989; 83:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39047/abstract/3\">",
"      Flores G, Weinstock DJ. The preparedness of pediatricians for emergencies in the office. What is broken, should we care, and how can we fix it? Arch Pediatr Adolesc Med 1996; 150:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39047/abstract/4\">",
"      Klig JE, O'Malley PJ. Pediatric office emergencies. Curr Opin Pediatr 2007; 19:591.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Periodic survey 27. American Academy of Pediatrics, Elk Grove Village, IL. 1995. file://www.aap.org/research/periodicsurvey/ps27exm.htm (Accessed on July 19, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39047/abstract/6\">",
"      Schweich PJ, DeAngelis C, Duggan AK. Preparedness of practicing pediatricians to manage emergencies. Pediatrics 1991; 88:223.",
"     </a>",
"    </li>",
"    <li>",
"     Massachusetts EMSC Task, Force. Office Preparedness for Pediatric Emergencies, 2nd, O'Malley, P (Eds), Massachusetts Department of Public Health, 2002.",
"    </li>",
"    <li>",
"     Bordley, WC, Frush, KS, Cinoman, M. Pediatrics. In: Management of Office Emergencies, Barton, CW (Eds), McGraw-Hill, New York 1999. p.323.",
"    </li>",
"    <li>",
"     Committee on Pediatric Emergency Medicine. Your office as an emergency care site. In: Emergency Medical Services for Children, Singer, J, Ludwig, S (Eds), American Academy of Pediatrics, Elk Grove Village 1992. p.31.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39047/abstract/10\">",
"      Hobgood C, Sherwood G, Frush K, et al. Teamwork training with nursing and medical students: does the method matter? Results of an interinstitutional, interdisciplinary collaboration. Qual Saf Health Care 2010; 19:e25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39047/abstract/11\">",
"      Bordley WC, Travers D, Scanlon P, et al. Office preparedness for pediatric emergencies: a randomized, controlled trial of an office-based training program. Pediatrics 2003; 112:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39047/abstract/12\">",
"      Toback SL, Fiedor M, Kilpela B, Reis EC. Impact of a pediatric primary care office-based mock code program on physician and staff confidence to perform life-saving skills. Pediatr Emerg Care 2006; 22:415.",
"     </a>",
"    </li>",
"    <li>",
"     Schmitt, BD. Pediatric Telephone Protocols: Office Version, 12th, American Academy of Pediatrics, Elk Grove Village 2009.",
"    </li>",
"    <li>",
"     American Academy of Pediatrics.  A report from the provisional section on pediatric telephone care and the Committee on Practice and Ambulatory Medicine. November, 1998. file://www.aap.org/sections/telecare/11_98.pdf (Accessed on July 19, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39047/abstract/15\">",
"      Shah AN, Frush K, Luo X, Wears RL. Effect of an intervention standardization system on pediatric dosing and equipment size determination: a crossover trial involving simulated resuscitation events. Arch Pediatr Adolesc Med 2003; 157:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39047/abstract/16\">",
"      Agarwal S, Swanson S, Murphy A, et al. Comparing the utility of a standard pediatric resuscitation cart with a pediatric resuscitation cart based on the Broselow tape: a randomized, controlled, crossover trial involving simulated resuscitation scenarios. Pediatrics 2005; 116:e326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39047/abstract/17\">",
"      Lerner C, Gaca AM, Frush DP, et al. Enhancing pediatric safety: assessing and improving resident competency in life-threatening events with a computer-based interactive resuscitation tool. Pediatr Radiol 2009; 39:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39047/abstract/18\">",
"      Hodge D 3rd. Pediatric emergency office equipment. Pediatr Emerg Care 1988; 4:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39047/abstract/19\">",
"      Wheeler DS, Kiefer ML, Poss WB. Pediatric emergency preparedness in the office. Am Fam Physician 2000; 61:3333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39047/abstract/20\">",
"      Sapien R, Hodge D 3rd. Equipping and preparing the office for emergencies. Pediatr Ann 1990; 19:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39047/abstract/21\">",
"      King B. \"Interfacility\" transport from the home or office. Pediatr Emerg Care 1997; 13:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39047/abstract/22\">",
"      Schuman, AJ. Be prepared: Equipping your office for medical emergencies. Contemp Pediatr 1996; 13:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39047/abstract/23\">",
"      Baker MD, Ludwig S. Pediatric emergency transport and the private practitioner. Pediatrics 1991; 88:691.",
"     </a>",
"    </li>",
"    <li>",
"     www.nhtsa.dot.gov/people/injury/ems/Interfacility/index.htm/  (Accessed on January 24, 2010).",
"    </li>",
"    <li>",
"     Frush, K. Study packet for the correct use of the Broselow pediatric emergency tape. Enhancing Pediatric Safety.  www.ncdhhs.gov/dhsr/EMS/pdf/kids/DEPS_Broselow_Study.pdf/ (Accessed on January 24, 2010).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5797 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-2.133.93.82-ACA0B7D5D4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_8_39047=[""].join("\n");
var outline_f38_8_39047=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19564779\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19564731\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19564737\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19564743\">",
"      OFFICE PREPAREDNESS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5170310\">",
"      Office-based self assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18522168\">",
"      Response plan",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H462165932\">",
"      - Mock resuscitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19564749\">",
"      Training",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19564755\">",
"      Triage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19564761\">",
"      Emergency equipment and medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19564767\">",
"      Transport of the critically ill child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19564773\">",
"      Documentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5170302\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19564779\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/5797\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/5797|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?16/52/17230\" title=\"algorithm 1\">",
"      Acute treatment of moderate asthma in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?41/12/42178\" title=\"algorithm 2\">",
"      Initial management of shock in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?17/38/18018\" title=\"algorithm 3\">",
"      Pediatric basic life support algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?11/37/11860\" title=\"algorithm 4\">",
"      Pediatric tachycardia algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?41/30/42470\" title=\"algorithm 5\">",
"      Pediatric cardiac arrest algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?20/4/20545\" title=\"algorithm 6\">",
"      Pediatric bradycardia algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/5797|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/12/40141\" title=\"table 1\">",
"      Office-based self assessment of pediatric emergency readiness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/44/17099\" title=\"table 2\">",
"      Basic and advanced pediatric life support courses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/32/12814\" title=\"table 3\">",
"      Pediatric office resuscitation supplies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/50/18221\" title=\"table 4\">",
"      Rapid overview for pediatric anaphylaxis treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/20/30029\" title=\"table 5\">",
"      Management of status epilepticus in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/0/8201?source=related_link\">",
"      Approach to hypoglycemia in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/22/29030?source=related_link\">",
"      Basic airway management in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/43/7864?source=related_link\">",
"      Basic life support in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/16/20746?source=related_link\">",
"      Guidelines for pediatric advanced life support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/59/26553?source=related_link\">",
"      Prehospital pediatrics and emergency medical services (EMS)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_8_39048="Estimation of cardiovascular risk in an individual patient without known cardiovascular disease";
var content_f38_8_39048=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Estimation of cardiovascular risk in an individual patient without known cardiovascular disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/8/39048/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/8/39048/contributors\">",
"     Peter WF Wilson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/8/39048/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/8/39048/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/8/39048/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/8/39048/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/8/39048/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atherosclerotic cardiovascular disease (CVD) is common in the general population, affecting the majority of adults past the age of 60 years. As a diagnostic category, CVD includes four major areas:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Coronary heart disease (CHD) manifested by myocardial infarction (MI), angina pectoris, heart failure (HF), and coronary death",
"     </li>",
"     <li>",
"      Cerebrovascular disease manifested by stroke and transient ischemic attack",
"     </li>",
"     <li>",
"      Peripheral artery disease manifested by intermittent claudication and critical limb ischemia",
"     </li>",
"     <li>",
"      Aortic atherosclerosis and thoracic or abdominal aortic aneurysm",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of atherosclerotic disease in any vascular territory is now recognized to significantly increase the likelihood of CVD in other vascular distributions. In the 2002 National Cholesterol Education Program report, the presence of noncoronary atherosclerotic vascular disease was considered to carry the same risk for future cardiac events as the presence of CHD, thereby classifying it as a CHD risk equivalent&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39048/abstract/1\">",
"     1",
"    </a>",
"    ]. Similarly, diabetes was characterized as a CHD risk equivalent in this report. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=see_link&amp;anchor=H4873275#H4873275\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\", section on 'Diabetes mellitus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although CHD is the most common manifestation of CVD, CHD represents only approximately 50 percent of the total number of first CVD events. The lifetime risk of CHD was illustrated in a study of 7733 participants, age 40 to 94, in the Framingham Heart Study who were initially free of CHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39048/abstract/2\">",
"     2",
"    </a>",
"    ]. The lifetime risk for individuals at age 40 was 49 percent in men and 32 percent in women. Even those who were apparently free from disease at age 70 had a lifetime risk of 35 percent and 24 percent in men and women, respectively. The lifetime risk of CHD varies importantly with the aggregate risk factor burden (",
"    <a class=\"graphic graphic_figure graphicRef69663 \" href=\"mobipreview.htm?25/2/25647\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39048/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Lifetime risk'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Many of the important risk factors for cardiovascular disease are modifiable by specific preventive measures. In the worldwide INTERHEART study of patients from 52 countries, nine potentially modifiable factors accounted for over 90 percent of the population-attributable risk of a first MI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39048/abstract/4\">",
"     4",
"    </a>",
"    ]. These included smoking, dyslipidemia, hypertension, diabetes, abdominal obesity, psychosocial factors (eg, depression, perceived stress, life events), daily consumption of fruits and vegetables, regular alcohol consumption, and regular physical activity. An overview of the multiple cardiovascular disease risk factors is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=see_link\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While a general estimate of the relative risk for CVD can be approximated by counting the number of traditional risk factors present in a patient, a more precise estimation of the absolute risk for a first CVD event is desirable when making treatment recommendations for a specific individual. The predictive value of risk factors and the use of multivariate risk models to estimate cardiovascular risk in an individual patient will be reviewed here. The use of the risk models in decision making for the management of hypercholesterolemia or initiation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy for primary prevention is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/32/14856?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of lipids (including hypercholesterolemia) in primary prevention\", section on 'Deciding whom to treat'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37066?source=see_link\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     WHO SHOULD UNDERGO RISK ESTIMATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Patients already at high risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with the following clinical characteristics are at very high risk for the development of cardiovascular disease events and do not need risk estimated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Established cardiovascular disease.",
"     </li>",
"     <li>",
"      Diabetes mellitus (type 1 or 2) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=see_link&amp;anchor=H4873275#H4873275\">",
"       \"Overview of the risk equivalents and established risk factors for cardiovascular disease\", section on 'Diabetes mellitus'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Chronic kidney disease (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34298?source=see_link\">",
"       \"Chronic kidney disease and coronary heart disease\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Hereditary dyslipidemias known to be associated with the premature development of atherosclerotic events (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/25/37274?source=see_link\">",
"       \"Inherited disorders of LDL-cholesterol metabolism\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Patients at increased risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;The (United States) National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III or ATP III) guidelines recommend estimating risk in individuals with two or more risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39048/abstract/1\">",
"     1",
"    </a>",
"    ]. However, this approach is likely to exclude many individuals who are at increased lifetime risk and for whom primary preventative strategies would be of value. Future guidelines recommendations, such as those from ATP IV, are likely to recommend estimation in more individuals, such as those with only one risk factor. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Limitations of current risk models'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PREDICTIVE VALUE OF RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many individuals in the general population have one or more risk factors for CHD and over 90 percent of CHD events occur in individuals with at least one risk factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39048/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. On the other hand, the absence of major risk factors predicts a much lower risk of CHD.",
"   </p>",
"   <p>",
"    The magnitude of the difference in risk was illustrated in a study that reviewed data from 366,559 subjects aged 18 to 59 who were entered into two large prospective studies, the Multiple Risk Factor Intervention Trial (MRFIT), and the Chicago Heart Association Project in Industry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39048/abstract/6\">",
"     6",
"    </a>",
"    ]. Patients at low risk, defined as serum cholesterol &lt;5.17",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    (&lt;200",
"    <span class=\"nowrap\">",
"     mg/dL),",
"    </span>",
"    blood pressure",
"    <span class=\"nowrap\">",
"     &le;120/80",
"    </span>",
"    mmHg, and no current cigarette smoking, comprised 6.9 percent of the cohort.",
"   </p>",
"   <p>",
"    After an average follow-up of 16 years for the MRFIT study and 22 years for the Chicago observational study, the low-risk patients had a significantly lower CHD mortality (0.2 to 8.8 versus 1.5 to 38 percent for those with &ge;1 risk factor) and lower all cardiovascular disease mortality (0.3 to 15.8 versus 2.1 to 53 percent) compared to higher-risk patients. Estimated greater life expectancy for low-risk men and women was 9.5 and 5.8 years, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Borderline risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency and predictive value of five major risk factors (blood pressure, low-density lipoprotein [LDL] and high-density lipoprotein [HDL] cholesterol, glucose intolerance, and smoking) was evaluated in a study of white non-Hispanic individuals without CHD in the Framingham Heart Study and the Third National Health and Nutrition Examination Survey (NHANES III) who were 35 to 74 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39048/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Borderline risk factors were also evaluated; they were defined as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Systolic pressure 120 to 139 mmHg",
"     </li>",
"     <li>",
"      Diastolic pressure 80 to 89 mmHg",
"     </li>",
"     <li>",
"      LDL-cholesterol 100 to 159",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.6 to 4.1",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      HDL-cholesterol 40 to 59",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.0 to 1.5",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Impaired fasting glucose without overt diabetes",
"     </li>",
"     <li>",
"      A past history of smoking",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following estimates were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      More than 90 percent of CHD events will occur in individuals who have at least one risk factor and approximately 8 percent will occur in individuals who have only borderline levels of multiple risk factors. Few events will occur in patients with no elevated or borderline risk factors. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Lifetime risk'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      In NHANES III, approximately 60 percent of men and 50 percent of women had one to two elevated risk factors and 26 percent of men and 41 percent of women had at least one borderline risk factor. The complete absence of any elevated or borderline risk factor was rare (0 to 0.4 percent) except for women between the ages of 35 to 44 (8.9 percent) or 45 to 54 (3.7 percent).",
"     </li>",
"     <li>",
"      ATP III risk, defined as an estimated 10-year absolute CHD risk of more than 10 percent, was present in approximately 38 percent of men and 5 percent of women.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Multiple risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the preceding study, ATP III risk primarily occurred in men over age 45 who had &ge;2 elevated risk factors or one elevated risk factor plus &ge;4 borderline risk factors and in women over age 55 who had &ge;3 elevated risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39048/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The increase in risk when multiple risk factors are present has also been noted in other studies in both Western and Asian populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39048/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. This was illustrated in a 22 year follow-up study of 20,000 men and women in Chicago [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39048/abstract/8\">",
"     8",
"    </a>",
"    ]. When two or all three major risk factors (serum cholesterol &ge;200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [&ge;5.2",
"    <span class=\"nowrap\">",
"     mmol/L],",
"    </span>",
"    elevated systolic and diastolic blood pressure",
"    <span class=\"nowrap\">",
"     [&ge;120/80",
"    </span>",
"    mmHg], and cigarette smoking) were present, both men and women had a marked increase in the relative risk of coronary heart disease (5.5 and 5.7, respectively), cardiovascular disease (4.1 and 4.5), and all-cause mortality (3.2 and 2.3).",
"   </p>",
"   <p>",
"    The independent effects of systolic pressure and total cholesterol were illustrated in a larger study of 380,000 individuals from Asia, Australia, and New Zealand [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39048/abstract/9\">",
"     9",
"    </a>",
"    ]. The following observations were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Each 10 mmHg increase in systolic pressure was associated with a 21 to 34 percent increase in risk at all levels of serum cholesterol and higher levels of total cholesterol increased risk at all levels of systolic pressure. Adjustment for other risk factors had no appreciable effect on these findings.",
"     </li>",
"     <li>",
"      Patients in the higher categories of both total cholesterol (&ge;240",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [6.25",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      and systolic pressure (&ge;160 mmHg) had a seven-fold increase in CHD and an eightfold increase in stroke compared to patients in the lowest category of both total cholesterol (less than 183",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [4.75",
"      <span class=\"nowrap\">",
"       mL/mmol/L])",
"      </span>",
"      and systolic pressure (less than 130 mmHg). As in the preceding study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/8/39048/abstract/8\">",
"       8",
"      </a>",
"      ], these increases in risk were more than additive but less than multiplicative.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Multivariate risk models",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a consequence of the above observations, a number of multivariate risk models have been developed for estimating the risk of cardiovascular events in apparently healthy, asymptomatic individuals based upon assessment of multiple variables. An important component of these models is that many of the risk factors (eg, age, hypertension, serum LDL-cholesterol) are recognized as producing a graded increase in risk (",
"    <a class=\"graphic graphic_figure graphicRef55353 \" href=\"mobipreview.htm?24/31/25086\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39048/abstract/7\">",
"     7",
"    </a>",
"    ]. These models estimate risk of an individual over the next ten years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Framingham risk scores",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first Framingham risk score (1998) incorporated age, gender, LDL-cholesterol, HDL-cholesterol, blood pressure (including whether the patient is treated or not), diabetes, and smoking to derive an estimated risk of developing CHD (MI, coronary death, and angina) within 10 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39048/abstract/10\">",
"     10",
"    </a>",
"    ]. A validation study found that the Framingham CHD predictor performed well for prediction of CHD events in black and white women and men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39048/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Framingham risk score was modified (2002) by ATP III for use in their recommendations for screening for and treatment of dyslipidemia (",
"    <a class=\"graphic graphic_table graphicRef64978 graphicRef76742 \" href=\"mobipreview.htm?30/1/30751\">",
"     table 1A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39048/abstract/1\">",
"     1",
"    </a>",
"    ]. The modifications include elimination of diabetes from the algorithm, since it was considered to be a CHD equivalent, broadening of the age range, and inclusion of hypertension treatment and age-specific points for smoking and total cholesterol.",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     Framingham/ATP",
"    </span>",
"    III criteria were used to estimate the distribution of CHD risk in the United States in an analysis of data from NHANES III among 11,611 patients (age 20 to 79 years) without self-reported CHD, stroke, peripheral artery disease, or diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39048/abstract/12\">",
"     12",
"    </a>",
"    ]. The 10-year CHD risk results and the proportion of patients in each category were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low risk (&lt;10 percent CHD risk at 10 years) &ndash; 82 percent of patients",
"     </li>",
"     <li>",
"      Intermediate risk (10 to 20 percent) &ndash; 16 percent",
"     </li>",
"     <li>",
"      High risk (&gt;20 percent) &ndash; 3 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Not surprisingly, the frequency of high-risk patients increased with age and was greater in men than women.",
"   </p>",
"   <p>",
"    The Framingham risk scores discussed above do not include all of the potential adverse consequences of atherosclerosis, such as stroke, transient ischemic attack, claudication and heart failure. These patient-important vascular outcomes were included in the development of the 2008 Framingham general cardiovascular risk score, which was shown to have reliable predictive ability (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/63/10226?source=see_link\">",
"     calculator 1",
"    </a>",
"    and",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?43/28/44482?source=see_link\">",
"     calculator 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39048/abstract/13\">",
"     13",
"    </a>",
"    ]. The estimated risk of developing a cardiovascular event will be higher with this risk score than with those that predict only CHD events.",
"   </p>",
"   <p>",
"    Several studies have suggested that the Framingham criteria either overestimate or underestimate the risk of initial CHD events in other populations such as Japanese American and Hispanic men, in Native American women, in European and Asian populations as well as patients older than age 85 years, and in African American men and women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39048/abstract/11,14-22\">",
"     11,14-22",
"    </a>",
"    ]. These differences are partly explained by the research methods used, adjudication procedures, and time intervals studied. Multiple models, including SCORE and QRISK2, have been developed in an attempt to provide better predictive accuracy for European patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39048/abstract/17-21,23,24\">",
"     17-21,23,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     SCORE",
"    </span>",
"    &nbsp;&mdash;&nbsp;SCORE, which is recommended in the 2007 European Society of Cardiology guidelines on cardiovascular disease prevention in clinical practice, included data on more than 200,000 patients pooled from cohort studies in 12 European countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39048/abstract/17,21\">",
"     17,21",
"    </a>",
"    ]. Variables incorporated into the model included age, gender, systolic blood pressure, total cholesterol, HDL cholesterol, and cigarette smoking. The mean follow-up was 13 years, with the end point being cardiovascular death. A unique aspect of SCORE is that separate risk scores were calculated for high-risk and low-risk regions of Europe. The predictive value of SCORE was high in each component study cohort.",
"   </p>",
"   <p>",
"    SCORE differs from the earlier Framingham risk models (and others) in two important ways: it estimates the 10-year risk of any first fatal atherosclerotic event (eg, stroke or ruptured abdominal aneurysm), not just coronary heart disease-related deaths, and it estimates cardiovascular disease mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     QRISK and QRISK2",
"    </span>",
"    &nbsp;&mdash;&nbsp;The QRISK and the updated QRISK2 algorithms were developed to predict cardiovascular risk in patients from different ethnic groups living in England and Wales [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39048/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. The QRISK2 algorithm included risk predictors used in the modified",
"    <span class=\"nowrap\">",
"     Framingham/ATP",
"    </span>",
"    III model, as well as ethnicity, socioeconomic status, family history, and other medical variables such as diabetes, chronic renal disease, atrial fibrillation, and rheumatoid arthritis. QRISK2 more accurately identified those at risk than the modified",
"    <span class=\"nowrap\">",
"     Framingham/ATP",
"    </span>",
"    III model in this population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Reynolds risk score",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Reynolds risk score for men was developed from a prospective cohort of over 10,000 American men without diabetes and is similar to a model developed for women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39048/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/57/28570?source=see_link&amp;anchor=H29#H29\">",
"     \"Determinants and management of cardiovascular risk in women\", section on 'Reynolds risk score'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It differs from other models in the following ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In addition to MI, coronary revascularization and cardiovascular death, the patient important outcome of stroke is counted.",
"     </li>",
"     <li>",
"      It includes all the variables in the Framingham risk scores as well as the level of high-sensitivity C-reactive protein (CRP) and parental history of MI before age 60. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/0/27658?source=see_link\">",
"       \"C-reactive protein in cardiovascular disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Using internal validation, the Reynolds risk score outperformed the",
"    <span class=\"nowrap\">",
"     Framingham/ATP",
"    </span>",
"    III model in predictive accuracy model even when stroke was removed as an endpoint.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Limitations of current risk models",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following represent important limitations to current risk models:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Risk assessments that stratify patients according to the number of defined risk factors can identify high-risk persons, but they tend to falsely reassure persons deemed to be at low risk who may have multiple marginal abnormalities (",
"      <a class=\"graphic graphic_figure graphicRef69663 \" href=\"mobipreview.htm?25/2/25647\">",
"       figure 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/8/39048/abstract/3,5\">",
"       3,5",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Borderline risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk models identify patients who are more or less likely to develop cardiovascular disease within a defined period (eg, ten years for CHD in the Framingham model). Patients with less than a 10 percent likelihood are considered at low risk. However, this approach does not consider lifetime risk, which might be substantially higher and amenable to aggressive risk factor reduction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/8/39048/abstract/3,26-28\">",
"       3,26-28",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Lifetime risk'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Many of the current models were derived from cohort studies that included persons not on medications. The more frequent use of cholesterol lowering and antihypertensive medications in recent years and assessment of factors that might alter risk for a vascular event has become more complicated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/8/39048/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The severity and frequency of the first vascular disease event has decreased over the last 40 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/8/39048/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The relative effects of traditional risk factors differ according the vascular disease outcome being evaluated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/8/39048/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some risk models do not include patient important cardiovascular disease outcomes such as stroke, heart failure, or development of symptomatic peripheral artery disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Potential improvements to the risk models",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two potential ways to enhance the estimation of cardiovascular risk include the addition of laboratory tests to the models or to estimate lifetime risk in individuals with a low 10-year risk (0-10 percent). (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Lifetime risk'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The addition of laboratory testing to the traditional risk factors has been suggested by some [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39048/abstract/30-32\">",
"     30-32",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39048/abstract/33\">",
"     33",
"    </a>",
"    ], as a way to overcome the limitations discussed above. Biomarkers (such as hs-CRP as used in the Reynolds risk score above), imaging tests (such as coronary calcium score or carotid intima-media thickness), exercise testing or screening for novel genotypes are examples. Incorporation of new biomarker information is best accomplished with carefully designed studies that evaluate the utility of new measures with estimates of discrimination, need for calibration and whether recalibration is appropriate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39048/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. With the exception of the latter, these topics are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34665?source=see_link&amp;anchor=H5#H5\">",
"     \"Screening for cardiovascular risk with C-reactive protein\", section on 'Association with established risk factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/50/26409?source=see_link\">",
"     \"Screening for coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/44/30410?source=see_link&amp;anchor=H11#H11\">",
"     \"Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography\", section on 'CAC and prognosis in asymptomatic patients'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/37/34394?source=see_link&amp;anchor=H10122160#H10122160\">",
"     \"Overview of the possible risk factors for cardiovascular disease\", section on 'Arterial intima-media thickness'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potential benefit of adding a multiple biomarker score to a traditional risk-factor model has been evaluated and shows promise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39048/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Estimation of lifetime risk in lower-risk patients (0 to10 percent ten year risk) has been proposed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39048/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Lifetime risk'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Lifetime risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lifetime risk of developing cardiovascular disease (CVD) has been assessed in a variety of cohorts as well as a meta-analysis of 18 cohorts involving over 257,000 men and women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39048/abstract/3,37\">",
"     3,37",
"    </a>",
"    ]. Data from the Framingham Heart Study were used to assess long-term outcomes according to risk status in individuals at age 50 without known cardiovascular disease, and the authors of the meta-analysis assessed long-term outcomes for participants at ages 45, 55, 65, and 75 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39048/abstract/3,37\">",
"     3,37",
"    </a>",
"    ]. Risk factors within the participants were defined as follows:",
"   </p>",
"   <p>",
"    Optimal risk factors:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Total cholesterol &lt;180",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (4.7",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Untreated blood pressure",
"      <span class=\"nowrap\">",
"       &lt;120/&lt;80",
"      </span>",
"      mmHg",
"     </li>",
"     <li>",
"      Non-smoker",
"     </li>",
"     <li>",
"      No diabetes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Not optimal risk factors (among non-smokers without diabetes):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Total cholesterol 180 to 199",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (4.8 to 5.1",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Untreated systolic blood pressure 120 to 139 mmHg or diastolic blood pressure 80 to 89 mmHg",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Elevated risk factors (among non-smokers without diabetes):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Total cholesterol 200 to 239",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (5.2 to 6.1",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Untreated systolic blood pressure 140 to 159 mmHg or diastolic blood pressure 90 to 99 mmHg",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Major risk factors:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Treated hyperlipidemia or total cholesterol &ge;240",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (6.2",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Treated hypertension or untreated systolic pressure &ge;160 mmHg or diastolic pressure &ge;100 mmHg",
"     </li>",
"     <li>",
"      Current smoking",
"     </li>",
"     <li>",
"      Diabetes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following findings were noted in the Framingham study (",
"    <a class=\"graphic graphic_figure graphicRef69663 \" href=\"mobipreview.htm?25/2/25647\">",
"     figure 1",
"    </a>",
"    ) and confirmed in the meta-analysis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The lifetime risk of CVD increased progressively with the number and intensity of risk factors.",
"     </li>",
"     <li>",
"      Participants with optimal risk factors had, when compared to those with &ge;2 major risk factors, markedly lower lifetime risks of CVD at all age levels. As an example, among persons 45 years of age, those with all optimal risk factors had a lifetime risk of developing CVD of 4.1 percent compared with a 30.7 percent lifetime risk for those with two or more major risk factors.",
"     </li>",
"     <li>",
"      Although the difference was less pronounced, the lifetime cardiovascular risk was significantly lower in participants with optimal risk factors compared to those with &ge;1 not optimal risk factor. As an example, among persons 65 years of age, those with all optimal risk factors had a lifetime risk of developing CVD of 12.4 percent compared with a 25 percent lifetime risk for those with one or more not optimal risk factors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many individuals with a low 10-year risk, as calculated using the above models, will still have a high lifetime risk as the largest driver of risk in most risk calculators is age. This was modeled in a study of nearly 4000 individuals less than 50 years of age in the MESA and CARDIA studies in whom the burden of atherosclerosis was evaluated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39048/abstract/30\">",
"     30",
"    </a>",
"    ]. Ten-year and lifetime risks were assigned to each individual and patients were then divided into three groups: low 10-year (&lt;10 percent) and low-lifetime (&lt;39 percent) risk; low 10-year and high-lifetime (&ge;39 percent) risk; and high 10-year risk or diabetes. The groups were then compared with regard to both their baseline levels of subclinical atherosclerosis (carotid intima-media thickness or coronary artery calcium [CAC] score) and its progression. The group with a low 10-year and high-lifetime risk had both a significantly greater burden of baseline subclinical atherosclerosis as well as a significantly higher rate of CAC progression than the group with a low 10-year and low-lifetime risk. As expected, outcomes in these two groups were significantly better than those in the high 10-year risk group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Exercise testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise capacity, ST segment depression, attainment of target heart rate, and heart rate recovery, which are prognostic variables on exercise stress testing, may enhance the predictive value of the Framingham risk score and of the SCORE project. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/50/26409?source=see_link&amp;anchor=H10#H10\">",
"     \"Screening for coronary heart disease\", section on 'High-risk patients'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Risk model summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vascular disease risk models presented above may vary in terms of population studied, risk factors included, and outcomes counted. Health-care providers need to decide which model best fits their populations who are at risk to develop these vascular events. For clinicians, particularly those in the United States who follow recommendations made in the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III), we recommend use of the",
"    <span class=\"nowrap\">",
"     Framingham/ATP",
"    </span>",
"    III risk score [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39048/abstract/1\">",
"     1",
"    </a>",
"    ]",
"    <strong>",
"     .",
"    </strong>",
"    It is anticipated that the NHLBI ATP4 guidelines will update this prediction algorithm. For other clinicians, we suggest following recommendations made by regional, national, and international advisory groups. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/32/14856?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of lipids (including hypercholesterolemia) in primary prevention\", section on 'Deciding whom to treat'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     CLINICAL USE OF RISK ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estimation of cardiovascular risk using multivariate risk profiling was strongly endorsed by an",
"    <span class=\"nowrap\">",
"     AHA/ACC",
"    </span>",
"    Scientific Statement in 1999 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39048/abstract/38\">",
"     38",
"    </a>",
"    ]. The appropriate application of risk score assessment to patient management includes the following considerations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The ATP III recommendations for the treatment of hyperlipidemia are influenced by the coexistence of CHD and the number of cardiac risk factors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/8/39048/abstract/1\">",
"       1",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/32/14856?source=see_link&amp;anchor=H6#H6\">",
"       \"Treatment of lipids (including hypercholesterolemia) in primary prevention\", section on 'Deciding whom to treat'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The goal blood pressure in patients at high risk for the development of CVD is controversial, with some experts suggesting use of risk models and others not. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29737?source=see_link\">",
"       \"Blood pressure management in patients with atherosclerotic cardiovascular disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      It has been suggested that determination of a patient's calculated cardiovascular risk profile, and presentation of the results to the patient, may improve compliance with risk reduction measures (",
"      <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/63/10226?source=see_link\">",
"       calculator 1",
"      </a>",
"      and",
"      <a class=\"calc calc_professional\" href=\"mobipreview.htm?43/28/44482?source=see_link\">",
"       calculator 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/8/39048/abstract/38\">",
"       38",
"      </a>",
"      ]. However, no data are available to confirm this assertion.",
"     </li>",
"     <li>",
"      It has also been suggested that determination of a patient's risk profile should improve clinician recognition and treatment of modifiable risk factors. Because under-recognition of hypertension, hyperlipidemia, and other risk factors is a common problem, routine risk assessment may be an effective approach to improving their identification.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The estimation of total cardiovascular disease and coronary heart disease event risk is useful in individuals at increased risk both for patient education and for deciding when to initiate preventative strategies such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and statins.",
"   </p>",
"   <p>",
"    Multiple risk models have been developed and have been validated predominantly in populations similar to those from which they were derived. We suggest selecting a risk prediction model appropriate for the patient(s) under consideration when possible. We also believe that, for the purpose of deciding on whether to start therapy with either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or statin, risk models that predict MI, revascularization, cardiovascular death, and cerebrovascular events, but not claudication, be used.",
"   </p>",
"   <p>",
"    It must be kept in mind that the predicted risk may differ between two risk predication models, particularly if one model predicts coronary heart disease risk, while another predicts total cardiovascular risk. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Risk model summary'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39048/abstract/1\">",
"      National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39048/abstract/2\">",
"      Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. Lancet 1999; 353:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39048/abstract/3\">",
"      Lloyd-Jones DM, Leip EP, Larson MG, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 2006; 113:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39048/abstract/4\">",
"      Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39048/abstract/5\">",
"      Vasan RS, Sullivan LM, Wilson PW, et al. Relative importance of borderline and elevated levels of coronary heart disease risk factors. Ann Intern Med 2005; 142:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39048/abstract/6\">",
"      Stamler J, Stamler R, Neaton JD, et al. Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy: findings for 5 large cohorts of young adult and middle-aged men and women. JAMA 1999; 282:2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39048/abstract/7\">",
"      Jackson R, Lawes CM, Bennett DA, et al. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet 2005; 365:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39048/abstract/8\">",
"      Lowe LP, Greenland P, Ruth KJ, et al. Impact of major cardiovascular disease risk factors, particularly in combination, on 22-year mortality in women and men. Arch Intern Med 1998; 158:2007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39048/abstract/9\">",
"      Asia Pacific Cohort Studies Collaboration. Joint effects of systolic blood pressure and serum cholesterol on cardiovascular disease in the Asia Pacific region. Circulation 2005; 112:3384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39048/abstract/10\">",
"      Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97:1837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39048/abstract/11\">",
"      D'Agostino RB Sr, Grundy S, Sullivan LM, et al. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001; 286:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39048/abstract/12\">",
"      Ford ES, Giles WH, Mokdad AH. The distribution of 10-Year risk for coronary heart disease among US adults: findings from the National Health and Nutrition Examination Survey III. J Am Coll Cardiol 2004; 43:1791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39048/abstract/13\">",
"      D'Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008; 117:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39048/abstract/14\">",
"      Bastuji-Garin S, Deverly A, Moyse D, et al. The Framingham prediction rule is not valid in a European population of treated hypertensive patients. J Hypertens 2002; 20:1973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39048/abstract/15\">",
"      Brindle P, Emberson J, Lampe F, et al. Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. BMJ 2003; 327:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39048/abstract/16\">",
"      Liu J, Hong Y, D'Agostino RB Sr, et al. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. JAMA 2004; 291:2591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39048/abstract/17\">",
"      Conroy RM, Py&ouml;r&auml;l&auml; K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39048/abstract/18\">",
"      Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular M&uuml;nster (PROCAM) study. Circulation 2002; 105:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39048/abstract/19\">",
"      Joint British recommendations on prevention of coronary heart disease in clinical practice: summary. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, British Diabetic Association. BMJ 2000; 320:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39048/abstract/20\">",
"      Wallis EJ, Ramsay LE, Ul Haq I, et al. Coronary and cardiovascular risk estimation for primary prevention: validation of a new Sheffield table in the 1995 Scottish health survey population. BMJ 2000; 320:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39048/abstract/21\">",
"      Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur Heart J 2007; 28:2375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39048/abstract/22\">",
"      Sacco RL, Khatri M, Rundek T, et al. Improving global vascular risk prediction with behavioral and anthropometric factors. The multiethnic NOMAS (Northern Manhattan Cohort Study). J Am Coll Cardiol 2009; 54:2303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39048/abstract/23\">",
"      Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ 2007; 335:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39048/abstract/24\">",
"      Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 2008; 336:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39048/abstract/25\">",
"      Ridker PM, Paynter NP, Rifai N, et al. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation 2008; 118:2243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39048/abstract/26\">",
"      Ridker PM, Cook N. Should age and time be eliminated from cardiovascular risk prediction models? Rationale for the creation of a new national risk detection program. Circulation 2005; 111:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39048/abstract/27\">",
"      Vasan RS, D'Agostino RB Sr. Age and time need not and should not be eliminated from the coronary risk prediction models. Circulation 2005; 111:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39048/abstract/28\">",
"      Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285:2486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39048/abstract/29\">",
"      Wilson PW. Progressing from risk factors to omics. Circ Cardiovasc Genet 2008; 1:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39048/abstract/30\">",
"      Berry JD, Liu K, Folsom AR, et al. Prevalence and progression of subclinical atherosclerosis in younger adults with low short-term but high lifetime estimated risk for cardiovascular disease: the coronary artery risk development in young adults study and multi-ethnic study of atherosclerosis. Circulation 2009; 119:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39048/abstract/31\">",
"      Nambi V, Ballantyne CM. \"Risky business\": ten years is not a lifetime. Circulation 2009; 119:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39048/abstract/32\">",
"      Blankenberg S, Zeller T, Saarela O, et al. Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project. Circulation 2010; 121:2388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39048/abstract/33\">",
"      Scott IA. Evaluating cardiovascular risk assessment for asymptomatic people. BMJ 2009; 338:a2844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39048/abstract/34\">",
"      Tzoulaki I, Liberopoulos G, Ioannidis JP. Assessment of claims of improved prediction beyond the Framingham risk score. JAMA 2009; 302:2345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39048/abstract/35\">",
"      Wilson PW. Challenges to improve coronary heart disease risk assessment. JAMA 2009; 302:2369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39048/abstract/36\">",
"      Nambi V, Chambless L, Folsom AR, et al. Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study. J Am Coll Cardiol 2010; 55:1600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39048/abstract/37\">",
"      Berry JD, Dyer A, Cai X, et al. Lifetime risks of cardiovascular disease. N Engl J Med 2012; 366:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39048/abstract/38\">",
"      Grundy SM, Pasternak R, Greenland P, et al. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 1999; 100:1481.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1546 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-2.133.93.82-84A455F99E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_8_39048=[""].join("\n");
var outline_f38_8_39048=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      WHO SHOULD UNDERGO RISK ESTIMATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Patients already at high risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Patients at increased risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PREDICTIVE VALUE OF RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Borderline risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Multiple risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Multivariate risk models",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Framingham risk scores",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - SCORE",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - QRISK and QRISK2",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Reynolds risk score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Limitations of current risk models",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Potential improvements to the risk models",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Lifetime risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Exercise testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Risk model summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      CLINICAL USE OF RISK ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1546\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1546|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/2/25647\" title=\"figure 1\">",
"      Lifetime risk CVD at age 50",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/31/25086\" title=\"figure 2\">",
"      Number of risk factors and CVD risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1546|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/61/10206\" title=\"table 1A\">",
"      Framingham ATPIII score men",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/17/8478\" title=\"table 1B\">",
"      Framingham ATPIII score women",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/63/10226?source=related_link\" title=\"calculator 1\">",
"      Calculator: Framingham 10 year risk of general cardiovascular disease in women (2008 paper)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?43/28/44482?source=related_link\" title=\"calculator 2\">",
"      Calculator: Framingham 10 year risk of general cardiovascular disease in men (2008 paper)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37066?source=related_link\">",
"      Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29737?source=related_link\">",
"      Blood pressure management in patients with atherosclerotic cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/0/27658?source=related_link\">",
"      C-reactive protein in cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34298?source=related_link\">",
"      Chronic kidney disease and coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/57/28570?source=related_link\">",
"      Determinants and management of cardiovascular risk in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/44/30410?source=related_link\">",
"      Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/25/37274?source=related_link\">",
"      Inherited disorders of LDL-cholesterol metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/37/34394?source=related_link\">",
"      Overview of the possible risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=related_link\">",
"      Overview of the risk equivalents and established risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34665?source=related_link\">",
"      Screening for cardiovascular risk with C-reactive protein",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/50/26409?source=related_link\">",
"      Screening for coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/32/14856?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in primary prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_8_39049="Subcutaneous immunotherapy for allergic disease: Indications and efficacy";
var content_f38_8_39049=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Subcutaneous immunotherapy for allergic disease: Indications and efficacy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/8/39049/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/8/39049/contributors\">",
"     Philip S Norman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/8/39049/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/8/39049/contributors\">",
"     Peter S Creticos, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/8/39049/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/8/39049/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/8/39049/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunotherapy for allergic disease involves the gradual administration of increasing amounts of allergen to which the patient is sensitive, for the purpose of modulating the untoward immune response to that allergen and alleviating allergic symptoms. Immunotherapy is currently the only treatment that alters the abnormal immune response underlying allergic disease.",
"   </p>",
"   <p>",
"    Subcutaneous injection immunotherapy (SCIT) is the established form of this treatment. Oral forms of immunotherapy are not discussed in this topic review. The indications and efficacy for SCIT will be reviewed here. The therapeutic mechanisms of SCIT and the preparation of allergen extracts are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/27/27062?source=see_link\">",
"     \"Subcutaneous immunotherapy for allergic disease: Therapeutic mechanisms\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/49/15127?source=see_link\">",
"     \"An overview of allergen extracts\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indications for SCIT with aeroallergens (ie, inhaled allergens, such as pollens, animal danders, etc) will be reviewed here. There are several questions that should be addressed to determine if SCIT is appropriate for a specific patient. The indications for venom immunotherapy for treatment of stinging insect hypersensitivity are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/34/16936?source=see_link\">",
"     \"Hymenoptera venom immunotherapy: Efficacy, indications, and mechanism of action\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/51/7994?source=see_link&amp;anchor=H26#H26\">",
"     \"Stings of imported fire ants: Clinical manifestations, diagnosis, and treatment\", section on 'Venom immunotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Does the patient have a disorder that responds to immunotherapy?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subcutaneous allergen immunotherapy (SCIT) using preparations of aeroallergens may be indicated in the management of the following disorders:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Allergic rhinitis, with or without conjunctivitis, including:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Seasonal allergic",
"      <span class=\"nowrap\">",
"       rhinitis/conjunctivitis",
"      </span>",
"     </li>",
"     <li>",
"      Perennial allergic",
"      <span class=\"nowrap\">",
"       rhinitis/conjunctivitis",
"      </span>",
"     </li>",
"     <li>",
"      Seasonal + perennial allergic",
"      <span class=\"nowrap\">",
"       rhinitis/conjunctivitis",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Allergic asthma:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Seasonal allergic asthma",
"     </li>",
"     <li>",
"      Perennial allergic asthma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Allergic rhinitis + allergic asthma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with both asthma and allergic rhinitis derive particular benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39049/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Atopic dermatitis may respond to SCIT if the patient is sensitized to inhalant allergens, although this conclusion is based on a small number of studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39049/abstract/4\">",
"     4",
"    </a>",
"    ] of dust-mite allergic patients, including one randomized trial of 51 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39049/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Negative studies also exist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39049/abstract/7\">",
"     7",
"    </a>",
"    ]. The impact of immunotherapy on atopic dermatitis in patients sensitized to pollens or other aeroallergens has not been studied. Thus, the use of SCIT to treat atopic dermatitis requires careful observation of the patient&rsquo;s clinical status, especially during the buildup phase of treatment.",
"   </p>",
"   <p>",
"    In contrast, the utility of SCIT in the treatment of patients with chronic sinus disease or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    -exacerbated respiratory disease, who also have a component to allergic rhinitis or asthma, has not yet been established. Finally, there are other allergic diseases for which SCIT is rarely employed. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Disorders that are not treated with immunotherapy'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/4/30794?source=see_link\">",
"     \"Management of chronic rhinosinusitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/0/39944?source=see_link\">",
"     \"Aspirin exacerbated respiratory disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Is the allergen(s) clinically important?",
"    </span>",
"    &nbsp;&mdash;&nbsp;A patient is a candidate for allergen immunotherapy ONLY if it has been established that there is a clinically important allergic component to their disease. For patients with the disorders listed above, clinical relevance is established by the presence of BOTH of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptoms upon natural exposure to the allergen AND",
"     </li>",
"     <li>",
"      The presence of specific IgE to the allergen in question, demonstrated either through allergen skin testing or serum tests for allergen-specific IgE",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Have other measures been maximized?",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should ensure that the patient has maximized environmental control measures and is on an optimal medication regimen. If the patient has not been compliant with medications, the reasons for this should be explored in depth. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/48/34569?source=see_link\">",
"     \"Allergen avoidance in the treatment of asthma and allergic rhinitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    SCIT is usually recommended for the treatment of allergic respiratory disease only after a period of pharmacologic management and observation. Medications are relatively easy for most patients to use and, when effective, provide relief more rapidly than immunotherapy. A period of observation also allows the clinician to monitor the patient's disease over time, which is particularly important for adults with new-onset asthma, in whom the differential should include other pulmonary and systemic disorders that may present with respiratory symptoms [eg, gastroesophageal reflux disease, Churg-Strauss vasculitis, granulomatosis with polyangiitis (Wegener&rsquo;s)]. These conditions should be considered first before initiating SCIT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Is current management suboptimal?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the above questions have been addressed, it is appropriate to consider a trial of allergen immunotherapy in patients with significant allergic disease, for whom management is suboptimal for any of the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An inadequate or partial response to environmental control and pharmacotherapy",
"     </li>",
"     <li>",
"      Persistent symptoms on a seasonal",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      perennial basis",
"     </li>",
"     <li>",
"      Side effects related to medication use",
"     </li>",
"     <li>",
"      Cost burden associated with chronic medication use",
"     </li>",
"     <li>",
"      Non-compliance with maintenance medication regimen",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The indications for SCIT are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef78962 \" href=\"mobipreview.htm?17/6/17515\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies examining the efficacy of SCIT are confounded by several factors, including differing approaches to administration around the world and evolving definitions of effective allergen doses. The optimal approach has not been identified. However, despite these variables, the overall efficacy of SCIT in treating allergic disease is supported by an extensive body of evidence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Variables in the practice of SCIT",
"    </span>",
"    &nbsp;&mdash;&nbsp;One important variable in the administration of SCIT is the use of a single or multiple allergens. Specifically,",
"    <span class=\"nowrap\">",
"     allergy/immunology",
"    </span>",
"    specialists in the United States generally administer mixtures of all of the major allergens (or a representative of each group of allergens) to which the patient has been shown to be sensitive. In contrast, it is common in Europe to administer only the one or two allergens that appear to cause the most symptoms for that individual patient, under the assumption that immunizing the patient against one allergen can reduce overall allergic reactivity. The question of whether immunotherapy using a single allergen can confer cross-desensitization to unrelated allergens has been addressed directly in a small number of trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39049/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. For example, in a randomized trial of 20 adults allergic to both dust mite and timothy grass pollen, subjects underwent three years of SCIT with one allergen or the other [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39049/abstract/8\">",
"     8",
"    </a>",
"    ]. Both sensitivity during conjunctival challenge and immunologic changes demonstrated that immunotherapy was allergen-specific, although there was significant loss to follow-up and small numbers of patients completing the trial.",
"   </p>",
"   <p>",
"    A related issue is whether multiple allergens can be given simultaneously without compromising efficacy by diluting any single allergen. The effectiveness of using multiple allergens has not been extensively analyzed, since most of the studies of SCIT efficacy have used a single allergen. One literature review of 11 trials of SCIT found that the use of either one or two allergens was effective, but controlled trials involving higher numbers of allergens are lacking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39049/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The dose of allergen administered in immunotherapy is another important variable. It has now been established there is an effective dose range for most allergens, and a coordinated effort has been underway internationally to define that range for each of the important aeroallergens, although the process is far from complete. Many of the studies of efficacy were performed using lower doses of allergen than those currently recommended.",
"   </p>",
"   <p>",
"    Finally, there are differences in the preparation and processing of allergens worldwide, including the use of allergoids and depot preparations. The preparation of allergen extracts is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/49/15127?source=see_link\">",
"     \"An overview of allergen extracts\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Allergic rhinitis and conjunctivitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of randomized trials have demonstrated that allergen immunotherapy with specified allergens is efficacious in allergic rhinitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39049/abstract/13-27\">",
"     13-27",
"    </a>",
"    ]. These allergens are birch, mountain cedar, grass, ragweed, and parietaria pollens, cat, dog, Alternaria and Cladosporium molds, cockroach, and house dust mites.",
"   </p>",
"   <p>",
"    A 2007 meta-analysis evaluated 51 randomized trials published between 1950 and 2006 that assessed the efficacy of immunotherapy with pollen vaccines in the treatment of 2871 adults and children with allergic rhinitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39049/abstract/28\">",
"     28",
"    </a>",
"    ]. The duration of immunotherapy ranged from three days to three years, with an average number of 18 injections per subject. Patients receiving immunotherapy experienced a significant reduction (expressed as standard mean difference) in both symptom scores and medication use (-0.73 and -0.57, respectively).",
"   </p>",
"   <p>",
"    The magnitude of effect of SCIT on allergic rhinitis was assessed in a study of patients with allergic rhinoconjunctivitis, some of whom also had allergic asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39049/abstract/29\">",
"     29",
"    </a>",
"    ]. In this study, SCIT was approximately equivalent in efficacy to glucocorticoid nasal sprays. It is probable that the two therapies together are additive and that the combination of a glucocorticoid nasal spray and SCIT represents the most effective medical management of allergic rhinitis available, although SCIT has not been compared to other therapies in head-to-head trials.",
"   </p>",
"   <p>",
"    Most studies of the effect of immunotherapy on allergic conjunctivitis were performed in patients with concomitant rhinitis. However, one review examined the effects of SCIT on ocular allergy by analyzing 15 studies of varying rigor that documented ocular symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39049/abstract/30\">",
"     30",
"    </a>",
"    ]. All but three showed benefit in terms of reduced ocular symptoms scores, medication use, or decreased reactivity upon conjunctival provocation challenges.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Allergic asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Double-blind placebo controlled studies of specific allergens (short ragweed, mixed grass, D. pteronyssinus, Cladosporium, cat, or dog) have shown significant benefit in carefully selected patients with allergic asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39049/abstract/13,17,31,32\">",
"     13,17,31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several meta-analyses support the efficacy of SCIT in allergic asthma, although meta-analyses are prone to bias from non publication of negative studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39049/abstract/25,33,34\">",
"     25,33,34",
"    </a>",
"    ]. One included 75 trials involving 3188 asthmatic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39049/abstract/34\">",
"     34",
"    </a>",
"    ]. There were 36 trials of immunotherapy for house mite allergy, 20 for pollen allergy, 10 for animal dander allergy, 2 for Cladosporium mold allergy, and 6 trials using multiple allergens. Overall, there was a significant reduction in asthma symptoms and medication use, and improvement in bronchial hyperreactivity. For all allergens combined, the standardized mean difference in symptoms scores was -0.72 (95% CI -0.99 to -0.44), although it was not possible to quantitate the overall magnitude of effect in any greater detail.",
"   </p>",
"   <p>",
"    Part of the difficulty in assessing the benefit of immunotherapy in allergic respiratory disease has been the reliance on subjective measures of effect. Two carefully-designed trials are considered to have established the beneficial effect of SCIT in the treatment of allergic asthma and included objective outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39049/abstract/17,32\">",
"     17,32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first of these, an NIH-sponsored clinical trial, evaluated the safety and efficacy of immunotherapy in ragweed (RW)-induced seasonal asthma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/8/39049/abstract/32\">",
"       32",
"      </a>",
"      ]. In this randomized trial, patients were screened for eligibility based on documentation of asthma symptoms, medication usage, and worsening lung function (as measured by drop in peak flow) during an initial observation season. Seventy seven (77) patients met the defined criteria to subsequently be randomized to treatment with either RW immunotherapy or placebo, and during the next two RW seasons were monitored by the same clinical indices and underwent provocative challenges with allergen and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/32/10756?source=see_link\">",
"       methacholine",
"      </a>",
"      .",
"      <br/>",
"      <br/>",
"      The study demonstrated evidence of clinical benefit when the combined clinical parameters were statistically analyzed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/8/39049/abstract/32\">",
"       32",
"      </a>",
"      ]. Asthma symptoms improved in both treatment groups through the two seasons of \"active\" treatment, however, the placebo-treated patients required significantly more medication to control their asthma symptoms during the first year of SCIT. Furthermore, PEFR measurements in the RW-immunized patients improved in each treatment year and were significantly superior to placebo treatment in the second year of treatment.",
"      <br/>",
"      <br/>",
"      In addition, the RW-immunized group had improvement in hay fever symptoms, decreased skin provocation sensitivity to RW, reduced bronchial sensitivity upon challenge with RW, and immunologic changes characteristic of successful immunization (treatment-induced increase in \"protective\" IgG antibodies paralleled by suppression of the typical seasonal increase in ragweed-specific IgE) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/8/39049/abstract/32\">",
"       32",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/27/27062?source=see_link\">",
"       \"Subcutaneous immunotherapy for allergic disease: Therapeutic mechanisms\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Overall, this clinical study demonstrated limited but clinically objective evidence that SCIT could favorably improve asthma.",
"     </li>",
"     <li>",
"      A second randomized study in England of patients with milder asthma assessed the effects of two years of grass pollen SCIT or placebo SCIT in 44 patients with severe summer hay fever, of whom 36 had seasonal asthma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/8/39049/abstract/17\">",
"       17",
"      </a>",
"      ]. Medication use and seasonal chest symptoms were significantly lower in the grass pollen group, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/32/10756?source=see_link\">",
"       methacholine",
"      </a>",
"      -induced airway hyperreactivity during season was significantly improved.",
"     </li>",
"     <li>",
"      An open-label randomized trial of 65 children with milder asthma and sensitization to dust mite evaluated the effect of two years of SCIT with a modified allergen (dust mite allergoid) on the ability to reduce the amount of inhaled glucocorticoids required to control a patient&rsquo;s asthma symptoms, as determined by objective parameters [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/8/39049/abstract/35\">",
"       35",
"      </a>",
"      ]. Subjects in the SCIT group received a dust mite allergoid preparation, while others continued medical therapy with inhaled",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/45/39632?source=see_link\">",
"       fluticasone",
"      </a>",
"      . Patients receiving both SCIT and fluticasone were able to reduce their fluticasone dose significantly more than patients receiving fluticasone alone (54 versus 29 percent). Nearly one-half of the SCIT group was able to reduce the dose of inhaled glucocorticoid by an average of two or more treatment steps (according to current asthma guidelines), compared to 19 percent of the control group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon the collective body of evidence, SCIT was added to the National Asthma Education and Prevention Program guidelines for asthma management in 2007, and is recommended as an adjunct to standard pharmacotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39049/abstract/36\">",
"     36",
"    </a>",
"    ]. However, recognizing the heterogeneity of asthma, it remains difficult to predict the degree of improvement in clinical asthma symptoms that will be achieved with SCIT in a given individual patient. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/7/26745?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment of moderate persistent asthma in adolescents and adults\", section on 'Immunotherapy for allergic asthma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Careful selection of patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The studies reviewed previously reflect the belief of many experts that proper selection of patients is crucial for clinical success [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39049/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Asthma triggers vary significantly among individuals, and allergen exposure may be just one of several triggers that are important for a given patient. Thus, patients for whom allergen exposure is clearly an important trigger are more likely to experience meaningful benefit. As examples, a veterinary worker with cat allergy and work-aggravated asthma or a high school athlete with significant asthma during pollen seasons would be excellent candidates for SCIT. In contrast, SCIT might not produce clinically meaningful improvement in a patient with asthma that is most often triggered by viral illnesses, but who also has perennial allergies.",
"     </li>",
"     <li>",
"      The duration of allergic disease may be an important factor in predicting the success of SCIT. New-onset allergic asthma may be more responsive to SCIT than long-standing disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/8/39049/abstract/37\">",
"       37",
"      </a>",
"      ]. For example, a middle-aged patient who developed asthma recently after acquiring pets may be more responsive to SCIT than someone of the same age with sensitivity to the same allergens, but with lifelong asthma.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Effective allergens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effectiveness of SCIT for the treatment of inhalant allergy (allergic",
"    <span class=\"nowrap\">",
"     rhinitis/conjunctivitis",
"    </span>",
"    and allergic asthma) has been demonstrated by placebo-controlled studies for the following allergens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39049/abstract/13-15,28,39,40\">",
"     13-15,28,39,40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Tree pollens (birch and mountain cedar)",
"     </li>",
"     <li>",
"      Grass pollens (timothy and grass mixes)",
"     </li>",
"     <li>",
"      Weed pollens (ragweed and Parietaria)",
"     </li>",
"     <li>",
"      Animal danders (cat and dog)",
"     </li>",
"     <li>",
"      Dust mites (Dermatophagoides pteronyssinus and D. farinae)",
"     </li>",
"     <li>",
"      Molds (Alternaria and Cladosporium)",
"     </li>",
"     <li>",
"      Cockroach",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although other allergens are used in SCIT (other tree, grass, and weed pollens, molds and animals materials), their use is justified by analogy with proved extracts, rather than by specific placebo-controlled studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     ADDITIONAL CONSIDERATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Preventive effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of SCIT to children with allergic rhinitis can help prevent the subsequent development of allergic asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39049/abstract/41-46\">",
"     41-46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The long-term preventative effects of SCIT were evaluated in a follow-up analysis of 147 patients aged 16 to 25, who had participated as children (10 years prior) in a randomized trial of three years of SCIT with grass",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    birch pollen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39049/abstract/45\">",
"     45",
"    </a>",
"    ]. All patients had allergic rhinoconjunctivitis at the time of the initial study. Seven years after completion of treatment, patients who received SCIT demonstrated statistically significant improvements in rhinoconjunctivitis symptoms compared to those receiving other standard therapies. Among those treated with SCIT, 16 of 64 developed asthma compared to 24 of 53 in the control group (25 versus 45 percent, odds ratio 0.4, 95% CI 0.2-0.9).",
"   </p>",
"   <p>",
"    It is difficult to specify exactly which children should be treated with immunotherapy and at what age it should be initiated. We suggest immunotherapy for children with allergic rhinitis who require chronic pharmacotherapy and have a strong family history of asthma, especially when the",
"    <span class=\"nowrap\">",
"     parents/guardians",
"    </span>",
"    are motivated to prevent the development of asthma and understand the risks and benefits of the treatment. We generally begin therapy as soon as the child is mature enough to understand and cooperate with the injections. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Age of patient'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Referral",
"    </span>",
"    &nbsp;&mdash;&nbsp;Referral to a specialist in allergy and immunology (a recognized subspecialty of both internal medicine and pediatrics) should be sought for patients for whom immunotherapy may be appropriate.",
"    <span class=\"nowrap\">",
"     Allergists/immunologists",
"    </span>",
"    are trained in the interpretation of diagnostic tests for specific allergies, decisions about the allergens to be employed in immunotherapy, and formulation of allergen extracts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Special patient groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;The safety of SCIT in certain patient groups warrants special consideration, including individuals with severe asthma, those requiring beta-blockers, patients with autoimmune disease or immunodeficiency, and pregnant women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Severe or unstable asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of SCIT may impart unacceptable risk for patients with severe or unstable asthma, because these individuals are at greater risk for systemic allergic reactions involving severe bronchospasm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39049/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. This includes patients who require chronic oral glucocorticoid therapy or have had severe exacerbations requiring hospitalization or intubation in the previous six months. The WHO task force on Immunotherapy recommended that SCIT NOT be administered with FEV1 &lt;75 percent and that all asthmatics on IT be carefully monitored. These high-risk patients can sometimes be managed with anti-IgE therapy first, and once stabilized, may then be able to undergo SCIT while continuing to receive anti-IgE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39049/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/46/17130?source=see_link\">",
"     \"Anti-IgE therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Beta-blocker therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients on chronic beta blocker treatment for cardiovascular disease are at risk for a poor outcome if they have an anaphylactic reaction to an immunotherapy injection since they may not respond properly to epinephrine or other vasopressor agents used to treat the reaction. The physician who has prescribed the beta blocker may be able to substitute another drug that does not carry this risk. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/15/17656?source=see_link&amp;anchor=H15#H15\">",
"     \"Anaphylaxis induced by subcutaneous allergen immunotherapy\", section on 'Beta-adrenergic blockers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As with any therapeutic decision, the risk must be weighed against the benefit. For example, in the venom-sensitive patient who has experienced a life-threatening reaction, the benefit of venom immunotherapy likely outweighs the risk of using adrenaline to treat an untoward reaction to a venom injection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/34/16936?source=see_link&amp;anchor=H5913870#H5913870\">",
"     \"Hymenoptera venom immunotherapy: Efficacy, indications, and mechanism of action\", section on 'Patients requiring ACE inhibitors or beta blockers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Autoimmune disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Questions about the safety of administering SCIT to patients with autoimmune disease have been raised, based upon theoretical concern about modulating the immune response in a patient who may have aberrant immune regulation. Immunotherapy does not activate complement or anaphylatoxins (C3a and C5a). Unfortunately, there are no substantive data examining the issue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39049/abstract/51\">",
"     51",
"    </a>",
"    ]. Therefore, the decision to administer SCIT to a patient with concomitant allergic and autoimmune disease must be made cooperatively with the patient after careful consideration of the potential risks and benefits for that individual.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is our clinical experience that patients with established",
"    <span class=\"nowrap\">",
"     HIV/AIDS",
"    </span>",
"    and significant allergic disease can benefit from SCIT, particularly as improvements in the control of HIV transform this disease into a chronic condition. However, the safety of SCIT in patients newly-infected with HIV has not been studied to determine if immunotherapy could adversely impact progression of the infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;SCIT is not usually initiated during pregnancy, although it may be continued in women who were receiving the therapy prior to becoming pregnant. Dose adjustments during pregnancy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/52/3914?source=see_link&amp;anchor=H17#H17\">",
"     \"Recognition and management of allergic disease during pregnancy\", section on 'Allergen immunotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Age of patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;SCIT is appropriate for both adults and children, and there are no defined age limits for its administration. When proposing SCIT for pediatric patients, most clinicians wait until a child is at least five years of age so that they are mature enough to cooperate with repeated injections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39049/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children are believed to derive potentially greater benefit from immunotherapy, due to the potential of SCIT to prevent progression to more severe disease and allergic asthma. For this reason, therapy will occasionally be started in very young children. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Preventive effects'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There is no strict upper limit to the age at which immunotherapy can be beneficial. Several placebo-controlled studies that demonstrated efficacy have included subjects up to 60 years of age. A specific study in patients aged 54 and older found efficacy in rhinitis and asthma due to ragweed and birch pollens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39049/abstract/53\">",
"     53",
"    </a>",
"    ]. However, the presence of co-morbid cardiac or pulmonary conditions might increase the risk of a poor outcome following a systemic reaction. In addition, duration of disease is also important, especially in the treatment of allergic asthma. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Careful selection of patients'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Cost and convenience",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cost of immunotherapy is obviously dependent upon the care-delivery structure in which it is administered. However, in both European and American studies, SCIT was found to be cost-effective, particularly in patients who otherwise require both nasal and pulmonary inhaled medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39049/abstract/1,3,54-59\">",
"     1,3,54-59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immunotherapy requires multiple, regularly scheduled visits to a health care provider. In the United States, it is common practice to administer one or two sets of injections each week, beginning with low doses and gradually increasing into the effective therapeutic range for each allergen. Effective doses are typically reached within three to six months, after which visits are needed every two to four weeks for the remainder of treatment period.",
"   </p>",
"   <p>",
"    Patients must be able to adhere to the treatment schedule to obtain maximal benefit. Patients who frequently miss injections will have trouble advancing to the higher doses that confer most of the clinical effect. Students, persons working multiple jobs, and patients who are dependent upon others for transportation may have difficulty with this aspect of immunotherapy and may not be appropriate candidates. On the other hand, perfect compliance may not be essential for a good clinical outcome, as demonstrated in a study of over 3000 low income children with asthma who were treated with immunotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39049/abstract/57\">",
"     57",
"    </a>",
"    ]. Despite the fact that only 16 percent completed the recommended three years of treatment, resource use and cost of care for this group were significantly decreased compared to pretreatment levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Impact of SCIT with ongoing allergen exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with sensitivity to perennial allergens, such as dust mite or indoor animals, have been shown to benefit from SCIT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39049/abstract/14,51,60\">",
"     14,51,60",
"    </a>",
"    ]. However, studies are needed to address whether long-term treatment can alter the natural history of the disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The beneficial effects of SCIT begin during the first year of therapy and continue throughout the period in which the patient receives injections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39049/abstract/13,14,16,51\">",
"     13,14,16,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal duration of therapy is not known, although a minimum of three years has been identified in several studies as an effective initial treatment period, and one which provides some lasting benefit after the injections are discontinued:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective controlled trial of 40 asthmatic patients who were treated with standardized dust mite SCIT for one to eight years, found that in the three years after stopping therapy, the relapse rate was 48 percent in patients who had completed three or more years of treatment, compared with 62 percent in those who had completed less than three years, which was a statistically significant difference [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/8/39049/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another study of patients with allergic rhinitis and asthma attributable to dust mite allergy found that three years of SCIT achieved significant clinical benefit, and only a small additional improvement in rhinitis symptoms was gained from extending therapy to five years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/8/39049/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similar data have been reported for venom immunotherapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/59/13239?source=see_link&amp;anchor=H2#H2\">",
"       \"Hymenoptera venom immunotherapy: Determining duration of therapy\", section on 'Duration of treatment'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At present, there is consensus that an initial course of immunotherapy should consist of three to five years of maintenance treatment. After this, the clinician and patient should meet to review overall impact on quality of life, and based upon these factors, decide if treatment will be continued.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient's response to SCIT should be evaluated at least yearly, by questioning the individual about symptoms and medication requirements. Beyond this clinical history, neither repeat skin testing nor laboratory tests provide useful information about how well SCIT is working for a specific patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Persistence of benefit after discontinuation",
"    </span>",
"    &nbsp;&mdash;&nbsp;At present, there are no reliable biomarkers for determining which patients will experience lasting benefit. Neither skin tests nor serum IgG antibodies, local antibody production, or in vitro T-cell responses have been demonstrated to predict outcomes after the cessation of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39049/abstract/63,64\">",
"     63,64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A small number of studies have evaluated the persistence of benefit after discontinuation of SCIT, with variable results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39049/abstract/16,61,65,66\">",
"     16,61,65,66",
"    </a>",
"    ]. Long-term, blinded, placebo-controlled trials of SCIT are difficult to perform because of the prolonged time periods and significant patient effort involved. Until more data are available, it is not possible to give patients a precise estimate of how long the beneficial effects of SCIT will last after discontinuation of therapy. Patient age, extent and type of allergic disease, and other factors may be important, but these have not been specifically studied.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study randomized 30 patients with grass pollen-induced allergic rhinitis who had experienced relief from three to four years of SCIT to continued injections with either grass pollen or placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/8/39049/abstract/16\">",
"       16",
"      </a>",
"      ]. Another 15 patients who had not received prior SCIT were followed to control for the natural history of the disease. After discontinuation, symptoms scores in the third year of follow up showed no significant difference between the continued SCIT and placebo groups (median scores of 921 versus 504, respectively), and both groups had significantly lower scores than patients who had never received SCIT (median score 2863). Thus, this study found no relapse in the first three years after discontinuation of therapy.",
"     </li>",
"     <li>",
"      A study of 20 patients with ragweed allergic rhinitis treated with SCIT for three years or more were randomized to continue treatment for one more year or switch to placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/8/39049/abstract/65\">",
"       65",
"      </a>",
"      ]. The treated patients continued to show suppression of responses to nasal challenge with ragweed extract. The placebo patients showed a partial return of nasal responses to challenge but not to pretreatment levels. During the first ragweed season after randomization, neither group showed a significant relapse in symptom scores from previous seasons [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/8/39049/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, the previously described study of 40 patients with allergic asthma concluded that rates of relapse were significant [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/8/39049/abstract/61\">",
"       61",
"      </a>",
"      ]. During the initial three years after stopping immunotherapy, 55 percent of the group, as a whole, relapsed. Relapse was defined as recurrence of asthma symptoms persisting a week or longer, an FEV1 of 80 percent or less of the patient's value at the end of SCIT,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the need for regular inhaled bronchodilators or antiinflammatory medications. This study did not attempt to measure the severity of symptoms, so there may have been benefits that were not assessed. The findings may also reflect the more complex pathophysiology of asthma compared to allergic rhinitis. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Duration of therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In our practice, patients receiving SCIT are evaluated clinically each year to determine if any adjustments in dose or allergen mix are indicated. We continue therapy for at least three years in those who experience subjective benefit. After this period, we explain that they may expect continued relief for several more years if they choose to stop therapy, although there is a risk of relapse. In the case of relapse, it is possible to start immunotherapy again. Some patients choose to continue injections every three or four weeks more or less indefinitely, while others choose to take their chances on relapse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Disorders that are not treated with immunotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical studies do not support the routine use of allergen immunotherapy for food hypersensitivity, chronic urticaria",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    angioedema, atopic dermatitis, latex allergy, or drug allergies.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Food allergy - Immunotherapy for food allergy is an area of active research, although use of SCIT for food allergy is not recommended outside of research settings. Established protocols are not yet available. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44057?source=see_link&amp;anchor=H2#H2\">",
"       \"Future therapies for food allergy\", section on 'Food allergen-specific therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Oral allergy syndrome - Immunotherapy with pollen allergens is not typically administered",
"      <strong>",
"       solely",
"      </strong>",
"      for the purpose of treating oral allergy syndrome (also called pollen-food allergy syndrome, PFAS), because patients do not consistently experience improvement in symptoms. The utility of immunotherapy in PFAS is reviewed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/35/37430?source=see_link\">",
"       \"Management and prognosis of oral allergy syndrome (pollen-food allergy syndrome)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Latex allergy - Immunotherapy for latex allergy has been performed, although rates of systemic reactions were high. This is reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/8/40070?source=see_link&amp;anchor=H9#H9\">",
"       \"Latex allergy: Management\", section on 'Immunotherapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Drug allergy - Subcutaneous injection immunotherapy is not traditionally used in the treatment of drug allergy. However, oral and intravenous drug desensitizations, which work by a different mechanism than immunotherapy, have been established for some specific drugs. These protocols are presented in various topic reviews. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/62/29672?source=see_link\">",
"       \"Rapid drug desensitization for immediate hypersensitivity reactions\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26006?source=see_link\">",
"       \"Diagnostic challenge and desensitization protocols for NSAID reactions\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/57/43930?source=see_link&amp;anchor=H21#H21\">",
"       \"Infusion reactions to systemic chemotherapy\", section on 'Platinum drugs'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?41/5/42066?source=see_link\">",
"       \"Patient information: Allergy shots (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immunotherapy for allergic disease involves the gradual administration of increasing amounts of allergen to induce protective immunologic responses. It is currently the only means of altering the abnormal immune response that underlies allergic disease in a semi-permanent manner. Subcutaneous injection immunotherapy (SCIT) is the established form of this treatment. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      SCIT is effective in the treatment of allergic rhinitis, allergic conjunctivitis, and allergic asthma, in both children and adults. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above.) It is also used in the treatment of venom hypersensitivity, which is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/34/16936?source=see_link\">",
"       \"Hymenoptera venom immunotherapy: Efficacy, indications, and mechanism of action\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Severe or very labile asthma is a relative contraindication to SCIT, as patients with unstable asthma are at risk for severe bronchospasm during systemic reactions, and the risk is felt to outweigh the benefit in many cases. Administration of SCIT to patients receiving beta blockers should be avoided. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Special patient groups'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      SCIT can help prevent the progression of allergic disease and may be particularly valuable in helping children with allergic",
"      <span class=\"nowrap\">",
"       rhinitis/conjunctivitis",
"      </span>",
"      avoid the development of allergic asthma. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Preventive effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The allergens that are known to be effective for use in SCIT include several tree, grass, and weed pollens; cat and dog danders; dust mites; certain molds; and cockroach. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Effective allergens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As most commonly practiced, SCIT involves one or more injections per visit, administered at regularly scheduled intervals over a period of three to five years. Beneficial effects are usually seen within the first year of treatment. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Additional considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The magnitude of the effect of subcutaneous immunotherapy (SCIT) for allergic rhinitis is believed to be approximately equivalent to that of glucocorticoid nasal sprays, and the two together may be additive. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Allergic rhinitis and conjunctivitis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Role in therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In adults and children with moderate to severe allergic rhinitis (with or without conjunctivitis), we suggest SCIT for those who fulfill the criteria shown in the table (",
"      <a class=\"graphic graphic_table graphicRef78962 \" href=\"mobipreview.htm?17/6/17515\">",
"       table 1",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Allergic rhinitis and conjunctivitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition, we suggest SCIT for children with any severity of allergic",
"      <span class=\"nowrap\">",
"       rhinitis/conjunctivitis,",
"      </span>",
"      a family history of asthma, and caregivers who are motivated to minimize the child's chances of developing asthma in the future (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Preventive effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with mild to moderate allergic asthma, with or without rhinitis, we suggest SCIT for those who fulfill the criteria shown in the table (",
"      <a class=\"graphic graphic_table graphicRef78962 \" href=\"mobipreview.htm?17/6/17515\">",
"       table 1",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Patients with clear allergen-induced exacerbations or new onset disease are most likely to experience clinically-meaningful improvement. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Allergic asthma'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/1\">",
"      Omnes LF, Bousquet J, Scheinmann P, et al. Pharmacoeconomic assessment of specific immunotherapy versus current symptomatic treatment for allergic rhinitis and asthma in France. Eur Ann Allergy Clin Immunol 2007; 39:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/2\">",
"      Ramirez NC, Ledford DK. Immunotherapy for allergic asthma. Med Clin North Am 2002; 86:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/3\">",
"      Petersen KD, Gyrd-Hansen D, Dahl R. Health-economic analyses of subcutaneous specific immunotherapy for grass pollen and mite allergy. Allergol Immunopathol (Madr) 2005; 33:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/4\">",
"      Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol 2011; 127:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/5\">",
"      Bussmann C, Maintz L, Hart J, et al. Clinical improvement and immunological changes in atopic dermatitis patients undergoing subcutaneous immunotherapy with a house dust mite allergoid: a pilot study. Clin Exp Allergy 2007; 37:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/6\">",
"      Werfel T, Breuer K, Ru&eacute;ff F, et al. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study. Allergy 2006; 61:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/7\">",
"      Glover MT, Atherton DJ. A double-blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clin Exp Allergy 1992; 22:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/8\">",
"      Dreborg S, Lee TH, Kay AB, Durham SR. Immunotherapy is allergen-specific: a double-blind trial of mite or timothy extract in mite and grass dual-allergic patients. Int Arch Allergy Immunol 2012; 158:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/9\">",
"      Norman PS, Lichtenstein LM. The clinical and immunologic specificity of immunotherapy. J Allergy Clin Immunol 1978; 61:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/10\">",
"      Lack G, Nelson HS, Amran D, et al. Rush immunotherapy results in allergen-specific alterations in lymphocyte function and interferon-gamma production in CD4+ T cells. J Allergy Clin Immunol 1997; 99:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/11\">",
"      Nelson HS. Multiallergen immunotherapy for allergic rhinitis and asthma. J Allergy Clin Immunol 2009; 123:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/12\">",
"      Calder&oacute;n MA, Cox L, Casale TB, et al. Multiple-allergen and single-allergen immunotherapy strategies in polysensitized patients: looking at the published evidence. J Allergy Clin Immunol 2012; 129:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/13\">",
"      Norman PS. Immunotherapy: 1999-2004. J Allergy Clin Immunol 2004; 113:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/14\">",
"      Bousquet J, Lockey R, Malling HJ, et al. Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American academy of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1998; 81:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/15\">",
"      Nelson HS. Advances in upper airway diseases and allergen immunotherapy. J Allergy Clin Immunol 2004; 113:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/16\">",
"      Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999; 341:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/17\">",
"      Walker SM, Pajno GB, Lima MT, et al. Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial. J Allergy Clin Immunol 2001; 107:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/18\">",
"      Hedlin G, Silber G, Naclerio R, et al. Comparison of the in-vivo and in-vitro response to ragweed immunotherapy in children and adults with ragweed-induced rhinitis. Clin Exp Allergy 1990; 20:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/19\">",
"      Durham SR, Ying S, Varney VA, et al. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol 1996; 97:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/20\">",
"      Li JT. Immunotherapy for allergic rhinitis. Immunol Allergy Clin North Am 2000; 20:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/21\">",
"      Leynadier F, Banoun L, Dollois B, et al. Immunotherapy with a calcium phosphate-adsorbed five-grass-pollen extract in seasonal rhinoconjunctivitis: a double-blind, placebo-controlled study. Clin Exp Allergy 2001; 31:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/22\">",
"      Schmidt BM, Kusma M, Feuring M, et al. The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis. J Allergy Clin Immunol 2001; 108:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/23\">",
"      Ewbank PA, Murray J, Sanders K, et al. A double-blind, placebo-controlled immunotherapy dose-response study with standardized cat extract. J Allergy Clin Immunol 2003; 111:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/24\">",
"      Nanda A, O'connor M, Anand M, et al. Dose dependence and time course of the immunologic response to administration of standardized cat allergen extract. J Allergy Clin Immunol 2004; 114:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/25\">",
"      Ross RN, Nelson HS, Finegold I. Effectiveness of specific immunotherapy in the treatment of allergic rhinitis: an analysis of randomized, prospective, single- or double-blind, placebo-controlled studies. Clin Ther 2000; 22:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/26\">",
"      Lowell FC, Franklin W. A double-blind study of the effectiveness and specificity of injecton therapy in ragweed hay fever. N Engl J Med 1965; 273:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/27\">",
"      Alvarez-Cuesta E, Aragoneses-Gilsanz E, Mart&iacute;n-Garcia C, et al. Immunotherapy with depigmented glutaraldehyde-polymerized extracts: changes in quality of life. Clin Exp Allergy 2005; 35:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/28\">",
"      Calderon MA, Alves B, Jacobson M, et al. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007; :CD001936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/29\">",
"      Rak S, Heinrich C, Jacobsen L, et al. A double-blinded, comparative study of the effects of short preseason specific immunotherapy and topical steroids in patients with allergic rhinoconjunctivitis and asthma. J Allergy Clin Immunol 2001; 108:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/30\">",
"      Bielory L, Mongia A. Current opinion of immunotherapy for ocular allergy. Curr Opin Allergy Clin Immunol 2002; 2:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/31\">",
"      Bousquet J, Calvayrac P, Gu&eacute;rin B, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. I. In vivo and in vitro parameters after a short course of treatment. J Allergy Clin Immunol 1985; 76:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/32\">",
"      Creticos PS, Reed CE, Norman PS, et al. Ragweed immunotherapy in adult asthma. N Engl J Med 1996; 334:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/33\">",
"      Abramson MJ, Puy RM, Weiner JM. Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials. Am J Respir Crit Care Med 1995; 151:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/34\">",
"      Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Syst Rev 2003; :CD001186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/35\">",
"      Zielen S, Kardos P, Madonini E. Steroid-sparing effects with allergen-specific immunotherapy in children with asthma: a randomized controlled trial. J Allergy Clin Immunol 2010; 126:942.",
"     </a>",
"    </li>",
"    <li>",
"     National Asthma Education and Prevention Program: Expert Panel Report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD. National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051). www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on April 23, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/37\">",
"      Bousquet J, Hejjaoui A, Clauzel AM, et al. Specific immunotherapy with a standardized Dermatophagoides pteronyssinus extract. II. Prediction of efficacy of immunotherapy. J Allergy Clin Immunol 1988; 82:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/38\">",
"      Creticos PS. The consideration of immunotherapy in the treatment of allergic asthma. J Allergy Clin Immunol 2000; 105:S559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/39\">",
"      Ortolani C, Pastorello E, Moss RB, et al. Grass pollen immunotherapy: a single year double-blind, placebo-controlled study in patients with grass pollen-induced asthma and rhinitis. J Allergy Clin Immunol 1984; 73:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/40\">",
"      Kang BC, Johnson J, Morgan C, Chang JL. The role of immunotherapy in cockroach asthma. J Asthma 1988; 25:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/41\">",
"      Des Roches A, Paradis L, Menardo JL, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol 1997; 99:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/42\">",
"      Abramson M, Puy R, Weiner J. Immunotherapy in asthma: an updated systematic review. Allergy 1999; 54:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/43\">",
"      Polosa R, Al-Delaimy WK, Russo C, et al. Greater risk of incident asthma cases in adults with allergic rhinitis and effect of allergen immunotherapy: a retrospective cohort study. Respir Res 2005; 6:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/44\">",
"      Corren J. The connection between allergic rhinitis and bronchial asthma. Curr Opin Pulm Med 2007; 13:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/45\">",
"      Jacobsen L, Niggemann B, Dreborg S, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007; 62:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/46\">",
"      Jacobsen L, Valovirta E. How strong is the evidence that immunotherapy in children prevents the progression of allergy and asthma? Curr Opin Allergy Clin Immunol 2007; 7:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/47\">",
"      Amin HS, Liss GM, Bernstein DI. Evaluation of near-fatal reactions to allergen immunotherapy injections. J Allergy Clin Immunol 2006; 117:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/48\">",
"      Reid MJ, Lockey RF, Turkeltaub PC, Platts-Mills TA. Survey of fatalities from skin testing and immunotherapy 1985-1989. J Allergy Clin Immunol 1993; 92:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/49\">",
"      Kopp MV, Hamelmann E, Zielen S, et al. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clin Exp Allergy 2009; 39:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/50\">",
"      Massanari M, Nelson H, Casale T, et al. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol 2010; 125:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/51\">",
"      Joint Task Force on Practice Parameters, American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and Immunology, Joint Council of Allergy, Asthma and Immunology. Allergen immunotherapy: a practice parameter second update. J Allergy Clin Immunol 2007; 120:S25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/52\">",
"      van Wijk RG. When to initiate immunotherapy in children with allergic disease? Lessons from the paediatric studies. Curr Opin Allergy Clin Immunol 2008; 8:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/53\">",
"      Asero R. Efficacy of injection immunotherapy with ragweed and birch pollen in elderly patients. Int Arch Allergy Immunol 2004; 135:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/54\">",
"      Sch&auml;dlich PK, Brecht JG. Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany. Pharmacoeconomics 2000; 17:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/55\">",
"      Incorvaia C, Agostinis F, Amoroso S, et al. Pharmacoeconomics of subcutaneous allergen immunotherapy. Eur Ann Allergy Clin Immunol 2007; 39 Spec No:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/56\">",
"      Hankin CS, Cox L, Lang D, et al. Allergen immunotherapy and health care cost benefits for children with allergic rhinitis: a large-scale, retrospective, matched cohort study. Ann Allergy Asthma Immunol 2010; 104:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/57\">",
"      Hankin CS, Cox L, Lang D, et al. Allergy immunotherapy among Medicaid-enrolled children with allergic rhinitis: patterns of care, resource use, and costs. J Allergy Clin Immunol 2008; 121:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/58\">",
"      Br&uuml;ggenj&uuml;rgen B, Reinhold T, Brehler R, et al. Cost-effectiveness of specific subcutaneous immunotherapy in patients with allergic rhinitis and allergic asthma. Ann Allergy Asthma Immunol 2008; 101:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/59\">",
"      Simoens S. The cost-effectiveness of immunotherapy for respiratory allergy: a review. Allergy 2012; 67:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/60\">",
"      Li JT, Lockey RF, Bernstien IL, et al. Allergen immunotherapy: a practice parameter. Ann Allergy Asthma Immunol 2003; 90:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/61\">",
"      Des Roches A, Paradis L, Knani J, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. V. Duration of the efficacy of immunotherapy after its cessation. Allergy 1996; 51:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/62\">",
"      Tabar AI, Arroabarren E, Echechip&iacute;a S, et al. Three years of specific immunotherapy may be sufficient in house dust mite respiratory allergy. J Allergy Clin Immunol 2011; 127:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/63\">",
"      Platts-Mills TA, von Maur RK, Ishizaka K, et al. IgA and IgG anti-ragweed antibodies in nasal secretions. Quantitative measurements of antibodies and correlation with inhibition of histamine release. J Clin Invest 1976; 57:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/64\">",
"      Jacobsen L, N��chel Petersen B, Wihl JA, et al. Immunotherapy with partially purified and standardized tree pollen extracts. IV. Results from long-term (6-year) follow-up. Allergy 1997; 52:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/65\">",
"      Naclerio RM, Proud D, Moylan B, et al. A double-blind study of the discontinuation of ragweed immunotherapy. J Allergy Clin Immunol 1997; 100:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39049/abstract/66\">",
"      Mosbech H, Osterballe O. Does the effect of immunotherapy last after termination of treatment? Follow-up study in patients with grass pollen rhinitis. Allergy 1988; 43:523.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 361 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-458F631DC3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_8_39049=[""].join("\n");
var outline_f38_8_39049=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Does the patient have a disorder that responds to immunotherapy?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Is the allergen(s) clinically important?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Have other measures been maximized?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Is current management suboptimal?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Variables in the practice of SCIT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Allergic rhinitis and conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Allergic asthma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Careful selection of patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Effective allergens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ADDITIONAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Preventive effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Referral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Special patient groups",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Severe or unstable asthma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Beta-blocker therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Autoimmune disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - HIV infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Age of patient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Cost and convenience",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Impact of SCIT with ongoing allergen exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Persistence of benefit after discontinuation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Disorders that are not treated with immunotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Role in therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/361\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/361|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/6/17515\" title=\"table 1\">",
"      Indications for SCIT",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/48/34569?source=related_link\">",
"      Allergen avoidance in the treatment of asthma and allergic rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/49/15127?source=related_link\">",
"      An overview of allergen extracts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/15/17656?source=related_link\">",
"      Anaphylaxis induced by subcutaneous allergen immunotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/46/17130?source=related_link\">",
"      Anti-IgE therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/0/39944?source=related_link\">",
"      Aspirin exacerbated respiratory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26006?source=related_link\">",
"      Diagnostic challenge and desensitization protocols for NSAID reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44057?source=related_link\">",
"      Future therapies for food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/59/13239?source=related_link\">",
"      Hymenoptera venom immunotherapy: Determining duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/34/16936?source=related_link\">",
"      Hymenoptera venom immunotherapy: Efficacy, indications, and mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/57/43930?source=related_link\">",
"      Infusion reactions to systemic chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/8/40070?source=related_link\">",
"      Latex allergy: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/35/37430?source=related_link\">",
"      Management and prognosis of oral allergy syndrome (pollen-food allergy syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/4/30794?source=related_link\">",
"      Management of chronic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?41/5/42066?source=related_link\">",
"      Patient information: Allergy shots (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/62/29672?source=related_link\">",
"      Rapid drug desensitization for immediate hypersensitivity reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/52/3914?source=related_link\">",
"      Recognition and management of allergic disease during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/51/7994?source=related_link\">",
"      Stings of imported fire ants: Clinical manifestations, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/27/27062?source=related_link\">",
"      Subcutaneous immunotherapy for allergic disease: Therapeutic mechanisms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/7/26745?source=related_link\">",
"      Treatment of moderate persistent asthma in adolescents and adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_8_39050="Chemotherapy and radiation therapy in the management of osteosarcoma";
var content_f38_8_39050=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chemotherapy and radiation therapy in the management of osteosarcoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/8/39050/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/8/39050/contributors\">",
"     Katherine A Janeway, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/8/39050/contributors\">",
"     Allen M Goorin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/8/39050/contributors\">",
"     Robert Maki, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/8/39050/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/8/39050/contributors\">",
"     Alberto S Pappo, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/8/39050/contributors\">",
"     Thomas F DeLaney, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/8/39050/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/8/39050/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/8/39050/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteosarcomas are primary malignant tumors of bone that are characterized by the production of osteoid or immature bone by the malignant cells. Osteosarcomas are uncommon; only about 750 to 900 cases are diagnosed each year in the US, of which 400 are in children and adolescents under the age of 20 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/22/20842?source=see_link\">",
"     \"Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will cover the use of adjuvant and neoadjuvant chemotherapy and radiation therapy (RT) in the management of osteosarcoma. The same principles apply to other primary bone tumors such as fibrosarcoma and angiosarcoma, and they are treated similarly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The surgical management of patients with primary bone tumors, the clinical features, epidemiology, diagnosis, pathology and pathogenesis of osteosarcoma, management of osteosarcomas arising in the head and neck, management of chondrosarcomas and of chordomas and chondrosarcomas arising in the skull base, and the treatment of Ewing sarcoma are addressed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/51/37690?source=see_link\">",
"     \"Bone sarcomas: Preoperative evaluation, histologic classification, and principles of surgical management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/22/20842?source=see_link\">",
"     \"Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34602?source=see_link&amp;anchor=H13#H13\">",
"     \"Head and neck sarcomas\", section on 'Osteosarcoma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/39/35450?source=see_link\">",
"     \"Chondrosarcoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/40/7815?source=see_link\">",
"     \"Chordoma and chondrosarcoma of the skull base\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/50/14122?source=see_link\">",
"     \"Treatment of the Ewing sarcoma family of tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1780929\">",
"    <span class=\"h1\">",
"     PROGNOSIS AND EVOLUTION OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The survival of patients with malignant bone sarcomas has improved dramatically over the past 30 years, largely as a result of the use of effective chemotherapy. Previously 80 to 90 percent of patients with bone sarcomas developed metastases despite achieving local tumor control, and died of their disease. It was surmised (and subsequently demonstrated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/5\">",
"     5",
"    </a>",
"    ]) that subclinical metastatic disease was present at the time of diagnosis in the majority of patients and that chemotherapy can successfully eradicate these deposits if initiated at a time when disease burden is low. The benefits of chemotherapy are best illustrated by a systematic review of the literature, which showed that long-term survival after local tumor control without chemotherapy was only 16 percent (95% CI 9 to 23 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/6\">",
"     6",
"    </a>",
"    ]. In contrast, the addition of systemic chemotherapy with three or more drugs provided a five-year overall survival rate of 70 percent.",
"   </p>",
"   <p>",
"    Chemotherapy is now considered a standard component of osteosarcoma treatment, both in children and in adults. The choice of regimen and optimal timing (ie, preoperative versus postoperative) are controversial; however, many centers preferentially utilize preoperative chemotherapy, particularly if a limb-sparing procedure is being contemplated for an extremity osteosarcoma. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Neoadjuvant versus adjuvant chemotherapy'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/51/37690?source=see_link\">",
"     \"Bone sarcomas: Preoperative evaluation, histologic classification, and principles of surgical management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With modern therapy, at least two-thirds of children, adolescents, and adults under the age of 40 with nonmetastatic extremity osteosarcomas will be long-term survivors and presumably cured of their disease. In addition, up to 35 to 40 percent of those with limited pulmonary metastases may be cured with multimodality therapy. In contrast, long-term survival can be expected in less than 20 percent of all other patients who present with or develop overt metastatic disease. In most (but not all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/7\">",
"     7",
"    </a>",
"    ]) series, prognosis is worse for adults than for children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/8-11\">",
"     8-11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRIMARY MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Adjuvant chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;More than 80 percent of patients with osteosarcoma treated with surgery alone develop metastatic disease, despite achieving local control. It is presumed that subclinical metastases are present at diagnosis in the majority of patients. Chemotherapy can eradicate these deposits if initiated at a time when disease burden is low.",
"   </p>",
"   <p>",
"    Initially, postoperative chemotherapy was used, and five-year survival rates rose from less than 20 percent to between 40 and 60 percent in the 1970s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/12\">",
"     12",
"    </a>",
"    ]. Two subsequent randomized studies conducted in the 1980s demonstrated a significant relapse-free and overall survival benefit for adjuvant chemotherapy that persisted over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/13-16\">",
"     13-16",
"    </a>",
"    ], although the trials were limited in size and the survival benefits modest. The chemotherapy regimens used in these studies included high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (HDMTX) plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/21/14679?source=see_link\">",
"     dactinomycin",
"    </a>",
"    and either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/13\">",
"     13",
"    </a>",
"    ], or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Neoadjuvant chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The concept of induction or neoadjuvant chemotherapy arose in concert with the evolving use of limb-sparing surgery. Because of the time needed for fabrication of custom metallic endoprostheses, chemotherapy was often given while awaiting definitive surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/17\">",
"     17",
"    </a>",
"    ]. Accumulating experience with this approach led to the suggestion that induction chemotherapy might also be improving survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Neoadjuvant versus adjuvant chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;These observations ultimately led to a randomized clinical study conducted between 1986 and 1993 by the Pediatric Oncology Group (POG trial 8651) that compared immediate surgery and postoperative chemotherapy versus 10 weeks of the same chemotherapy regimen followed by surgery in 100 patients under the age of 30 with nonmetastatic high-grade osteosarcoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/18\">",
"     18",
"    </a>",
"    ]. Chemotherapy consisted of alternating courses of HDMTX with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    rescue,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/21/14679?source=see_link\">",
"     dactinomycin",
"    </a>",
"    (BCD) (",
"    <a class=\"graphic graphic_table graphicRef63000 \" href=\"mobipreview.htm?13/18/13613\">",
"     table 1",
"    </a>",
"    ). The five-year relapse-free survival rates were similar between the two groups (65 versus 61 percent for adjuvant and neoadjuvant therapy, respectively) as was the limb salvage rate (55 and 50 percent for immediate and delayed surgery, respectively).",
"   </p>",
"   <p>",
"    The study was criticized for the relatively low rate of limb-sparing surgery in both groups (by modern standards) and the inclusion of BCD as a component of the regimen. The contribution of BCD to the therapeutic efficacy of this regimen is unclear, while it can clearly contribute to long-term",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    -related pulmonary toxicity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/31/12794?source=see_link\">",
"     \"Bleomycin-induced lung injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nevertheless, this trial established that survival was similarly improved by either presurgical or postsurgical chemotherapy and established a benchmark outcome for future studies (five-year event-free survival 65 percent).",
"   </p>",
"   <p>",
"    Due to its success in killing cancer cells (although actual tumor shrinkage during treatment is not common, particularly with chondroblastic osteosarcomas), neoadjuvant chemotherapy has evolved to a method of increasing the proportion of patients who are suitable candidates for limb-salvage surgery. The majority of limb-sparing surgical procedures for extremity osteosarcomas are now performed at institutions using presurgical chemotherapy.",
"   </p>",
"   <p>",
"    While it is clear that the number of patients with osteosarcoma who are deemed suitable candidates for limb-sparing surgery has increased in parallel with the increasing use of presurgical chemotherapy, this finding may reflect improvements in reconstructive techniques and the increased experience and confidence of tumor surgeons rather than a benefit attributable to the use of induction chemotherapy. A major concern in this regard is the possibility that inexperienced surgeons may expand selection criteria to accommodate inappropriate candidates who might be better served by amputation. Neoadjuvant chemotherapy is never a substitute for sound surgical principles.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8080619\">",
"    <span class=\"h4\">",
"     Histology and response to chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Response to neoadjuvant chemotherapy is histology dependent (",
"    <a class=\"graphic graphic_table graphicRef70051 \" href=\"mobipreview.htm?13/44/14029\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. In the larger series, in which 1058 patients received presurgical chemotherapy for osteosarcoma over a 20-year period, the likelihood of a \"good\" response (&gt;90 percent necrosis) was significantly higher for fibroblastic and telangiectatic osteosarcomas (83 and 80 percent, respectively) compared to chondroblastic (43 percent) or osteoblastic osteosarcomas (58 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/19\">",
"     19",
"    </a>",
"    ]. Five-year survival rates paralleled the quality of the response to induction chemotherapy (83, 75, 62, and 60 percent for fibroblastic, telangiectatic, osteoblastic, and chondroblastic osteosarcomas, respectively).",
"   </p>",
"   <p>",
"    For the two principal subtypes (osteoblastic and chondroblastic), the difference in &ldquo;good&rdquo; response rate has not translated into any survival difference. Thus, the lack of a &ldquo;good&rdquo; response to induction chemotherapy does not necessarily predict a poor outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h4\">",
"     Tailored postoperative chemotherapy based upon initial response",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the most compelling rationales for neoadjuvant chemotherapy is its ability to function as an in vivo drug trial to determine the drug sensitivity of an individual tumor and to customize postoperative therapy. A grading system for assessing the effect of preoperative chemotherapy on the tumor was developed at Memorial Sloan Kettering and is in widespread use (",
"    <a class=\"graphic graphic_table graphicRef58829 \" href=\"mobipreview.htm?13/58/14251\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Responsiveness of an osteosarcoma to neoadjuvant chemotherapy is a major determinant of clinical outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/19-26\">",
"     19-26",
"    </a>",
"    ]. Five-year survival rates for patients with an extremity sarcoma and a \"good\" response to chemotherapy (as defined by 90 percent or more necrosis in the surgical specimen) are significantly higher than for those with a lesser response (71 to 80 versus 45 to 60 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/19,20,25,27\">",
"     19,20,25,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Response to chemotherapy is usually defined by histologic appearance in the resected specimen (",
"    <a class=\"graphic graphic_picture graphicRef87015 \" href=\"mobipreview.htm?15/41/16024\">",
"     picture 1",
"    </a>",
"    ). However, at least some data suggests that three-phase thallium scintigraphy is a useful method for noninvasively evaluating tumor response to neoadjuvant chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. This approach may be most useful in a patient with an equivocal clinical response for whom alternative chemotherapy might be attempted prior to resection.",
"   </p>",
"   <p>",
"    Patients with a near-complete absence of viable tumor cells in the resection specimen after neoadjuvant therapy tend to do well when the same therapy is continued after surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/12,21-23,31\">",
"     12,21-23,31",
"    </a>",
"    ]. However, when the tumor contains 10 percent or more residual viable cells after neoadjuvant chemotherapy, a change in the chemotherapeutic regimen might be beneficial. This strategy of altering the postoperative chemotherapy regimen based upon the response to the neoadjuvant regimen was pioneered in the T10 protocol at the Memorial Sloan-Kettering Cancer Center (MSKCC) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/12,31\">",
"     12,31",
"    </a>",
"    ] and confirmed by at least one other group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, this strategy came under scrutiny for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With more mature follow-up, the initial beneficial results from the T10 protocol have not been sustained at MSKCC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Major cooperative groups (eg, Children's Cancer Group, German Society for Pediatric Oncology, Scandinavian Sarcoma Group) have been unable to confirm that altering the postoperative chemotherapy regimen in patients with a less than complete response to presurgical chemotherapy improves their overall outcome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/35-39\">",
"       35-39",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As noted above, POG trial 8651 failed to show a survival benefit for neoadjuvant as compared to adjuvant chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/18\">",
"     18",
"    </a>",
"    ]. It seems reasonable to conclude from these data that the administration of presurgical chemotherapy (with or without treatment individualization based upon initial tumor response) does not appear to have improved cure rates.",
"   </p>",
"   <p>",
"    On the other hand, experience with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    <span class=\"nowrap\">",
"     (I/E)",
"    </span>",
"    has once again brought the issue of modifying postsurgical treatment based upon response to induction therapy to the forefront [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/32,33,40,41\">",
"     32,33,40,41",
"    </a>",
"    ]. The high level of antitumor activity of",
"    <span class=\"nowrap\">",
"     I/E",
"    </span>",
"    in patients with measurable metastatic osteosarcoma (66 percent in one trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/40\">",
"     40",
"    </a>",
"    ]) has prompted investigators to consider the use of",
"    <span class=\"nowrap\">",
"     I/E",
"    </span>",
"    in patients with resectable disease who have a poor initial histologic response to standard chemotherapy.",
"   </p>",
"   <p>",
"    Because of the potential for additional gonadal and renal toxicity from the addition of these agents to standard chemotherapy, the Children's Oncology Group (COG) performed a pilot trial showing that the addition of",
"    <span class=\"nowrap\">",
"     I/E",
"    </span>",
"    to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and HDMTX was feasible and safe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/41\">",
"     41",
"    </a>",
"    ]. Subsequently, an international multigroup trial (COG AOST 0331, the EURAMOS1 trial) was developed to test prospectively the benefit of altering postoperative chemotherapy based upon the response to initial chemotherapy; this study has completed accruing patients with resectable osteosarcoma, but results are not yet available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/42\">",
"     42",
"    </a>",
"    ]. Patients who had a poor histological response to standard induction chemotherapy were randomly assigned to HDMTX, cisplatin, and doxorubicin with or without",
"    <span class=\"nowrap\">",
"     I/E",
"    </span>",
"    after resection. Patients with a good histologic response after induction chemotherapy were randomly assigned to continued HDMTX, cisplatin, and doxorubicin with or without the addition of pegylated interferon alpha 2b.",
"   </p>",
"   <p>",
"    Until results of this trial are available, we suggest not pursuing a change in the chemotherapeutic regimen after surgery in patients who have less than a complete response to neoadjuvant chemotherapy. Although tumor necrosis correlates with outcomes, detection of this feature at such a late stage may not offer the chance to target therapy, and therefore, better methods to identify chemoresistant tumors at diagnosis are needed. Regardless of the regimen chosen, based on available evidence, in patients with localized disease of an extremity, we suggest resuming chemotherapy within 21 days after definitive surgery, when feasible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Choice of regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no worldwide consensus on a standard chemotherapy approach for osteosarcoma. The development of adjuvant chemotherapy has been largely empiric, with the majority of regimens incorporating",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , with or without high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (HDMTX, 6 to 12",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    rescue) (",
"    <a class=\"graphic graphic_table graphicRef68668 \" href=\"mobipreview.htm?11/40/11917\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/14,15,33,37,44-47\">",
"     14,15,33,37,44-47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/55/33658?source=see_link\">",
"     \"Therapeutic use and toxicity of high-dose methotrexate\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5448439\">",
"    <span class=\"h4\">",
"     Role of methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of HDMTX has been questioned, particularly in adults:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nearly all of the trials purporting to show benefit for chemotherapy regimens that include HDMTX are phase II trials that have been conducted predominantly in children, although many have enrolled patients up to age 40 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Neither of the two randomized studies comparing HDMTX plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      versus",
"      <span class=\"nowrap\">",
"       doxorubicin/cisplatin",
"      </span>",
"      alone have shown an advantage to three-drug therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/38,46\">",
"       38,46",
"      </a>",
"      ]. However, one of these studies was criticized because the outcome in the group receiving HDMTX, cisplatin, and doxorubicin was particularly poor by modern standards (41 percent five-year disease-free survival compared to 57 percent with",
"      <span class=\"nowrap\">",
"       doxorubicin/cisplatin",
"      </span>",
"      alone) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A single randomized trial comparing higher as compared to intermediate doses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      did not show a survival advantage for high-dose therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/48\">",
"       48",
"      </a>",
"      ]. However, a benefit for HDMTX is supported by at least one phase II trial demonstrates a superior outcome with high-dose as compared to intermediate-dose methotrexate in the context of a multiagent chemotherapy regimen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/24\">",
"       24",
"      </a>",
"      ]. Furthermore, many studies have shown a correlation between peak serum levels of methotrexate, tumor response, and outcome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/36,49-51\">",
"       36,49-51",
"      </a>",
"      ]. Thus, it is possible that determining a benefit for HDMTX has been compromised by the use of insufficient doses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/52\">",
"       52",
"      </a>",
"      ] or administration schedules.",
"     </li>",
"     <li>",
"      Additional information comes from a literature-based systematic review of chemotherapy trials for localized high-grade osteosarcoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/6\">",
"       6",
"      </a>",
"      ]. In an analysis of 18 trials, almost all conducted in patients under the age of 40, treatment with three or more drugs (including",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      ) was associated with a significant improvement in both event-free survival (hazard ratio [HR] 0.701, 95% CI 0.615-0.799) and overall survival (HR 0.792, 95% CI 0.677-0.926) compared to a two-drug regimen. However, only two of the trials included in this analysis were randomized trials comparing a three-drug regimen containing methotrexate doxorubicin and cisplatin versus a two-drug regimen.",
"     </li>",
"     <li>",
"      Investigators at St. Jude&rsquo;s Hospital have demonstrated good outcomes (five-year event free and overall survival rates 66 and 75 percent) with a non-",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      -containing chemotherapy regimen consisting of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The role of HDMTX in chemotherapy for osteosarcoma requires further study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/54\">",
"     54",
"    </a>",
"    ]. Until further information is available, we and others consider that a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    -containing regimen represents a standard approach for children and adults age 40 or younger.",
"   </p>",
"   <p>",
"    The optimal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    -containing regimen is not established. For institutions that are participating, enrollment of eligible children into COG AOST 0331 is preferred [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/42\">",
"     42",
"    </a>",
"    ]. For the treatment of children and adolescents, many centers that are not participating in the trial use the T10 protocol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/34\">",
"     34",
"    </a>",
"    ]. However, for patients who are not participating in the AOST 0331 trial, we consider the control arm of the protocol (MAP: high dose methotrexate plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ) (",
"    <a class=\"graphic graphic_table graphicRef62611 \" href=\"mobipreview.htm?14/2/14381\">",
"     table 5",
"    </a>",
"    ) to represent a reasonable and appropriate standard treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/42\">",
"     42",
"    </a>",
"    ]. At least some data suggest that substitution of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    for cisplatin is associated with inferior long-term outcomes, at least in patients with metastatic disease at diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A five-week cycle of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    day 1) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    (25",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    days 1 to 3), followed by two weekly doses of HDMTX (6 to 12",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    rescue), is often employed in younger adult patients, with three cycles administered preoperatively and three postoperatively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/56\">",
"     56",
"    </a>",
"    ]. This regimen, which represented the control arm in this randomized trial examining the benefit of adding mifamurtide to chemotherapy, was associated with a 71 percent three-year event-free survival rate. Approximately one-third of the enrolled patients were over the age of 15. (See",
"    <a class=\"local\" href=\"#H1781007\">",
"     'Benefit of mifamurtide'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Older adults are more commonly offered the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , although control arm of the AOST 0331 protocol (MAP chemotherapy) (",
"    <a class=\"graphic graphic_table graphicRef62611 \" href=\"mobipreview.htm?14/2/14381\">",
"     table 5",
"    </a>",
"    ) is also a reasonable standard of care in this population. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Chemotherapy for adults'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Practical tips on administration of HDMTX, including the rationale for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    rescue and prevention and management of prolonged high plasma MTX levels, is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/55/33658?source=see_link\">",
"     \"Therapeutic use and toxicity of high-dose methotrexate\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h4\">",
"     Benefit of adding a fourth drug",
"    </span>",
"    &nbsp;&mdash;&nbsp;The upfront addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    to HDMTX,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    improves initial tumor response rates, but it also increases toxicity, and the influence on overall and event-free survival is unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/56-60\">",
"     56-60",
"    </a>",
"    ]. A meta-analysis of 14 trials in localized osteosarcoma (the majority studying the addition of ifosfamide to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    plus doxorubicin and cisplatin) concluded that treatment effect was not significantly better with four as compared to three drugs (HR for event-free survival 0.956, 95% CI 0.779-1.177, HR for overall survival 1.043, 95% CI 0.851-1.280) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/6\">",
"     6",
"    </a>",
"    ]. Thus, the routine addition of ifosfamide (with or without etoposide) to adjuvant chemotherapy for osteosarcoma is difficult to recommend outside of a clinical trial. It is not known if adding or changing to ifosfamide for poor responders will help increase overall survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1781007\">",
"    <span class=\"h5\">",
"     Benefit of mifamurtide",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    in conjunction with the liposomal formulation of the immune stimulant muramyl tripeptide phosphatidylethanolamine (MTP-PE, mifamurtide, Junovan&reg;) was evaluated in a single large phase III study involving 677 patients (age up to 30 years) with nonmetastatic osteosarcoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/56\">",
"     56",
"    </a>",
"    ]. All patients received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , and were randomized in a 2 x 2 scheme to receive or not receive ifosfamide, and then to receive or not receive liposome encapsulated mifamurtide (see",
"    <a class=\"local\" href=\"#H22\">",
"     'Newer and investigational approaches'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The addition of mifamurtide significantly improved the overall survival rate (78 versus 70 percent at six years), a finding which led to European regulatory approval of this agent for patients with osteosarcoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/61\">",
"     61",
"    </a>",
"    ]. However, the results of this trial are controversial for several reasons. The initial published report stated that there was an interaction between",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    and mifamurtide that prevented the results from being analyzed as originally intended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/62\">",
"     62",
"    </a>",
"    ]. In addition, the improvement in event free survival (67 versus 61 percent) with mifamurtide did not reach statistical significance, which is very unusual in an oncology study in which the intervention leads to a statistically significant improvement in overall survival. As a result of these controversies, there is interest in further studying the efficacy of this agent in osteosarcoma prior to including mifamurtide as a standard component of chemotherapy for osteosarcoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/56,63,64\">",
"     56,63,64",
"    </a>",
"    ]. Although the drug has received regulatory approval in Europe and some other countries, further development of this agent (and drug approval in the United States) may prove difficult given a \"not approvable\" letter for use of mifamurtide in the adjuvant setting from the US Food and Drug Administration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h4\">",
"     Chemotherapy for adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intensive treatment with chemotherapy and resection is warranted in adults, since osteosarcoma is a potentially curable tumor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/9,57\">",
"     9,57",
"    </a>",
"    ]. Similar to children, the lack of a near-complete response to neoadjuvant chemotherapy predicts a poor prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In many (but not all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/65\">",
"     65",
"    </a>",
"    ]) series, adults, especially older adults, have a worse prognosis than do children with osteosarcoma. This was shown in a population-based series from the Surveillance, Epidemiology, and End Results (SEER) database of the National Cancer Institute [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/10\">",
"     10",
"    </a>",
"    ]. Of the 3482 cases of osteosarcoma reported between 1973 and 2004, there were 1855 cases in the 0 to 24 age group, 974 cases in adults 25 to 59 years of age, and 653 in adults 60 to &ge;85 years of age. Five-year survival rates in the three age groups were 62, 59, and 24 percent, respectively. When broken down by decade of age, five-year survival rates for adults in their 50s, middle to late 60s, and 80 to 84 years were 50, 17, and 11 percent, respectively.",
"   </p>",
"   <p>",
"    The optimal chemotherapy regimen for adults (at least those over the age of 40) is not established; almost all of the trials included in the systematic review discussed above were limited to individuals age 40 or younger [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/6\">",
"     6",
"    </a>",
"    ]. Only one trial enrolled older adults up to the age of 65 (range 14 to 62; median 42 years) and failed to show a benefit for the addition of HDMTX to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Older adults are most often offered",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (AP, doxorubicin 25",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day days 1 to 3, cisplatin 100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    day 1, every three weeks for six cycles) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/3,38,46\">",
"     3,38,46",
"    </a>",
"    ]. However, the dose and tolerability of high-dose cisplatin and the role of HDMTX remain unanswered questions. A",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    -containing regimen is a reasonable standard of care in this population, if patients can tolerate it. Options include a five-week cycle of cisplatin (100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    day 1) and doxorubicin (25",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    days 1 to 3), followed by two weekly doses of HDMTX (6 to 12",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    rescue), with three cycles administered preoperatively and three postoperatively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/56\">",
"     56",
"    </a>",
"    ], or the control arm of the AOST 0331 protocol (MAP chemotherapy) (",
"    <a class=\"graphic graphic_table graphicRef62611 \" href=\"mobipreview.htm?14/2/14381\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/42\">",
"     42",
"    </a>",
"    ], recognizing that dose reductions may be necessary in older adults. Monitoring renal function before and during treatment is paramount in such patients to minimize the risk of irreversible renal failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to Ewing sarcoma, conventional osteosarcoma is relatively resistant to radiation therapy (RT), although the small cell variant may be more radiosensitive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/66\">",
"     66",
"    </a>",
"    ]. Primary RT is usually inadequate to achieve local control, particularly for bulky tumors; surgery is preferred if possible. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/50/14122?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of the Ewing sarcoma family of tumors\", section on 'Local treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/51/37690?source=see_link\">",
"     \"Bone sarcomas: Preoperative evaluation, histologic classification, and principles of surgical management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prophylactic whole lung radiation has been used in an attempt to improve outcomes following surgery for nonmetastatic localized disease; however, it is not effective in the absence of systemic chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/67-69\">",
"     67-69",
"    </a>",
"    ]. Furthermore, in patients treated with effective surgery and chemotherapy, adjuvant radiation does not improve survival and increases the risk for secondary tumors; it should be considered only in the setting of an unresectable or incompletely resected primary tumor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There has been renewed interest in the use of RT for patients whose tumors respond to chemotherapy and in whom surgery would be debilitating. One report described a five-year local control rate of 56 percent among 31 patients with nonmetastatic extremity osteosarcoma who refused surgery and were instead treated with radiotherapy (median dose 60 Gy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/71\">",
"     71",
"    </a>",
"    ]. The five-year metastasis-free survival rate was 91 percent, and there were no local failures among the 11 patients who responded well to chemotherapy (ie, had both a radiographic and biochemical response with normalization of serum alkaline phosphatase). Among patients who achieved local control, 86 percent had \"excellent\" limb function. However, this single study does not represent sufficient data to recommend the use of RT as a replacement for surgery in patients with resectable tumors.",
"   </p>",
"   <p>",
"    The benefit of RT for local control may need to be readdressed in view of the availability of newer radiation techniques such as intensity modulated RT (IMRT), proton beam irradiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/72\">",
"     72",
"    </a>",
"    ], and carbon ion radiotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery and systemic chemotherapy are the mainstays of treatment for patients with nonmetastatic osteosarcomas. Preoperative as compared to postoperative administration may permit a greater number of patients with extremity tumors to undergo limb-sparing procedures. However, chemotherapy is not a substitute for sound surgical judgment when assessing the need for amputation. It is reasonable to proceed to immediate surgery followed by adjuvant chemotherapy if the nature of the resection would not necessarily be influenced by a good response to chemotherapy.",
"   </p>",
"   <p>",
"    Response to neoadjuvant chemotherapy is a major prognostic factor. It is unclear whether outcomes can be improved in poor responders by changes in the postoperative chemotherapy regimen.",
"   </p>",
"   <p>",
"    The optimal regimen has not been established; however, the available evidence supports the benefit of a three-drug as compared to a two-drug regimen in particular for children and younger adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For children and adolescents, we recommend the MAP regimen as was used in the control arm of the AOST 0331 protocol (",
"    <a class=\"graphic graphic_table graphicRef62611 \" href=\"mobipreview.htm?14/2/14381\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/42\">",
"     42",
"    </a>",
"    ]. If preoperative therapy is chosen, we administer 10 weeks of chemotherapy prior to surgery and continue postoperative chemotherapy for 29 weeks, beginning three weeks postoperatively. Where available, mifamurtide (MTP-PE) can be used in addition to chemotherapy.",
"   </p>",
"   <p>",
"    For adult patients under the age of 40, we use the same regimen as in children and adolescents. For older patients, in whom the biology of the tumor may be somewhat different, we generally employ",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    only, although a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    -containing regimen is also a reasonable approach.",
"   </p>",
"   <p>",
"    There is no role for adjuvant RT except in patients with incompletely resected osteosarcomas and possibly in the rare patient with a small cell osteosarcoma. RT for local control can be used in patients who decline surgery or for whom there is no effective surgical option.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     TREATMENT OF PATIENTS WITH METASTATIC DISEASE AT DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who present with overtly metastatic osteosarcoma have a poor prognosis; long-term survival rates with standard chemotherapy and surgery range from 10 to 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/7,26,58,74,75\">",
"     7,26,58,74,75",
"    </a>",
"    ]. This is in contrast to patients with apparently localized disease at presentation, two-thirds of whom will achieve long-term survival with appropriate therapy.",
"   </p>",
"   <p>",
"    Analogous to the situation with primary osteosarcomas, the ability to control all foci of macroscopic disease is an essential element for successful treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/25,76,77\">",
"     25,76,77",
"    </a>",
"    ]. The minority of patients with overt metastatic disease who achieve long-term survival and are presumably cured have usually been treated with a combination of surgery, chemotherapy, and sometimes RT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/7,75,78-80\">",
"     7,75,78-80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The location of the metastases is of prognostic importance. Patients with only pulmonary disease appear to have a chance of long-term event-free survival on the order of 20 to 30 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/79,81\">",
"     79,81",
"    </a>",
"    ]. In contrast, most series report a dismal prognosis for patients with bone metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/55,82,83\">",
"     55,82,83",
"    </a>",
"    ], with the exception of a single study that added",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    and high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    to standard chemotherapy (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Choice of chemotherapy'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although it might be argued that pulmonary lesions are more susceptible to chemotherapy than are bone metastases, there is also a tendency to surgically pursue pulmonary lesions more aggressively. In some studies, long-term survival correlates with the number of pulmonary nodules at diagnosis and the ability to successfully resect those that persist after chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/7,40,79,80,84-86\">",
"     7,40,79,80,84-86",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/15/13560?source=see_link\">",
"     \"Surgical resection of pulmonary metastases: Outcomes by histology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/32/13834?source=see_link\">",
"     \"Surgical resection of pulmonary metastases: Benefits; indications; preoperative evaluation and techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As noted previously, patients with bone metastases do less well. There are some long-term survivors among patients in whom bone disease has been treated aggressively (usually with chemotherapy in addition to complete resection, sometimes with irradiation) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/40,74,83,87\">",
"     40,74,83,87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Choice of chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optimal management for patients who present with metastatic osteosarcoma has not been defined by randomized clinical trials, and thus, there is no single standard approach. The most active drugs in patients with measurable disease (HDMTX,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    ) have single-agent response rates between 20 and 40 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/55,82,84,88-90\">",
"     55,82,84,88-90",
"    </a>",
"    ]. Response rates are higher with multiagent regimens but a lower proportion of patients treated for metastatic disease show a good histological response to neoadjuvant chemotherapy as compared to those with apparently localized disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/49,78,91\">",
"     49,78,91",
"    </a>",
"    ]. This suggests an underlying difference in the biological behavior.",
"   </p>",
"   <p>",
"    In an effort to improve outcomes, the Pediatric Oncology Group and others have utilized a strategy of applying novel agents to patients with newly diagnosed metastatic disease prior to standard therapy (termed the \"therapeutic window\" approach) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/40,55,80,84\">",
"     40,55,80,84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Using this approach, POG identified the combination of",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"      ifosfamide",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"      etoposide",
"     </a>",
"    </span>",
"    as effective induction therapy, particularly for those with metastatic bone disease. In one report, 43 patients under the age of 30 with measurable metastatic osteosarcoma at diagnosis (28 lung only, 12 with metastatic bone involvement, with or without lung metastases), received two three-week courses of etoposide and high-dose ifosfamide (17.5",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per cycle) with hematopoietic growth factor support, followed by surgery and an additional 34 weeks of \"continuation therapy\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/40\">",
"     40",
"    </a>",
"    ]. Postoperative therapy consisted of ten courses of HDMTX with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    rescue, four courses of",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"      doxorubicin",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"      cisplatin",
"     </a>",
"     ,",
"    </span>",
"    one course of doxorubicin alone, and three additional courses of etoposide plus lower-dose ifosfamide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment-related toxicity was prominent, and included 83 percent grade 4 neutropenia, 24 percent sepsis, 29 percent grade 4 thrombocytopenia, and five patients with Fanconi's syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/44/18120?source=see_link\">",
"     \"Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis\"",
"    </a>",
"    .) However, the overall response rate was 59 percent, and it was 80 percent for patients with synchronous bone metastases. The projected two-year progression-free survival rates were 34 and 58 percent for patients with lung-only and bone involvement, respectively. These results are superior to any other reports of patients with metastatic disease at diagnosis, particularly bone metastases.",
"   </p>",
"   <p>",
"    Nevertheless, few patients with metastatic osteosarcoma are cured, and new therapeutic approaches are needed.",
"   </p>",
"   <p>",
"    Dose-intensive chemotherapy with peripheral blood stem cell support is ineffective in metastatic osteosarcoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/92-94\">",
"     92-94",
"    </a>",
"    ]. For patients who present with overt metastatic disease, participation in experimental trials should be encouraged. Such a trial, AOST06P1, is testing the feasibility of adding",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    to multiagent chemotherapy (MAP chemotherapy plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/95\">",
"     95",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H264018\">",
"     'Bisphosphonates'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     POSTTREATMENT SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;For all bone sarcomas, there are no prospective data that address the appropriate schedule or selection of tests for surveillance after initial treatment for localized disease. Consensus-based guidelines from the National Comprehensive Cancer Network (NCCN) and from the Children's Oncology Group recommend physical examination, a complete blood count, chest imaging, and local imaging of the primary site every three months for two years, every four months for year three, every six months for years 4 and 5, and annually thereafter (",
"    <a class=\"graphic graphic_table graphicRef55623 \" href=\"mobipreview.htm?17/11/17597\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/96,97\">",
"     96,97",
"    </a>",
"    ]. The appropriate duration of follow-up is unknown; however, the vast majority of recurrences are observed within 10 years.",
"   </p>",
"   <p>",
"    At diagnosis, an initial technetium bone scan is performed to explore for bone metastases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/22/20842?source=see_link\">",
"     \"Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A restaging bone scan may be performed in some institutions at the completion of therapy (and is included in imaging guidelines from the Children&rsquo;s Oncology Group (",
"    <a class=\"graphic graphic_table graphicRef55623 \" href=\"mobipreview.htm?17/11/17597\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/97\">",
"     97",
"    </a>",
"    ]), but it is rarely positive. At most institutions, bone scans (as well as PET scans) are utilized primarily for evaluation of new symptoms following therapy. In the uncommon subset of patients with unresectable tumors (eg, in the proximal sacrum), PET scan may be preferable to bone scan for following the patient after radiation therapy since bone scans can show persistent activity reflective of ongoing bone remodeling in this setting.",
"   </p>",
"   <p>",
"    Following primary therapy, long term follow-up of patients should continue indefinitely, because of treatment-related toxicity (including secondary malignancy) and the possibility of a late relapse, which may occur as late as 20 years after therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     TREATMENT OF RECURRENT DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a disease recurrence after resection alone can often be salvaged with additional surgery and chemotherapy, although their long-term survival is inferior to that of patients who received conventional multiagent chemotherapy in conjunction with surgery upfront [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/99,100\">",
"     99,100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of relapse in patients who have already received adjuvant",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    neoadjuvant chemotherapy is a more difficult situation. Such patients usually have received most of the effective drugs, and presumably their tumors are more chemotherapy-resistant than those that have never been exposed to antineoplastic agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nevertheless, salvage is still possible and is more likely in patients with a longer relapse-free interval. In a large database of 565 osteosarcoma patients who relapsed after being treated on one of three different neoadjuvant chemotherapy protocols within the European Osteosarcoma Intergroup, five year survival post-relapse in those whose disease recurred after two years versus within two years of randomization was 35 versus 14 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/102\">",
"     102",
"    </a>",
"    ]. Other favorable prognostic factors in recurrent osteosarcoma include no more than one or two pulmonary nodules, the presence of unilateral pulmonary involvement, lack of pleural disruption, and achieving a second surgical remission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/27,99,103-105\">",
"     27,99,103-105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The predominant site of disease relapse is in the lung, but the increasing use of",
"    <span class=\"nowrap\">",
"     adjuvant/neoadjuvant",
"    </span>",
"    chemotherapy for localized osteosarcoma may have changed the pattern of relapse. Patients whose disease recurs following adjuvant chemotherapy tend to relapse later and with fewer pulmonary lesions than those treated with surgery alone; they also have a higher chance of relapsing at distant bony sites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/101,106-108\">",
"     101,106-108",
"    </a>",
"    ]. However, others have observed no change in relapse pattern with the increasing use of upfront intensive chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/109\">",
"     109",
"    </a>",
"    ]. Although rare, the possibility of metachronous, sometimes multiple osteosarcomas must be considered in a patient who has what appears to be isolated bone relapse without pulmonary involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/110\">",
"     110",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Therapeutic approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The therapeutic approach to recurrent disease and the likelihood of prolonged survival are related to the location, extent, and timing of relapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/99,104,111\">",
"     99,104,111",
"    </a>",
"    ]. Attempted resection is probably the most appropriate initial treatment for patients who relapse late (ie, beyond one year after initial therapy) with a small number of pulmonary nodules that do not invade the pleura and that can be completely resected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/77,112-119\">",
"     77,112-119",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete resection of all metastatic sites is a prerequisite for long-term survival. The importance of resection can be illustrated by a series of 249 consecutive patients who developed a second or subsequent recurrence after modern combined modality treatment of osteosarcoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/111\">",
"     111",
"    </a>",
"    ]. While only one of 205 patients with recurrence survived past five years without surgical remission, the five-year survival and event-free survival rates were 32 and 18 percent for 119 second, 26 and 0 percent for 45 third, 28 and 13 percent for 20 fourth, and 53 and 0 percent for five fifth recurrences, respectively, in which a surgical remission was achieved.",
"   </p>",
"   <p>",
"    Some patients with isolated pulmonary metastases that develop more than one year after original treatment will be long-term survivors with just surgical removal of their lung nodules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/77,112\">",
"     77,112",
"    </a>",
"    ]. Multiple procedures may be necessary, although the odds of long-term survival decrease with each subsequent relapse. Many investigators advocate the use of postthoracotomy chemotherapy (and even lung irradiation) to destroy presumed residual microscopic deposits after surgical treatment of overt metastatic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/120\">",
"     120",
"    </a>",
"    ]. The contribution of such therapy to long-term outcomes has not been examined in a controlled study and remains to be defined. However, it is probably reasonable to administer such treatment to patients who undergo resection of more than three lesions appearing within six months to one year of surgery.",
"   </p>",
"   <p>",
"    Patients who relapse early (ie, within six months of surgery) seem to fare poorly even if their disease is amenable to complete resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/77,103,113,121\">",
"     77,103,113,121",
"    </a>",
"    ]. This is most likely because of drug resistance that develops during chemotherapy. Although aggressive use of surgery, chemotherapy, and at times RT aimed at eradicating all sites of disease can lead to prolonged survival in some of these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/101,103,114,120,122-124\">",
"     101,103,114,120,122-124",
"    </a>",
"    ], it is difficult to be overly optimistic about the chances of cure after early relapse, especially relapse involving nonpulmonary sites or unresectable pulmonary disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/21,103,113,115\">",
"     21,103,113,115",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Unresectable disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who relapse with unresectable metastatic disease are most often incurable and should be considered for palliative therapy (eg, RT) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/125\">",
"     125",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For selected patients with a limited volume of unresectable disease, particularly those who have no prior exposure to systemic chemotherapy, consideration should be given to administering chemotherapy before resection. While chemotherapy rarely produces a complete response at metastatic sites, some patients with inoperable metastases (including the rare patient with bone metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/126\">",
"     126",
"    </a>",
"    ]) may respond sufficiently to permit complete resection at a later date. While it has not been shown that chemotherapy given before or after resection of metastatic lung disease improves patient survival in comparison to patients who have resection of metastases alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/85\">",
"     85",
"    </a>",
"    ], there are no randomized trials that directly address this issue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Choice of chemotherapy regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of these patients will already have received standard chemotherapy with HDMTX,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    . Combinations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    are more active than either agent alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/80,127\">",
"     80,127",
"    </a>",
"    ] and commonly used, without or with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    (ICE) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/128-130\">",
"     128-130",
"    </a>",
"    ]. In general, response rates are lower than in the setting of newly diagnosed disease. However, although ifosfamide clearly shows a higher response rate in newly diagnosed patients, objective responses have been reported in patients whose disease relapses after they have received ifosfamide-containing adjuvant therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/80,128,131\">",
"     80,128,131",
"    </a>",
"    ]. Combinations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    with etoposide are also active [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/132\">",
"     132",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In an early report 14 of 42 children with recurrent osteosarcoma (33 percent) responded to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    daily for three days) and lower dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    (2",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    daily for three days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/131\">",
"     131",
"    </a>",
"    ]. With the expectation that adding G-CSF would permit dose intensification, a phase I trial of etoposide and escalating doses of ifosfamide in patients with recurrent osteosarcoma was completed; in a preliminary report, six of 13 patients exhibited a partial response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/133\">",
"     133",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another option is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/132,134,135\">",
"     132,134,135",
"    </a>",
"    ] or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/136\">",
"     136",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H186011297\">",
"    <span class=\"h2\">",
"     Samarium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Samarium-153 lexidronam is a bone-seeking radiopharmaceutical that may provide pain palliation for patients with an unresectable local recurrence or skeletal metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/137,138\">",
"     137,138",
"    </a>",
"    ]. However, as a radioactive agent that is taken up by bone, Samarium-153 can be toxic to bone marrow and can leave patients transfusion dependent. Thus, marrow reserve should be considered before its use. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33924?source=see_link&amp;anchor=H5#H5\">",
"     \"Radiation therapy for the management of painful bone metastases\", section on 'Radiopharmaceuticals'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     NEWER AND INVESTIGATIONAL APPROACHES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A study of the mTOR inhibitor ridaforolimus in patients with metastatic sarcoma suggests potential activity for this class of compounds in patients with osteosarcoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/139\">",
"     139",
"    </a>",
"    ], raising the possibility of using agents of this drug class in patients with metastatic disease.",
"   </p>",
"   <p>",
"    Among other interesting agents that may have clinical utility are inhibitors of insulin-like growth factor I receptor (IGF IR), since IGF signaling is critical for bone formation during development. Early studies with a variety of monoclonal antibodies and small molecule inhibitors of the IGF IR are underway.",
"   </p>",
"   <p>",
"    A study evaluating the feasibility of adding",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    to standard chemotherapy for patients with HER2-positive osteosarcoma was just completed by the Children's Oncology Group (COG) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/140\">",
"     140",
"    </a>",
"    ]. The results of this study are not yet available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H264018\">",
"    <span class=\"h2\">",
"     Bisphosphonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous in vitro and xenograft studies support the concept that bisphosphonates have activity against osteosarcoma alone or in combination with chemotherapy (reviewed in [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/141\">",
"     141",
"    </a>",
"    ]); the safety of combining",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    with chemotherapy in patients with newly diagnosed osteosarcoma has been shown in a small phase II trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/141\">",
"     141",
"    </a>",
"    ]. However, until further data are available, this approach should not be considered outside of the context of a clinical trial. The COG is evaluating the feasibility of adding",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    to standard chemotherapy for patients with metastatic osteosarcoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Immunotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immune responses may influence the survival of patients with osteosarcoma. Cytotoxic lymphocytes are present in such patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/142,143\">",
"     142,143",
"    </a>",
"    ], and in at least one study, the degree of lymphocytic infiltration correlated with survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/143\">",
"     143",
"    </a>",
"    ]. These findings have prompted investigators to explore a variety of immunotherapeutic approaches for patients with advanced osteosarcoma.",
"   </p>",
"   <p>",
"    The addition of Bacille Calmette-Guerin (BCG) and interferon did not improve survival when added to multiagent chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/144,145\">",
"     144,145",
"    </a>",
"    ]. However, as noted above, liposomal muramyl tripeptide-phosphatidyl-ethanolamine (mifamurtide), an agent derived from BCG that activates macrophages and increases circulating cytokine levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/146,147\">",
"     146,147",
"    </a>",
"    ], was studied in a randomized study, described above, in which patients were assigned, using a 2 x 2 factorial design, to standard chemotherapy with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    and then to receive or not receive mifamurtide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/56\">",
"     56",
"    </a>",
"    ]. The addition of mifamurtide to standard chemotherapy significantly improved overall survival but there was only a trend toward improved event-free survival. (See",
"    <a class=\"local\" href=\"#H1781007\">",
"     'Benefit of mifamurtide'",
"    </a>",
"    above.).",
"   </p>",
"   <p>",
"    However, when the analysis was restricted to the 91 patients with metastatic disease at diagnosis, there was only a nonstatistically significant trend toward improved five-year event free survival (42 versus 26 percent) and overall survival (53 versus 40 percent) that favored mifamurtide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/148\">",
"     148",
"    </a>",
"    ]. Thus, the role of mifamurtide in patients with metastatic osteosarcoma remains uncertain and a further randomized trial seems warranted.",
"   </p>",
"   <p>",
"    Another immunotherapeutic approach that is being pursued for pulmonary metastatic disease is inhalation of aerosolized granulocyte macrophage colony-stimulating factor (GM-CSF). GM-CSF stimulates the proliferation and differentiation of hematopoietic progenitor cells and augments the functional activity of neutrophils, monocytes, macrophages, and dendritic cells. &nbsp;Early data using aerosolized GM-CSF in a variety of cancers with pulmonary metastases suggested potential efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/149,150\">",
"     149,150",
"    </a>",
"    ]. However, benefit could not be shown in a trial of inhaled GM-CSF in 43 patients with pulmonary relapse from osteosarcoma in the American Osteosarcoma Study Group [AOST] protocol 0221 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/151\">",
"     151",
"    </a>",
"    ]. There was no detectable immunostimulatory effect on the pulmonary metastases or suggestion of improved outcomes post relapse. Aerosolized GM-CSF is not a standard approach and should only be considered in the context of a clinical trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/63/33778?source=see_link\">",
"       \"Patient information: Bone cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8081126\">",
"    <span class=\"h2\">",
"     Localized disease",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The survival of patients with malignant bone sarcomas has improved dramatically over the past 30 years, largely owing to chemotherapeutic advances. Adjuvant chemotherapy significantly improves survival compared to surgery alone and is considered a standard component of therapy for both children and adults. (See",
"      <a class=\"local\" href=\"#H1780929\">",
"       'Prognosis and evolution of treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal timing of chemotherapy (ie, preoperative versus postoperative) has not been established. There is no survival benefit for neoadjuvant as compared to adjuvant chemotherapy, but many centers preferentially utilize preoperative chemotherapy, particularly if a limb-sparing procedure is being contemplated for an extremity osteosarcoma. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Neoadjuvant versus adjuvant chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For children, adolescents, and young adults up to age 40, we suggest a",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      -containing chemotherapy regimen over a two-drug non-methotrexate containing regimen (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5448439\">",
"       'Role of methotrexate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      -containing regimen has not been established. For children, adolescents, and young adults up to age 40 with localized osteosarcoma, the control arm of the recently closed protocol AOST0331 (MAP chemotherapy, HDMTX plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      , (",
"      <a class=\"graphic graphic_table graphicRef62611 \" href=\"mobipreview.htm?14/2/14381\">",
"       table 5",
"      </a>",
"      )) is a reasonable and appropriate choice for standard therapy. If preoperative therapy is chosen, we administer 10 weeks of chemotherapy prior to surgery and continue postoperative chemotherapy for 29 weeks, starting one week postoperatively.",
"     </li>",
"     <li>",
"      For most patients, we suggest against a four-drug as compared to a three-drug regimen (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). However, in countries where mifamurtide is available, mifamurtide in conjunction with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      chemotherapy may be used. (See",
"      <a class=\"local\" href=\"#H1781007\">",
"       'Benefit of mifamurtide'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For older adults, the benefit of HDMTX is unproven, and we suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      alone (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). However, a HDMTX-containing regimen is a reasonable alternative in patients with adequate renal function. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Chemotherapy for adults'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Practical tips on administration of HDMTX, including therapeutic drug monitoring, the rationale for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      rescue and prevention and management of prolonged high plasma MTX levels, are discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/55/33658?source=see_link\">",
"       \"Therapeutic use and toxicity of high-dose methotrexate\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients who demonstrate an intolerance for HDMTX and for institutions that cannot provide pharmacokinetic monitoring for HDMTX, the combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      appears to be a reasonable alternative. (See",
"      <a class=\"local\" href=\"#H5448439\">",
"       'Role of methotrexate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients treated off protocol, we suggest not pursuing a change in the chemotherapeutic regimen after surgery in patients who have less than a complete response to the initial neoadjuvant chemotherapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Tailored postoperative chemotherapy based upon initial response'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no role for adjuvant RT in patients with completely resected osteosarcoma, and for most patients, we recommend not pursuing this approach because of the risk for late toxicity (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We restrict the use of adjuvant RT to those patients with incompletely resected sarcomas and for the rare patient with a small cell osteosarcoma. RT should be considered as the primary modality for local control only for patients who decline surgery or for whom there is no effective surgical option. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Radiation therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Metastatic disease at diagnosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who present with overtly metastatic osteosarcoma have a poor prognosis, although long-term survival is possible in up to 50 percent of those with isolated pulmonary metastases who are treated with combined systemic and surgical therapy. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Treatment of patients with metastatic disease at diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/32/13834?source=see_link\">",
"       \"Surgical resection of pulmonary metastases: Benefits; indications; preoperative evaluation and techniques\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/15/13560?source=see_link\">",
"       \"Surgical resection of pulmonary metastases: Outcomes by histology\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For children and adolescents with metastatic osteosarcoma at the time of diagnosis who do not have a surgical option, there is no single standard approach to treatment, and these patients should be encouraged to enroll on clinical trials testing new therapies. We prefer that these patients be enrolled in the current study protocol of the Childrens Oncology Group, AOST06P1, which is testing the benefit of adding",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      to multiagent chemotherapy (MAP chemotherapy plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/8/39050/abstract/95\">",
"       95",
"      </a>",
"      ]. If protocol enrollment is not available or if patients are ineligible, treatment with the control arm of the AOST0331 protocol (MAP chemotherapy alone, (",
"      <a class=\"graphic graphic_table graphicRef62611 \" href=\"mobipreview.htm?14/2/14381\">",
"       table 5",
"      </a>",
"      )) or as per AOST06P1 without zoledronic acid (MAP plus ifosfamide and etoposide) are reasonable and appropriate choices for standard therapy. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Choice of chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2220224\">",
"    <span class=\"h2\">",
"     Posttreatment surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;We follow guidelines for posttreatment surveillance from the Children&rsquo;s Oncology Group, which are outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef55623 \" href=\"mobipreview.htm?17/11/17597\">",
"     table 6",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Posttreatment surveillance'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Recurrent disease",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The predominant site of disease relapse following initially successful treatment is lung. Attempted resection is probably the most appropriate initial treatment for patients who relapse beyond one year after initial therapy with a small number of pulmonary nodules that do not invade the pleura and that can be completely resected. Although some of these patients may be cured with resection alone, most receive a combination of surgery plus chemotherapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/15/13560?source=see_link\">",
"       \"Surgical resection of pulmonary metastases: Outcomes by histology\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/32/13834?source=see_link\">",
"       \"Surgical resection of pulmonary metastases: Benefits; indications; preoperative evaluation and techniques\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients who relapse with unresectable metastatic disease are incurable and should be considered for palliative therapy (eg, RT, chemotherapy). However, in selected patients with a limited volume of unresectable disease, particularly those who have no prior exposure to systemic chemotherapy, consideration should be given to administering chemotherapy before resection. While chemotherapy rarely produces a complete response at metastatic sites, some patients with inoperable metastases may respond sufficiently to permit complete resection at a later date. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Therapeutic approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The choice of chemotherapy depends upon prior treatment. Most patients will have already received HDMTX,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      . For these patients, we suggest treatment on a research study, when feasible. Off study, we typically use",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      , without or with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      (ICE). If chemotherapy has not been previously administered, we suggest the same regimens as are used for primary management. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Choice of chemotherapy regimen'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Gurney JG, Swensen AR, Bulterys M. Malignant bone tumors. In: Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975-1995 (Pub #99-4649), Ries LA, Smith MAS, Gurney JG, et al (Eds), SEER program, National Cancer Institute, Bethesda, MD 1999. p.99.",
"    </li>",
"    <li>",
"     Data from the American Cancer Society file://www.cancer.org/docroot/home/index.asp (Accessed on June 01, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/3\">",
"      Bramwell VH, Steward WP, Nooij M, et al. Neoadjuvant chemotherapy with doxorubicin and cisplatin in malignant fibrous histiocytoma of bone: A European Osteosarcoma Intergroup study. J Clin Oncol 1999; 17:3260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/4\">",
"      Palmerini E, Maki RG, Staals EL, et al. Primary Angiosarcoma of Bone: A Retrospective Analysis of 60 Patients From 2 Institutions. Am J Clin Oncol 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/5\">",
"      Bruland OS, H&oslash;if&oslash;dt H, Saeter G, et al. Hematogenous micrometastases in osteosarcoma patients. Clin Cancer Res 2005; 11:4666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/6\">",
"      Anninga JK, Gelderblom H, Fiocco M, et al. Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? Eur J Cancer 2011; 47:2431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/7\">",
"      Aljubran AH, Griffin A, Pintilie M, Blackstein M. Osteosarcoma in adolescents and adults: survival analysis with and without lung metastases. Ann Oncol 2009; 20:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/8\">",
"      Longhi A, Errani C, Gonzales-Arabio D, et al. Osteosarcoma in patients older than 65 years. J Clin Oncol 2008; 26:5368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/9\">",
"      Grimer RJ, Cannon SR, Taminiau AM, et al. Osteosarcoma over the age of forty. Eur J Cancer 2003; 39:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/10\">",
"      Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 2009; 115:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/11\">",
"      Janeway KA, Barkauskas DA, Krailo MD, et al. Outcome for adolescent and young adult patients with osteosarcoma: a report from the Children's Oncology Group. Cancer 2012; 118:4597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/12\">",
"      Rosen G, Marcove RC, Huvos AG, et al. Primary osteogenic sarcoma: eight-year experience with adjuvant chemotherapy. J Cancer Res Clin Oncol 1983; 106 Suppl:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/13\">",
"      Eilber F, Giuliano A, Eckardt J, et al. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol 1987; 5:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/14\">",
"      Link MP, Goorin AM, Miser AW, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986; 314:1600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/15\">",
"      Link MP, Goorin AM, Horowitz M, et al. Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the Multi-Institutional Osteosarcoma Study. Clin Orthop Relat Res 1991; :8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/16\">",
"      Bernthal NM, Federman N, Eilber FR, et al. Long-term results (&gt;25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcoma. Cancer 2012; 118:5888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/17\">",
"      Rosen G. Preoperative (neoadjuvant) chemotherapy for osteogenic sarcoma: a ten year experience. Orthopedics 1985; 8:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/18\">",
"      Goorin AM, Schwartzentruber DJ, Devidas M, et al. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol 2003; 21:1574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/19\">",
"      Bacci G, Bertoni F, Longhi A, et al. Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity. Histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor. Cancer 2003; 97:3068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/20\">",
"      Hauben EI, Weeden S, Pringle J, et al. Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup. Eur J Cancer 2002; 38:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/21\">",
"      Picci P, Sangiorgi L, Rougraff BT, et al. Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma. J Clin Oncol 1994; 12:2699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/22\">",
"      Bielack SS, Kempf-Bielack B, Winkler K. Osteosarcoma: relationship of response to preoperative chemotherapy and type of surgery to local recurrence. J Clin Oncol 1996; 14:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/23\">",
"      Kawai A, Healey JH, Boland PJ, et al. Prognostic factors for patients with sarcomas of the pelvic bones. Cancer 1998; 82:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/24\">",
"      Bacci G, Picci P, Ruggieri P, et al. Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. The Istituto Rizzoli Experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin. Cancer 1990; 65:2539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/25\">",
"      Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002; 20:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/26\">",
"      Petrilli AS, de Camargo B, Filho VO, et al. Results of the Brazilian Osteosarcoma Treatment Group Studies III and IV: prognostic factors and impact on survival. J Clin Oncol 2006; 24:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/27\">",
"      Bacci G, Longhi A, Versari M, et al. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 2006; 106:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/28\">",
"      Imbriaco M, Yeh SD, Yeung H, et al. Thallium-201 scintigraphy for the evaluation of tumor response to preoperative chemotherapy in patients with osteosarcoma. Cancer 1997; 80:1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/29\">",
"      Ilhan IE, Vural G, Berberoglu S, et al. Quantitative thallium-201 scintigraphy in childhood osteosarcoma: Comparison with technetuim-99m MDP and magnetic resonance imaging in the evaluation of chemotherapeutic response. Pediatr Hematol Oncol 2005; 22:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/30\">",
"      Kaste SC, Billips C, Tan M, et al. Thallium bone imaging as an indicator of response and outcome in nonmetastatic primary extremity osteosarcoma. Pediatr Radiol 2001; 31:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/31\">",
"      Rosen G, Caparros B, Huvos AG, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 1982; 49:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/32\">",
"      Bacci G, Picci P, Ferrari S, et al. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer 1993; 72:3227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/33\">",
"      Bacci G, Ferrari S, Bertoni F, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol 2000; 18:4016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/34\">",
"      Meyers PA, Heller G, Healey J, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol 1992; 10:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/35\">",
"      Provisor AJ, Ettinger LJ, Nachman JB, et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol 1997; 15:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/36\">",
"      Saeter G, Alveg&aring;rd TA, Elomaa I, et al. Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: a Scandinavian Sarcoma Group study. J Clin Oncol 1991; 9:1766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/37\">",
"      Winkler K, Beron G, Delling G, et al. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol 1988; 6:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/38\">",
"      Souhami RL, Craft AW, Van der Eijken JW, et al. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet 1997; 350:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/39\">",
"      Smeland S, M&uuml;ller C, Alvegard TA, et al. Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer 2003; 39:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/40\">",
"      Goorin AM, Harris MB, Bernstein M, et al. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. J Clin Oncol 2002; 20:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/41\">",
"      Schwartz CL, Wexler LH, Devidas M, et al. P9754 therapeutic intensification in non-metastatic osteosarcoma: a COG trial (abstract). Proc Am Soc Clin Oncol 2004; 23:798a.",
"     </a>",
"    </li>",
"    <li>",
"     Protocol information available online at file://www.clinicaltrials.gov/ct2/show/NCT00134030?term=AOST+0331&amp;rank=1 (Accessed on July 19, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/43\">",
"      Imran H, Enders F, Krailo M, et al. Effect of time to resumption of chemotherapy after definitive surgery on prognosis for non-metastatic osteosarcoma. J Bone Joint Surg Am 2009; 91:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/44\">",
"      Ferguson WS, Goorin AM. Current treatment of osteosarcoma. Cancer Invest 2001; 19:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/45\">",
"      Lewis IJ, Weeden S, Machin D, et al. Received dose and dose-intensity of chemotherapy and outcome in nonmetastatic extremity osteosarcoma. European Osteosarcoma Intergroup. J Clin Oncol 2000; 18:4028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/46\">",
"      Bramwell VH, Burgers M, Sneath R, et al. A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. J Clin Oncol 1992; 10:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/47\">",
"      Daw NC, Neel MD, Rao BN, et al. Frontline treatment of localized osteosarcoma without methotrexate: results of the St. Jude Children's Research Hospital OS99 Trial. Cancer 2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/48\">",
"      Krailo M, Ertel I, Makley J, et al. A randomized study comparing high-dose methotrexate with moderate-dose methotrexate as components of adjuvant chemotherapy in childhood nonmetastatic osteosarcoma: a report from the Childrens Cancer Study Group. Med Pediatr Oncol 1987; 15:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/49\">",
"      Bacci G, Ferrari S, Delepine N, et al. Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. J Clin Oncol 1998; 16:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/50\">",
"      Delepine N, Delepine G, Jasmin C, et al. Importance of age and methotrexate dosage: prognosis in children and young adults with high-grade osteosarcomas. Biomed Pharmacother 1988; 42:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/51\">",
"      Graf N, Winkler K, Betlemovic M, et al. Methotrexate pharmacokinetics and prognosis in osteosarcoma. J Clin Oncol 1994; 12:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/52\">",
"      Zelcer S, Kellick M, Wexler LH, et al. Methotrexate levels and outcome in osteosarcoma. Pediatr Blood Cancer 2005; 44:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/53\">",
"      Daw NC, Neel MD, Rao BN, et al. Frontline treatment of localized osteosarcoma without methotrexate: results of the St. Jude Children's Research Hospital OS99 trial. Cancer 2011; 117:2770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/54\">",
"      van Dalen EC, de Camargo B. Methotrexate for high-grade osteosarcoma in children and young adults. Cochrane Database Syst Rev 2009; :CD006325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/55\">",
"      Ferguson WS, Harris MB, Goorin AM, et al. Presurgical window of carboplatin and surgery and multidrug chemotherapy for the treatment of newly diagnosed metastatic or unresectable osteosarcoma: Pediatric Oncology Group Trial. J Pediatr Hematol Oncol 2001; 23:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/56\">",
"      Meyers PA, Schwartz CL, Krailo MD, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group. J Clin Oncol 2008; 26:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/57\">",
"      Patel SJ, Lynch JW Jr, Johnson T, et al. Dose-intense ifosfamide/doxorubicin/cisplatin based chemotherapy for osteosarcoma in adults. Am J Clin Oncol 2002; 25:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/58\">",
"      Bacci G, Briccoli A, Ferrari S, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli's 4th protocol. Eur J Cancer 2001; 37:2030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/59\">",
"      Zalupski MM, Rankin C, Ryan JR, et al. Adjuvant therapy of osteosarcoma--A Phase II trial: Southwest Oncology Group study 9139. Cancer 2004; 100:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/60\">",
"      Ferrari S, Ruggieri P, Cefalo G, et al. Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1. J Clin Oncol 2012; 30:2112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/61\">",
"      Bielack S, Carrle D, Casali PG. Osteosarcoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20:iv137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/62\">",
"      Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 2005; 23:2004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/63\">",
"      Bielack SS, Marina N, Ferrari S, et al. Osteosarcoma: the same old drugs or more? J Clin Oncol 2008; 26:3102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/64\">",
"      Hunsberger S, Freidlin B, Smith MA. Complexities in interpretation of osteosarcoma clinical trial results. J Clin Oncol 2008; 26:3103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/65\">",
"      Harting MT, Lally KP, Andrassy RJ, et al. Age as a prognostic factor for patients with osteosarcoma: an analysis of 438 patients. J Cancer Res Clin Oncol 2010; 136:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/66\">",
"      Stea B, Cavazzana A, Kinsella TJ. Small-cell osteosarcoma: correlation of in vitro and clinical radiation response. Int J Radiat Oncol Biol Phys 1988; 15:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/67\">",
"      Zaharia M, Caceres E, Valdivia S, et al. Postoperative whole lung irradiation with or without adriamycin in osteogenic sarcoma. Int J Radiat Oncol Biol Phys 1986; 12:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/68\">",
"      Whelan JS, Burcombe RJ, Janinis J, et al. A systematic review of the role of pulmonary irradiation in the management of primary bone tumours. Ann Oncol 2002; 13:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/69\">",
"      Age and dose of chemotherapy as major prognostic factors in a trial of adjuvant therapy of osteosarcoma combining two alternating drug combinations and early prophylactic lung irradiation. French Bone Tumor Study Group. Cancer 1988; 61:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/70\">",
"      DeLaney TF, Park L, Goldberg SI, et al. Radiotherapy for local control of osteosarcoma. Int J Radiat Oncol Biol Phys 2005; 61:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/71\">",
"      Machak GN, Tkachev SI, Solovyev YN, et al. Neoadjuvant chemotherapy and local radiotherapy for high-grade osteosarcoma of the extremities. Mayo Clin Proc 2003; 78:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/72\">",
"      Ciernik IF, Niemierko A, Harmon DC, et al. Proton-based radiotherapy for unresectable or incompletely resected osteosarcoma. Cancer 2011; 117:4522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/73\">",
"      Matsunobu A, Imai R, Kamada T, et al. Impact of carbon ion radiotherapy for unresectable osteosarcoma of the trunk. Cancer 2012; 118:4555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/74\">",
"      Kager L, Zoubek A, P&ouml;tschger U, et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 2003; 21:2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/75\">",
"      Mialou V, Philip T, Kalifa C, et al. Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome--the French pediatric experience. Cancer 2005; 104:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/76\">",
"      Bacci G, Briccoli A, Ferrari S, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities with synchronous lung metastases: treatment with cisplatin, adriamycin and high dose of methotrexate and ifosfamide. Oncol Rep 2000; 7:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/77\">",
"      Goorin AM, Delorey MJ, Lack EE, et al. Prognostic significance of complete surgical resection of pulmonary metastases in patients with osteogenic sarcoma: analysis of 32 patients. J Clin Oncol 1984; 2:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/78\">",
"      Bacci G, Briccoli A, Ferrari S, et al. [Osteosarcoma of the extremities metastatic at presentation. Results obtained with primary chemotherapy followed by simultaneous resection of the primary and metastatic lesion]. Minerva Chir 1993; 48:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/79\">",
"      Bacci G, Rocca M, Salone M, et al. High grade osteosarcoma of the extremities with lung metastases at presentation: treatment with neoadjuvant chemotherapy and simultaneous resection of primary and metastatic lesions. J Surg Oncol 2008; 98:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/80\">",
"      Harris MB, Cantor AB, Goorin AM, et al. Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previously untreated: a Pediatric Oncology Group study. Med Pediatr Oncol 1995; 24:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/81\">",
"      Bacci G, Briccoli A, Rocca M, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. Ann Oncol 2003; 14:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/82\">",
"      Meyers PA, Heller G, Healey JH, et al. Osteogenic sarcoma with clinically detectable metastasis at initial presentation. J Clin Oncol 1993; 11:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/83\">",
"      Bacci G, Picci P, Ferrari S, et al. Synchronous multifocal osteosarcoma: results in twelve patients treated with neoadjuvant chemotherapy and simultaneous resection of all involved bones. Ann Oncol 1996; 7:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/84\">",
"      Harris MB, Gieser P, Goorin AM, et al. Treatment of metastatic osteosarcoma at diagnosis: a Pediatric Oncology Group Study. J Clin Oncol 1998; 16:3641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/85\">",
"      Thompson RC Jr, Cheng EY, Clohisy DR, et al. Results of treatment for metastatic osteosarcoma with neoadjuvant chemotherapy and surgery. Clin Orthop Relat Res 2002; :240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/86\">",
"      Mialou V, Philip T, P&eacute;rol D, et al. [Metastatic osteosarcoma: prognosis factors and treatment]. Bull Cancer 2001; 88:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/87\">",
"      Leavey PJ, Day MD, Booth T, Maale G. Skip metastasis in osteosarcoma. J Pediatr Hematol Oncol 2003; 25:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/88\">",
"      Benjamin RS, Baker LH, O'Bryan RM, et al. Chemotherapy for metastic osteosarcoma--studies by the M.D. Anderson Hospital and the Southwest Oncology Group. Cancer Treat Rep 1978; 62:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/89\">",
"      Edmonson JH, Creagan ET, Gilchrist GS. Phase II study of high-dose methotrexate in patients with unresectable metastatic osteosarcoma. Cancer Treat Rep 1981; 65:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/90\">",
"      Baum ES, Gaynon P, Greenberg L, et al. Phase II study of cis-dichlorodiammineplatinum(II) in childhood osteosarcoma: Children's Cancer Study Group Report. Cancer Treat Rep 1979; 63:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/91\">",
"      Bacci G, Picci P, Briccoli A, et al. Osteosarcoma of the extremity metastatic at presentation: results achieved in 26 patients treated with combined therapy (primary chemotherapy followed by simultaneous resection of the primary and metastatic lesions). Tumori 1992; 78:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/92\">",
"      Hawkins DS, Felgenhauer J, Park J, et al. Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas. Cancer 2002; 95:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/93\">",
"      Fagioli F, Aglietta M, Tienghi A, et al. High-dose chemotherapy in the treatment of relapsed osteosarcoma: an Italian sarcoma group study. J Clin Oncol 2002; 20:2150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/94\">",
"      Miniero R, Brach del Prever A, Vassallo E, et al. Feasibility of high-dose chemotherapy and autologous peripheral blood stem cell transplantation in children with high grade osteosarcoma. Bone Marrow Transplant 1998; 22 Suppl 5:S37.",
"     </a>",
"    </li>",
"    <li>",
"     Protocol information available at www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=543987&amp;version=HealthProfessional&amp;protocolsearchid=6307581 (Accessed on June 07, 2011).",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/97\">",
"      Meyer JS, Nadel HR, Marina N, et al. Imaging guidelines for children with Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group Bone Tumor Committee. Pediatr Blood Cancer 2008; 51:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/98\">",
"      Ferrari S, Briccoli A, Mercuri M, et al. Late relapse in osteosarcoma. J Pediatr Hematol Oncol 2006; 28:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/99\">",
"      Hawkins DS, Arndt CA. Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy. Cancer 2003; 98:2447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/100\">",
"      Bacci G, Forni C, Longhi A, et al. Local recurrence and local control of non-metastatic osteosarcoma of the extremities: a 27-year experience in a single institution. J Surg Oncol 2007; 96:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/101\">",
"      Goorin AM, Shuster JJ, Baker A, et al. Changing pattern of pulmonary metastases with adjuvant chemotherapy in patients with osteosarcoma: results from the multiinstitutional osteosarcoma study. J Clin Oncol 1991; 9:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/102\">",
"      Gelderblom H, Jinks RC, Sydes M, et al. Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials. Eur J Cancer 2011; 47:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/103\">",
"      Kempf-Bielack B, Bielack SS, J&uuml;rgens H, et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 2005; 23:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/104\">",
"      Ferrari S, Briccoli A, Mercuri M, et al. Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. J Clin Oncol 2003; 21:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/105\">",
"      Chou AJ, Merola PR, Wexler LH, et al. Treatment of osteosarcoma at first recurrence after contemporary therapy: the Memorial Sloan-Kettering Cancer Center experience. Cancer 2005; 104:2214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/106\">",
"      Bacci G, Ferrari S, Longhi A, et al. Pattern of relapse in patients with osteosarcoma of the extremities treated with neoadjuvant chemotherapy. Eur J Cancer 2001; 37:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/107\">",
"      Jaffe N, Smith E, Abelson HT, Frei E 3rd. Osteogenic sarcoma: alterations in the pattern of pulmonary metastases with adjuvant chemotherapy. J Clin Oncol 1983; 1:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/108\">",
"      Bacci G, Balladelli A, Forni C, et al. Adjuvant and neo-adjuvant chemotherapy for Ewing's sarcoma family tumors and osteosarcoma of the extremity: further outcome for patients event-free survivors 5 years from the beginning of treatment. Ann Oncol 2007; 18:2037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/109\">",
"      Chi SN, Conklin LS, Qin J, et al. The patterns of relapse in osteosarcoma: the Memorial Sloan-Kettering experience. Pediatr Blood Cancer 2004; 42:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/110\">",
"      Jaffe N, Pearson P, Yasko AW, et al. Single and multiple metachronous osteosarcoma tumors after therapy. Cancer 2003; 98:2457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/111\">",
"      Bielack SS, Kempf-Bielack B, Branscheid D, et al. Second and subsequent recurrences of osteosarcoma: presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoma study group patients. J Clin Oncol 2009; 27:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/112\">",
"      Meyer WH, Schell MJ, Kumar AP, et al. Thoracotomy for pulmonary metastatic osteosarcoma. An analysis of prognostic indicators of survival. Cancer 1987; 59:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/113\">",
"      Ferrari S, Bacci G, Picci P, et al. Long-term follow-up and post-relapse survival in patients with non-metastatic osteosarcoma of the extremity treated with neoadjuvant chemotherapy. Ann Oncol 1997; 8:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/114\">",
"      Ettinger LJ, Douglass HO Jr, Mindell ER, et al. Adjuvant adriamycin and cisplatin in newly diagnosed, nonmetastatic osteosarcoma of the extremity. J Clin Oncol 1986; 4:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/115\">",
"      Briccoli A, Rocca M, Salone M, et al. Resection of recurrent pulmonary metastases in patients with osteosarcoma. Cancer 2005; 104:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/116\">",
"      Jameson MB, Evans BD, Gray DH, et al. Adjuvant chemotherapy for non-metastatic osteosarcoma of the extremities in two New Zealand cancer centres. Aust N Z J Med 1995; 25:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/117\">",
"      Rosenburg SA, Flye MW, Conkle D, et al. Treatment of osteogenic sarcoma. II. Aggressive resection of pulmonary metastases. Cancer Treat Rep 1979; 63:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/118\">",
"      al-Jilaihawi AN, Bullimore J, Mott M, Wisheart JD. Combined chemotherapy and surgery for pulmonary metastases from osteogenic sarcoma. Results of 10 years experience. Eur J Cardiothorac Surg 1988; 2:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/119\">",
"      Ellis PM, Tattersall MH, McCaughan B, Stalley P. Osteosarcoma and pulmonary metastases: 15-year experience from a single institution. Aust N Z J Surg 1997; 67:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/120\">",
"      Tabone MD, Kalifa C, Rodary C, et al. Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy. J Clin Oncol 1994; 12:2614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/121\">",
"      Tsuchiya H, Kanazawa Y, Abdel-Wanis ME, et al. Effect of timing of pulmonary metastases identification on prognosis of patients with osteosarcoma: the Japanese Musculoskeletal Oncology Group study. J Clin Oncol 2002; 20:3470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/122\">",
"      Solheim OP, Saeter G, Elomaa I, Alveg&aring;rd TA. The treatment of osteosarcoma: present trends. The Scandinavian Sarcoma Group experience. Ann Oncol 1992; 3 Suppl 2:S7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/123\">",
"      Babin SR, Simon P, Babin-Boilletot A, Bellocq JP. Can amputation be avoided in local recurrence after limb salvage for high grade osteosarcoma? A case report and a review of the literature. Int Orthop 1995; 19:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/124\">",
"      Morgan E, Baum E, Bleyer WA, et al. Treatment of patients with metastatic osteogenic sarcoma: a report from the Children's Cancer Study Group. Cancer Treat Rep 1984; 68:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/125\">",
"      Mahajan A, Woo SY, Kornguth DG, et al. Multimodality treatment of osteosarcoma: radiation in a high-risk cohort. Pediatr Blood Cancer 2008; 50:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/126\">",
"      San-Julian M, Diaz-de-Rada P, Noain E, Sierrasesumaga L. Bone metastases from osteosarcoma. Int Orthop 2003; 27:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/127\">",
"      Kung F, Hayes FA, Krischer J, et al. Clinical trial of etoposide (VP-16) in children with recurrent malignant solid tumors. A phase II study from the Pediatric Oncology Group. Invest New Drugs 1988; 6:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/128\">",
"      Miser JS, Kinsella TJ, Triche TJ, et al. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol 1987; 5:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/129\">",
"      Cairo MS, Shen V, Krailo MD, et al. Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children's cancer group report. J Pediatr Hematol Oncol 2001; 23:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/130\">",
"      Gentet JC, Brunat-Mentigny M, Demaille MC, et al. Ifosfamide and etoposide in childhood osteosarcoma. A phase II study of the French Society of Paediatric Oncology. Eur J Cancer 1997; 33:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/131\">",
"      Kung FH, Pratt CB, Vega RA, et al. Ifosfamide/etoposide combination in the treatment of recurrent malignant solid tumors of childhood. A Pediatric Oncology Group Phase II study. Cancer 1993; 71:1898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/132\">",
"      Berger M, Massimo B, Grignani G, et al. Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed high-risk osteosarcoma patients. Cancer 2009; 115:2980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/133\">",
"      Miser J, Kinsella T, Triche T, et al. Treatment of recurrent sarcomas in children and young adults: the use of multimodality approach including ifosfamide and etoposide (abstract). Proc Am Soc Clin Oncol 1988; 7:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/134\">",
"      Mantadakis E, Herrera L, Leavey PJ, et al. Fractionated cyclophosphamide and etoposide for children with advanced or refractory solid tumors: a phase II window study. J Clin Oncol 2000; 18:2576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/135\">",
"      Rodr&iacute;guez-Galindo C, Daw NC, Kaste SC, et al. Treatment of refractory osteosarcoma with fractionated cyclophosphamide and etoposide. J Pediatr Hematol Oncol 2002; 24:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/136\">",
"      Navid F, Willert JR, McCarville MB, et al. Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer 2008; 113:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/137\">",
"      Anderson PM, Wiseman GA, Dispenzieri A, et al. High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol 2002; 20:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/138\">",
"      Loeb DM, Garrett-Mayer E, Hobbs RF, et al. Dose-finding study of 153Sm-EDTMP in patients with poor-prognosis osteosarcoma. Cancer 2009; 115:2514.",
"     </a>",
"    </li>",
"    <li>",
"     Chawla SP, Sankhala KK, Chua V, et al. A phase II study of AP23573 (an mTOR inhibitor) in patients (pts) with advanced sarcomas (abstract). J Clin Oncol 2005; 24: 833s. Abstract available online at www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD (Accessed May 26, 2006).",
"    </li>",
"    <li>",
"     Website for children's cancer trials www.curesearch.org/our_research/clinical_trials/ (Accessed on June 07, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/141\">",
"      Meyers PA, Healey JH, Chou AJ, et al. Addition of pamidronate to chemotherapy for the treatment of osteosarcoma. Cancer 2011; 117:1736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/142\">",
"      Trieb K, Lechleitner T, Lang S, et al. Evaluation of HLA-DR expression and T-lymphocyte infiltration in osteosarcoma. Pathol Res Pract 1998; 194:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/143\">",
"      Goorin AM, Perez-Atayde A, Gebhardt M, et al. Weekly high-dose methotrexate and doxorubicin for osteosarcoma: the Dana-Farber Cancer Institute/the Children's Hospital--study III. J Clin Oncol 1987; 5:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/144\">",
"      Winkler K, Beron G, Kotz R, et al. Adjuvant chemotherapy in osteosarcoma - effects of cisplatinum, BCD, and fibroblast interferon in sequential combination with HD-MTX and adriamycin. Preliminary results of the COSS 80 study. J Cancer Res Clin Oncol 1983; 106 Suppl:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/145\">",
"      Rosenburg SA, Chabner BA, Young RC, et al. Treatment of osteogenic sarcoma. I. Effect of adjuvant high-dose methotrexate after amputation. Cancer Treat Rep 1979; 63:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/146\">",
"      Kleinerman ES, Jia SF, Griffin J, et al. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration. J Clin Oncol 1992; 10:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/147\">",
"      Kleinerman ES, Gano JB, Johnston DA, et al. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma. Am J Clin Oncol 1995; 18:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/148\">",
"      Chou AJ, Kleinerman ES, Krailo MD, et al. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group. Cancer 2009; 115:5339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/149\">",
"      Rao RD, Anderson PM, Arndt CA, et al. Aerosolized granulocyte macrophage colony-stimulating factor (GM-CSF) therapy in metastatic cancer. Am J Clin Oncol 2003; 26:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/150\">",
"      Anderson PM, Markovic SN, Sloan JA, et al. Aerosol granulocyte macrophage-colony stimulating factor: a low toxicity, lung-specific biological therapy in patients with lung metastases. Clin Cancer Res 1999; 5:2316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/8/39050/abstract/151\">",
"      Arndt CA, Koshkina NV, Inwards CY, et al. Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: effects on disease-free survival and immunomodulation. a report from the Children's Oncology Group. Clin Cancer Res 2010; 16:4024.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7723 Version 22.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-61.234.146.186-EA4EE1DDAC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_8_39050=[""].join("\n");
var outline_f38_8_39050=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1780929\">",
"      PROGNOSIS AND EVOLUTION OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRIMARY MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Adjuvant chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Neoadjuvant chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Neoadjuvant versus adjuvant chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8080619\">",
"      Histology and response to chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Tailored postoperative chemotherapy based upon initial response",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Choice of regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5448439\">",
"      Role of methotrexate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Benefit of adding a fourth drug",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H1781007\">",
"      - Benefit of mifamurtide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Chemotherapy for adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TREATMENT OF PATIENTS WITH METASTATIC DISEASE AT DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Choice of chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      POSTTREATMENT SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      TREATMENT OF RECURRENT DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Therapeutic approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Unresectable disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Choice of chemotherapy regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H186011297\">",
"      Samarium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      NEWER AND INVESTIGATIONAL APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H264018\">",
"      Bisphosphonates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Immunotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8081126\">",
"      Localized disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Metastatic disease at diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2220224\">",
"      Posttreatment surveillance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Recurrent disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/7723\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7723|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/41/16024\" title=\"picture 1\">",
"      Complete tumor necrosis of osteosarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7723|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/18/13613\" title=\"table 1\">",
"      Chemo nonmet osteosarc POG 8651",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/44/14029\" title=\"table 2\">",
"      Osteogenic sarcomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/58/14251\" title=\"table 3\">",
"      Histol grading post preop chemo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/40/11917\" title=\"table 4\">",
"      Mod osteosarcoma protocols",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/2/14381\" title=\"table 5\">",
"      MAP chemo osteosarcoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/11/17597\" title=\"table 6\">",
"      Imaging guidelines for newly diagnosed osteosarcoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/31/12794?source=related_link\">",
"      Bleomycin-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/51/37690?source=related_link\">",
"      Bone sarcomas: Preoperative evaluation, histologic classification, and principles of surgical management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/39/35450?source=related_link\">",
"      Chondrosarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/40/7815?source=related_link\">",
"      Chordoma and chondrosarcoma of the skull base",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/44/18120?source=related_link\">",
"      Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34602?source=related_link\">",
"      Head and neck sarcomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/22/20842?source=related_link\">",
"      Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/63/33778?source=related_link\">",
"      Patient information: Bone cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33924?source=related_link\">",
"      Radiation therapy for the management of painful bone metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/32/13834?source=related_link\">",
"      Surgical resection of pulmonary metastases: Benefits; indications; preoperative evaluation and techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/15/13560?source=related_link\">",
"      Surgical resection of pulmonary metastases: Outcomes by histology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/55/33658?source=related_link\">",
"      Therapeutic use and toxicity of high-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/50/14122?source=related_link\">",
"      Treatment of the Ewing sarcoma family of tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_8_39051="First SCD risk Brugada syndrome";
var content_f38_8_39051=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F68496&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F68496&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Probability of SCD or VF during follow-up (mean 24 months) in 547 patients with type 1 Brugada syndrome with no prior history of SCD: Risk increased with syncope, spontaneously abnormal ECG, and inducible sustained ventricular arrhythmia at EP testing",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Noninducible, percent (95% CI)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Inducible, percent (95% CI)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"        Prior syncope",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"3\" rowspan=\"1\">",
"        ECG",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Spontaneously abnormal",
"       </td>",
"       <td class=\"sublist_other\">",
"        4.1 (1.4-11.7)",
"       </td>",
"       <td class=\"sublist_other\">",
"        27.2 (17.3-40.0)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Abnormal after drug challenge",
"       </td>",
"       <td class=\"sublist_other\">",
"        1.2 (0.2-6.6)",
"       </td>",
"       <td class=\"sublist_other\">",
"        9.7 (2.3-33.1)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"        No prior syncope",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"3\" rowspan=\"1\">",
"        ECG",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Spontaneously abnormal",
"       </td>",
"       <td class=\"sublist_other\">",
"        1.8 (0.6-5.1)",
"       </td>",
"       <td class=\"sublist_other\">",
"        14.0 (8.1-23.0)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Abnormal after drug challenge",
"       </td>",
"       <td class=\"sublist_other\">",
"        0.5 (0.1-2.7)",
"       </td>",
"       <td class=\"sublist_other\">",
"        4.5 (1.0-17.1)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Brugada J, Brugada R, Brugada P. Circulation 2003; 108:3092.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_8_39051=[""].join("\n");
var outline_f38_8_39051=null;
var title_f38_8_39052="Leukocyte adhesion deficiency";
var content_f38_8_39052=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F66375&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F66375&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Leukocyte adhesion deficiency syndromes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       &nbsp;",
"      </td>",
"      <td class=\"subtitle1\">",
"       LAD I",
"      </td>",
"      <td class=\"subtitle1\">",
"       LAD II",
"      </td>",
"      <td class=\"subtitle1\">",
"       LADIII",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"       Clinical manifestation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Recurrent severe infections",
"      </td>",
"      <td>",
"       +++",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       +++",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\" colspan=\"4\" rowspan=\"1\">",
"       Neutrophilia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       basal",
"      </td>",
"      <td class=\"sublist_other\">",
"       +",
"      </td>",
"      <td class=\"sublist_other\">",
"       +++",
"      </td>",
"      <td class=\"sublist_other\">",
"       ++",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       with infecton",
"      </td>",
"      <td class=\"sublist_other\">",
"       +++",
"      </td>",
"      <td class=\"sublist_other\">",
"       +++",
"      </td>",
"      <td class=\"sublist_other\">",
"       +++",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Periodontitis",
"      </td>",
"      <td>",
"       ++",
"      </td>",
"      <td>",
"       ++",
"      </td>",
"      <td>",
"       ?",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Skin infection",
"      </td>",
"      <td>",
"       ++",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       ++",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Delayed separation of the umbilical cord",
"      </td>",
"      <td>",
"       +++",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       +",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Developmental abnormalities",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       +++",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Bleeding tendency",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       +++",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"       Laboratory findings",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       CD18 expression",
"      </td>",
"      <td>",
"       &darr; &darr; &darr; or absent",
"      </td>",
"      <td>",
"       NL",
"      </td>",
"      <td>",
"       NL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       SLeX expression",
"      </td>",
"      <td>",
"       NL",
"      </td>",
"      <td>",
"       absent",
"      </td>",
"      <td>",
"       NL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Neutrophil motility",
"      </td>",
"      <td>",
"       &darr; &darr; &darr;",
"      </td>",
"      <td>",
"       &darr; &darr;",
"      </td>",
"      <td>",
"       &darr; &darr;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Neutrophil rolling",
"      </td>",
"      <td>",
"       NL",
"      </td>",
"      <td>",
"       &darr; &darr; &darr;",
"      </td>",
"      <td>",
"       NL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Neutrophil adherence",
"      </td>",
"      <td>",
"       &darr; &darr; &darr;",
"      </td>",
"      <td>",
"       &darr;",
"      </td>",
"      <td>",
"       &darr; &darr; &darr;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Opsonophagocytic activity",
"      </td>",
"      <td>",
"       &darr;",
"      </td>",
"      <td>",
"       NL",
"      </td>",
"      <td>",
"       NL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       T and B cell function",
"      </td>",
"      <td>",
"       &darr;",
"      </td>",
"      <td>",
"       NL",
"      </td>",
"      <td>",
"       ?",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_8_39052=[""].join("\n");
var outline_f38_8_39052=null;
var title_f38_8_39053="Warfarin in AF";
var content_f38_8_39053=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F79839&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F79839&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 479px\">",
"   <div class=\"ttl\">",
"    Benefit of warfarin in chronic atrial fibrillation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 459px; height: 239px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Efficacy of anticoagulation with warfarin to prevent ischemic stroke and other thromboemboli in four major studies. An intention to treat approach was used and transient ischemic attack and hemorrhage were excluded. The numbers at the top represent the risk reduction with warfarin therapy which ranged from 45 to 82 percent.",
"    <div class=\"footnotes\">",
"     SPAF: Stroke Prevention in Atrial Fibrillation; AFASAK: Copenhagen AFASAK Study; BAATAF: Boston Area Anticoagulation Trial for Atrial Fibrillation; and CAFA: Canadian Atrial Fibrillation Anticoagulation Study.",
"     <br>",
"      * The data in the warfarin group in the SPAK assumes that half of the events were attributable to warfarin toxicity.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from Connolly SJ, Laupacis AN, Gent M, et al. J Am Coll Cardiol 1991; 18:349.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_8_39053=[""].join("\n");
var outline_f38_8_39053=null;
var title_f38_8_39054="Risk factors CV dis transplant";
var content_f38_8_39054=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F51988&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F51988&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 530px\">",
"   <div class=\"ttl\">",
"    Schematic depiction of risk factors for atherosclerosis in transplant recipients",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 510px; height: 279px; background-image: url(data:image/gif;base64,R0lGODlh/gEXAeYAAP///4CAgH9/f39/9j8/8r+/+gAAAMDAwEBAQO/v/RAQEPDw8AAA7i8v8d/f/GBgYCAgIKCgoODg4H+ymc/P+09P85+f+D+MZtDQ0F9f9DAwMK+v+R8f8L/YzHBwcFBQULCwsG9v9ZCQkI+P9w8P78/i2ABmMz8/P/I/P+/18t/r5fq/v0+Vch95TC+CWfZ/f5/Fsq/Pv2+ojPzf34+8pV+ff/3v7/EvL/ifnw9vP/vPz/ePj/NPT/mvr/RfX+8PD/Vvb+4AAPAfH29vbwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAD+ARcBAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvc3d7f4OHi4+Tl5ufo6err7O3u7/Dx8vP09fb3+Pn6+/z9/v8AAwocSLCgwYMIEypcyLChw2MHAkicSLGixYsYM2rcyBHjgYcgDwY4IaCkyZMoU6pcybKly5cpTwQISXNgAAHUBMysydPfzZw7ewrN93Oazn0ROypdyrSp06dQM34cOqiotKP6RsLcyrWr169gw66USbUqTqNB8VlNiLXsWkQq/2hMgJGCkYwSnFLgtdRW7VmFfYe+NRTDBYwOE1gwutCBUwkZlwLbG2xQck/KhHKoGKQXhqC4AEqwuEADAGMAHViwaAxgwgUWeGHEUF03hesJdTt0gAFDhecOMWqcBhDj9d5ElulhLjDIgQNMBGpRSHCJeaXkNTEL6uCiUIocdSfIUNGiRIrSjMmrUE9DcYkYpiG3B1BjQusarXPIOHyh9QUVJbRAHAspkFcXcmndgxkDgwwwACYMquIgIiFQcEl01yUolHao9VdIDZ61EBdkgzAmlyAT0ACDYXsNZwIAOQwS4wT2ddhajS+yUN8ELbCGyBAIRCXkkEQWiRECfxUSIf8ADibwoCADJFDABhkQYCEAGxBQgYUFFGCBBQAwkGUGgjhQJZgAWLBBBRU4ScAIghTApnUUVPAmBWg6AGeWBGwAAAEEDOBAAlU+acFzA4zZIAEZUKcmm27CySQAZmp5pSPY0cShCjEWEuBsNxLCGI0o2teBDC3Y5yIALwryIqk2wvoiabp1cCAiAhjggZG89uorR0giwoCDAwQKQAPMFdAAkwQkQAEJWLbpAAdOkhACmAyAWQGYHBSQwLZ/hpDACMgmwIFz506L7nQjJEACdQNUSK0DYGaQgbfIAhDCgwQwly0A4O6LZXQEiEuut+eGSamFFHAASaYhcWhajSl4Zlr/j6gJGJppHZTQnWklmEdcf6eBygJ8qYUaK46tKQZAgYrk6kFWSRLCQJcFZPCgBWRmAOaEf8qp8wDdAq0wkwNQgKGcQQNQAIb9jvDkACOMEAIhPgOQLgkjWDdhww5W2XSEE5JALIP9Og21v4LwTMCSjUAMksQp1ODCBaQJsuIgE9yt2Gl9u2BfYRe4gFfheONVAt4X4AVrB/3JKogMd7uwGXIPKDCVgjUPsiTQJDwL5ZP9vomzk08e7eDTcRKc7NpAE5s6AA2vWeYADUQ3obI4W5g22Q/ejHPTrI+tbwbPwc2I3A9JjAiIlgxXik4iaEBU54J8PjUHUz/oLpMVCJKA/wNGAw/Au0zCmXbx/VKw7J8UFOAw7YIQ0C2lzyXAYLwAuHul72xD2p8kBUC11Y9tfaKU8hbBPIc4zxDkuYT0SHEUDWhIHgtq0JMcwADqMIkDBGiAn/SVuwaQL3Xm20ADGtAo4q2NSSucWu7Cl6b3OaCEYLqhldwXQn4FcELfWmH41vdCBjWsYAuM2QV58sBjHAUDCpAA5yDBMw3GImvBaGBDmmgMrHgAAVN8RMJGB4tpDUOLDOFiMbCyAAhEYDLYKwgaF6IVsdjxjl45wQMGcQAFLKAeauTHHBWSlF8ZUkgPAOMgPrBH5ZAEj5CMpCQnyRKylOUaCzAAIRagOXoU8v+QTUFAkEBJSqhs7pLVgAAGCCECCKDSERJ5pSwlgYA3EiJIs1RELHPJy0XschAYMMAqe1mIXxLzmIMAgSIJEYBlItOYyDwmFA8BARFEEwDQvGYvDfDHQvSxm8fMpjZziYBTDuIBH4imOMcpywdckJPmzOU62YlKETTSEBGAQDc/Wcp+EimetpgnPctyAOshAgEzw+YjKcnQhqLEkroQ6ECHkslESEABqwwkNAapColOVCiqTEQArKfRZ3A0FR79KE9qqQgNiKCkzjgpKlKqUk0tURB9fEAcsyHTU9C0piBR5iI8YICdYqOnpvipMfjpz6YyBaAPuegiODkERVgHf9D/6d+lCOEcQnwpEtOZBFJLodRi1NGhaJUkRHnCTUVAsaqJ0B6EaHc1Q3zVipCokFhvOouyEgOmyhjrP8qZCCgWVRHac1KDpEQlKwkiS1tympewRSkwTalKXGJOpYzFrBZe1kqKStNzQgCoES6Pr7Lw6zAAmwzB+mNXiFiABgwAAaMOy0HGypeymOUsaK1pfNQagLUoy7pi9VaA+dKZvh6UJWY54FnaAlPa/GSu5yzPlbtQrTBYiwzX9sOeh5CtAiDAIeHlbGc9+xnphOagoqHQgEDrl4PcR0azOWh/TzLf+khLgqvGzAC2zIV2g8FdJ6KWIQU9xAM04Mby4jV00BJg/9BM1yXUeQ6+610dhiZkXuYATb9TakABl4cAfUb0wMkocBdRvBBNFmLBrcSmbfFKtO71D1oDoOH4yofhGyPNXdQR2JsEYaEPk1G+V0tAvk6LSwGz+Bja8W9XT+HfRFzLEN/aKoKoEtJBiMCPbpQxYvHKQQ8SLYQjDEEJT3jh4oJQhAK0QAPY5L0KCFHCIFaylpbMwAB808nV0A7c7sqJtB0CQ1aloSGUFrcnJ+QDAY4ARvMpCI1WkYyTMNorjtLkWwwYGIImRJfStKY29a9YUXJaYy1ErwI8SE4V0CwHlFunBE6KXsWSFCEIYF0LACp19zotVQKQ0GB+JMwA0Kkkxv8oYUlo2hVP9CMuPv2LUFuxYAAYQfiUOwAyGVd0BSBBBQSVrnMpuWs3HNTvnNat6hIiAYj2FsDQVIC6KpEqQoXiGyktiGCBAysPuGctqO0Lax/ZOgyK8Pkk3K/iSQ1K6mPOCAKFaoWxz7+ubk6xuDcIRG95KBflpDUBgGwAHPbfO5GAAaQYUEebdadwm5ChGbQk/B6weLHzIZPu1aXkGbBpg8g4pTjgJ6N5HFcuR4gBNNBIfgMgmEa9RlsC7umkrxbmhJA5c2xXAT8xDYjQKh594fcnr1OLyBZ/YXPI5LT3KZdSbL83VTSQTkGUHAQn/0ZbLspyWhC8F4IGFAEsIPP/3DlWaYAq8pu9jmjcNeBJKoyOnNGc9gMWogEezMAMp4YmuQvlAQbYidOxaYCFpvX0kFxrAOrud6tvN+qGMDQinh0KwiNCyY0WDHnrztJBIMCdTg3+U04Jz4G7nsCwL4TsD0H7UDSg84NQsmk9XxNJYyDBB8DuILp8jmYaP9DJj4Z39QECjApCk70XREXTUfy+Hh/U4d/o+/2h7+0HQPs4NWg6ROBMWPydFyq2RvPHDxcVYADwAQpggAAAXutQcv43gIAXfyYFgfkgWwKHTfgnCO7EDqP3Cv+3Cx5geqg3gnlEgfdggYYgSikIVeXggK7wgbnwZcI3gx3BggixYIaQ/30KYAhtxQ4gkIGtAIO3kDnD9EpMRYO9ckoLBk6+J2l993Q76A4IMHIeaIK2IFsawISuAAJFiA5nRYJpBVFOmIOuRFjJ1H/q8GdVCA0YwHRa6AqwpQ4BGAtYYX2HwFJxWGlWSA2dFoR7KAt99IeXoAFoWA5zCAtPZAAAlX2CEAGsBwDp1w5q6IfOIGkKCAsq52LpcIibFgD1d4cjl2Db14Xt8AGCCAlCCAtEaAsRYAAGAAJyKIG7IAAeQF6IMImauH7woHJP2FGnuAoLgAAa0IuyAHq6EouKUCu3Ygp6IQm5coG3lBYaMBWiGA9UR4nJIAF094ayAAGuqH/dZ1QmQP8jLQAfp/AYkgAkiTCJB2hLDBgPvIiNxwBFCXULweSKK7eJ4igIxQEAKiAcsOGPMOAaFiMDeGOOE1AcMlA3p0EDlwMDjnMBNVACvoEawTFBSJcIfYhNCZWH1giNPvWLp9CKl0gLIoCPAKaPitAqNIAfABIaAtIB5ZEC5UEcLyMirOIZqgEgAiID9vEdKSAD+PEekOMfPClsh8COAHAAimSG8sBJpBiSx+AB5qcLH4CSICkOHGICiHMgMCAcL1KUoXIqF5ADjdEqkhNBXwkjt1KUktNnB6UhKnd+3OgO3rcKqXgKC/ABGhCVtqAAKAmE47CVGVMXQrkZYekhNFIYh3P/lqXiKoLAAiuCF62yHZHDMnCZg9JmCFEkVfXQfiglkqIgWwhQl1W3DoQJADRAMvChAokpCIYjHi/jAo6pMq0ikx5yARZTAm6JmdTne0uEACAgVJOhSMQoCnlJClCUlYCGjIlQmTUwkS1wATIQljlQOD/pN7TJKo/JnYJQjoKwOAfZm5CZmYSglIOwK8mJSW6EAJpIVqL5CZa4XfEJZbJYCGI5CRG0CZKxkYTgiJB2DxLgnq7ol57gjfgYhYDXSfSJmvdJCPkpCdDDnwmCnnwEAdw3D62IklQoCsboio9oCyDwRwvwABkKavVpDJwIbQnin4Xgiic4W/gYoqCwoa7Y/6G1cAAG8AFYaJoAmKIvtwx9YaGEoAHgSA+yhY+C6QmZWKC40EauqADMWXBA+lciCIYNtVYuWgiMVIGA6YrH6QkyuqSx8KEpqaJVOgxHiIRGsjlESggeUI/3YFivWApEZQBTuoUo6Yo2+KNA1QhbWggqqA+GJaehgHdnWguctKcPEKZU+qeL8KaEAKP7EExHGgpgegsEagAKEAA++qiQqpEodlFRxA+taArCeAsnSVueqgzreUmSeobC2Q8R0KeaQGy2AEUuiAyvWhaBWkzqiUwYAIsDV5K8mqYhEauLFAGOaA9ryqbQShG22qChmoJPBgEHgAFk2g5fiKXe2hVr5f+qyPoQyjoILvaeGPSgVzGuSwlKomRI08oQv+pNBjWNgKSu4seu3fqtJUgV5SoIIlB3D4Cj8LCiBsYKBhsK48cP81oIcYiryoGv8oewEqsKC6sP/9pv1FiIdhl/OjADhwAEOvAJImsJMwCykXCxsFSxqaCy+GCKkZCPAKCL6foIP4ACg4ACKyAIOvsJPVsJOIADznhBEhABJhoKCQsKLmsPIQcJnikIVVmzjYADPiAEIDsDQuADLwAAKLADPMADKPsCKOADNgAAK7ACQQsAODC2IGsDPjC2ZasDPNC1XLuzcosCPSAILzADezsDbyu0ANADKIC3Zruzgku4SCkIIOD/ATJKqZ+QtJ+wtPWwgZBAnP1GrLsoZo3AAz0ABDsAADZwAzuwsygABDawAz4AAECwtYILAC/wA0AQtDxgAysgBADAA5/bAx8rBDpwunU7AzcwAzbQs0GAAnsrBCtgAzyAAzogBDYwA0L7Ai/QvM8LuH2GAc20p/jorsnnLM1hXZMQVpQgufPQtKgop73aDNn3EQ9kAz8AADpwAzy7s3Vrtjj7A9L7AkHgult7u/SLAjrgA5wLsjsABISgsztgvGK7tfsLvzhrtmD7A6Ort3srwfR7WovbuHvKvY1QPM0mCXo1vuyaDpQLCQE6CBHAsebAlMeouYuAAzeLAkEAsj/b/7MrgLNBcLZny7/z28NU+wMrIL0HHMQ+oMMg28A3LAhJzLc3gLNCzMQPbJ5Fa6IoibTJ58ETYgEU0DWdRR2fRQGhdSj6UloPM8LnYL6QgK2EoK3sIAHGuJkPxLmC4Llcm7f1m8R0C788DAAFDLq2S7+rW7uCMLI6W7tlq8cNDAA/ULYvsAMnC7r7K72PbAOJ/JuCgAEBq6Ce8EBYzC/cU2/MpTu8Bl3z1jTUxWyJGxIlDAnoanKf6g0LcKeuGGDO476DEL+B28R3jLPKewM3wAN77La+nLcv0MQowMhNDMw9iwNNfAN5m8g94MtkC7wocAPRu7fNbL2WnFRX3Hg6d/8+Z4NnB+c0/FVl28wQaPwI1TgI9moOCxAAX+qKzgS5Z6Sv3XxtCIczHpZfB6dCI5Z7NLHKj9CsL0aw4YCoKNmF9CwM5CtS3Xt2x8IchjZk9GNkAoRk/cNnqewQ6fwIHllpedoNAYCSCbLQWWTPjhB5j2d5/WNncybOF40ve2bOHwcSAv0ITslHKvwNNmpizMSyzdDQiGDSFBoSHf0IpVoINDsO1gd6mGsW5SDUh0DUmiDV63DTjvC0hRC14vBlw1SS+8qvYj0WKB25QF0IVp0OKvfKt8ixszoOq6gISYFOpDRKHfEA6omEcUqxSnvWhJDW6HCNkwCxhpC+v2CiBnr/CB/NCRKwrd4U0qOQqDPl12hN2YIA2OYQj5RwwoZgud+whI/ASYbKCaCnzjLLCu751El1pZF0Aqx9R+GqEII9Ce1sCGwMDqA90Aaw05aQibrN26Mw0lxdCs9KJO/6K/EKEJpNCa08qWwdDXuZhZEwW5eqCcb4CCOtiK2AqMNtVmYMELMtCeu8gt3Qo5Ggo47L2PgYr9ld3aaQSVHqqCj6Ucs9CQR9UKYYrf4UT7LFo5Lwoc+NiusNS/horKWAoEsX4M05UOEtCYsdEe6pAK891lmaICgoCfDNp52wqBreCNlNWwpO2igp3Wh6DsWt3x4BAPU9CWYI4UvnASNK1a3Q/xcXLgkfXqeccOOqLVIkzQqrWuBQ9t3TNuEUXkkz0eCSIKXuqQEwzoQaYNm30BbaCtmIgOChxwkc7oosduNJnQr3uNvyDaqGCOWioBMrrs7ZqysjeghQBxSXLKWVgAGb2sKagAEfgOBbjo9MntiR/QExdqzhCAw6geRynb0Q8ADMutOgR+a1EG0GLQnVBAIGbgmK6GeOEAEw3t2owHKR+FdC7mmMrrSgF+Y4ZeiI3neEbQiZpGyGcFVTtgriyxeemICa0NyawIiT4OexkLHT9ukBFeqRi6dulcmHHgHHqeuIELCUIVeXkESNEMJ8gYCT7rSa3AkBSwn3/QoNm12+Pv9wwO4JuUKMmIyAxR7mtW0IEAACy65BigUljIVZj2UpkvUlBTAsYAJZrEZ4FF0skSXGsGYdj1IB4Isckn0JTBkKi53V1d4KvN5yga4IFZMil0MJPiIIHhIJQ3BP4z5ep/4Itg4AP+jCNkMsuZUsy/JtviUtwTVcHFQAYKzyUtJu56JttOMn/aIu6hIu4xJ3yDHalvCOnpDTkXCirbDtC04OEiM4HUADMXnxkOD03pmyA0vuHX/eZDqFIu85OKNcVZQ18cVeRONq7wUwQ9MtFydnWnxAD5c+LrTRl7CePTgJAwuIm7la3e53RpWf4ZEqjVEcAekbiIEaqsEaNQIDEon/lsYRN+VuCdlOCE277pgGYZhWOl1TYTw2QKdzceTMcfJlY0Tk9pbw1p5w29hOo60As57+8IjwHTJgK3pDmyowGwXSAinQATnAAhOgHurBnbLvmqrpHuZonpaQ8ADgAY0E+RJWY2T0PTkmPmyWPfCiYw5wcWHVXO3zPo71+cKPCUK/CY0fCVr9Ckct5kgfdSrgGjmAH2KpI+SoGx5yIq1RGjliji+yIhDpCBmfCaK/SVUJCAECAISFAAyFAwOEDgwJhAMcBA0bhCENkw6KiQ0hAJeZBQSEBAUbmA0UAKUAAw0Ni6sFAKKGtoUCAbe7vLsGC73BwoQeusPBEBjHy8y9/w8PzdHS0QHG09fY2dOCzC0dHReEFzTfHSnghBMT6esmABcdhO4AHTIt68MCBgfaAAoSuyIgKMRtmYUMiWL1WygsF0MACww8vIWAX7YHIiZqk2AAoMaPu6qBHEky5KBeJeIBSNFCRQcX6VgQSuEyHIASMN+VAOBOxroU7kqkABDDZkMFGjZK3KUhAsGTxzg4SFhyokOGBwaO7Kgtwoeq0Z6BBSlyrNmHBXmpYNHigosY4i7AACDDhduahSa4cIHPXYoLFya4i2HXxc58ASBkxJZ11wEFhtKenUzo6kKvIzFA3riZci+OHj1nKyu69DLJppnlegzsWgAPux5YA4A6Nf9Jy/1IawShVVsy27bEAmcGwYBxA52HD6+tnJfDD7CvfVhsKGJo2lCbf8StbfpI3dgwal/wT7uwB8cNfDVvmzl7XLokKFA2TYPFyOufvtfIPVvFkQiAcFl+ygVA4H6FRJAedQhS5t5+VwXQWzRL2QLBfYQ82GA0/WFTHkgfcmYeeRg2yNFx9G04mYbsXbUABE5FcwAEt4BAoy0BnCDAjjz26OOPQAYp5JBEFvnjCbNpU6FG8j30m3YSqliIBsbdKOVZORqp5ZZcHmmNja0xg5ktCDBIyAHVpKnmmmy26eabcMYp55slMpYUSLw9JN54CtS5nwfGQXPlWWjOaeihiLb/iSECSQ4DnnxhDspenmRFNyB7UUoJgnExSuqpaKA1E2Bwgn5q3msAdtoPR+yReKVx15kqK1geTDhMiBDhOitwxYz0JEMXsifQlQjcueuxJJEn4DER2TIsssP991GzE8n2HgTLbogqtNxqFIGVwjRmCIzd2vbrROI+9Kx530qJQbblxutfoyFZCsCM8pq25ETbPsRqVYUmaoBsiRZs8MEIJ8ymn/lqpFmssTFobcOUYQDuRB+oCizDaOnY5ccghyzyyCTviCTFVT1wIFP3hYoyobY6maKe9PKb3csQ1oxzP64Gs2QApe5clQhBP0SttzFrxKLQqXXItDYiGLuLxeNy//w0Q+BhJbW/+3609NWeOQ32NRqYaciYALQ7NoDwolX0Q/aV9PXaZolNdzOs8UIaAhrfvVDcH+35Ua8kuZfALLeMQpIFFggTgioTPS4M4iDZ7fcyH7xNyKgAQHr5RF0zBPhHlH53cyEjMEB5IYiQtEkwrEwUuy2tr3Kbzp8fI5+f8xEiXO6rhr6Q8AsdTdbphHAwAEKEWEBABohsgLgpDmRAQAWqOGDBAASMQAgFFXQPQALWx1I9AQQoREgBFVQwwFSlSL9+JRtcXwn7FSDOPfYUNA6AA95jRQjQdz8GDKBxsXBeBqaiPe557xqWA14wMlWdpZAHYhKURrrQtTWNjP/Oa8ijQAMSQAJCbKACCWgEACxQAUJUwAIOUAUFOEALDhQgAVJxAAcokADvNWAWIVjEDwGQAfU5oAEOSMAQ46c4AmzgFCmEYQ6lMoIWUmADJHzEADzBikrg0AGNKIAqEMHCw9GwADb8IgRxl0FkaExcIkhaG5uBtokQrSSEO94uQuC9ClTCj4RoHQnASMMVWg8RtZDFCDzxPeUtjwAihIT6FkmKWbBiigAAJCFGEIsBjMACDbAA5DLQOKnIghYDJMEsaoeI/JGCAomcHYfYOEfHKCBSQCMEtmqJjawtRHB4kuNCmMMBTHAAIbFrnSI4+YkFHoIWTSzA62jxwwKIMZH/02xFLFjBihFkgI+nlKQ4CxAC5QFghies5ClUwQpWhrMUsVxdMyLISzLZSzz4quc0MgaSD06LeLk5XSTHV8Igjq91OjSlE/+HyGii8XskhBwPSfAIgxaifoRY4ixwyAEtMo8CA4UkDwGA0VXYsJJbHN8QHRFIAFASh9Cs5Br1yQyXASBuH6AlTSliNWz8oir+RMvpwOlCLKJvALWrwEclEYKGytQV1zsnKhYByvap7xMNyMBJY/dNQpAPE4twBSxIigrIgbIQpVDi9YboCk8g4quUiGk4pUHPndKmN7/gSKTsOgyuaCSfeNTpNpCnnUcAwJSGQKw0SKmcuu70RQKi/1ou+coMgGKjjiMpndII2xxJhNIWB7mGDpvj2J2CaVh9ouwyDtDBheQxWZbtJWdVi43S7pRR1YhAa2lbI2H6p6eiA+5geWsVwfIVAwbAFt+IKwxf9uOntDJuM+ZmFsb1gwKMlJJtdwqoCNySucEAJkOoNhbNClU72bxGIoUhy9Jsl6Yc0YC9wMvTj6yrKsY7L1jAt9BW1I9550ufLQZQP0aKcgQ35N4AHpGA/Y3CmpDwqvUed8xF1K+/k3mvPg8AK/r24lwMeS1Q2zbM2TLkiElsZ+NeCIAhFpF2fwyg8grw4uV9gqqjeF3rPiu9BiB4hlEMm3TtGgDjDJmvsZ0G5//G4oH5lhgsI0ifgp+pzYGmt3W1iF0JCVFCisZUx1I1BCscQAIEi0bD9USPB3TlYQCQVyNsJgkIdjsaEy9kedYswFSUOQBsXhXLo0gm66hcCzCvN5yawISQ22wLDdDod4y+l2+v0aSzRGSvAQULGg07Rklm8ca0s0QAEQdI9rV4FhilpApJOJUULhSMB110pAlhgIz0LNL9eoh5waIBEmuDutkA5SQqwecVNsCqtJtEBh4ROwqgD5JSVeoocEiAppoQEwRwwCmyjQr/ZfjI+kRua6I2awCIeJjgzkaT6QgnAQFbNLVrGJprWatxmQ28S35IvstL59ikJz0KWMy7PRP/73zNe44KmE3eGB3UfsS5JJcW078DFaaBl/vg0wiYwjbOcTahp23QiXSSo/EvyvR6GAsAwQOKkx4EzAw75aZrukfjsZLZ/OY8OoEBXi6flxO30hPZNZOdXAg0UYlRrK1S32Ae83nOXLbyDh0FwbtBrBEdLHO2hQRE8AEFQMADIAgToAKA6QzZuemGwLg0LK7dpL1o6arl+kf4KZpfpHzlCsgYBiWAQYLUHOeAD7zgb34yB53dVALQHABA8F3wOjcbIDbLjIrDKJ/LqOOYz7zmN78m4W5W3jpjFH3pbrSRj5frXtfAB8qO9oZpqBzlwAYM5iKUuunMpryV1kOqDpIF/0QA73q/V79bHy8NqQMw6sBG8mVwGLDYbeq0hS5arr6QA3jg6AHwufSJj7KlJZ8ugIHLTVgwDgDAoATkSMEEAjOU5MNABQCYQFFkkIIawIMeKsHH+lnQ/GXYTVnElV8LQXqn9wEGIF++Vgj7xn354n34ABcsoQIq0AJCQQPvcA8dUAPrMAE1EH/rcH8mMBcswAIqUAIt4IHyAAA0IBMlIH6qwUZqQ1u81w/BwjO/BwEK8AAR0Hc4Qn0MyC0OSAj1cAE50AE0IAOGcH8AkAOFwITJB4LskILf5w4w4ALnJ3PDIHq0JXTZIIAycn0GUCaWFwys9YPdZ2fJRxg7AQ/fJ/8OKjEPPIGCUIiCcTiFQmgP+PCCw/AwtPV411CG0oABXHeAYJcN22eG5RKEE4CEKeAC33CCN/EOKsECcNEBMvGE8TAPdniEAKACQTEURcEhBuABrFcIKkNb4tUPd7QMEvB7CpCDO7gQC4iI0BKEjXgBLOCI8WcXMqGEJQAYF7ATmBiHdOgXbSEDg1EY/XcMidd1uHNrdqV7DJGKNQKGYqg0PkiLssJ2KuIQWUEuvCACF0NTD4cNDedmcUSInpdxw6eNn8KNG2IZ3yKNhlA2lGV6laV1rggBOliKoOOP7ugp8Ngg3BEAeQcxC0dTgKU1hAACYDgdY0gSsxiQpjKQCNL/HwsAKKRIKnY1g6MBAQigjqaRaxQ5KxaZM7wgAc5oCLtzJpz3kjAJJ8XSedPQil0XhhEAkGOxkCW5jYf3KXbzjZ2SKVkyeEZ5lFpSeMzikMUBkfSYGn7Vk9v4d0hZlUCilL0wjxZBLicpNBGEARJygAGAIYeYGssllbKicTG5lnRyGgfJGl25M05jk173AGF3C2+2HIqHlny5DBk5ighQDD95ObiRch6Ag9PBg2mzMqnBk335mDVlgOoxmH7jEGAZkhowlstwbrYRlZD5masVkkPQC3k2FV4FOaDlbZ4xCtj1P6a5HTjIj3cpKutoFmcJmriJchDAWQY0AOHzCK15/wvpZQuHphFOZV3t1Q8C8AGKKQxl2R57mZvSmSGjyQu14zz/0zjs8zweZT2QUz/Y0woz1grceU7hc1UWcEIo5EDfEz6V8Ey1YE06VETa0zxTwV9XhRjYoBns4ZjT+Z9MtwvxtkO1QAFT4U2tgEIUUEInlEIdBUp6ZlAYRQI89EBoFQI99ENfhGIJ0E5ftmA+Zk3RBAAU2kOzdFmTVhqeCaD/+SDxBk/TVkWK9jqloFSKYEOJRAKKgFSHFQI3ZAusEE9RpggC5lSbEKQjygE+alh66BpPRxIEyKLT6aKJdTij4GNWqk2V1D15lqWHkGcbVUVehlazEE94Jp/wmWOLgP+kMtVDFTCm/jdzE2kbqyilLcqbhdBVtcBS2LkJJJSgXuUABdAApPBAqoA4Q0SmcgVPHfU9aaqlCxVJSlSmGSVPDTFz5ZgaeWmnuemi6DNWMWUBkmA94jlsloAK8EMAFpAAFfAKLdSqnQCkZTqiwhZXRmphitaqrToLsJpdcUppyWEemcqpaBmXOKNhXDgcUUqskGmsL6Nhfkin0cmsPemsKKNhcwocm0qtfWmtFKNhvYMgw8qt7uitoFeT+Cgay0qu1UqZd/NeHtkcdcquxUqVVnmvR4mVzECS7LGt9EqRasmWAruWtVkI6yqszfmvCps7kcceB7uwEHs5Xsge8xr/sRZ7OfGqHf56sRx7NZOlIuPasSKbL94hJSU7sii7M+dIsYyZsi5bLumqqcH6sjQLLYB4JeFaszpbdAOreR8AAQdTsLYQsIYCATnVs9UgtDvbdEWJr04bJPpKDfb6tFwStUtbru46K/NmrtvxpFfrYVzbIk8XtsX1te3KNFubtWfmtWbLXGSrHWl7JWrXtrz1IF26DJY6PqhpG3HbCwmwPSPwmssQnIwguFhIt1jbC73JAe/JXrtAuMJQcF1bZ8EACwUwAoXEDIdmXbXFtoirWlRKUooDnt9pP61ACxvgndkJCeVpCtZTpgakms4jYP9TPvpTnpdKubywXo/QQKoK/z4V0GoK9gi10GCwNAvp2T7CW22qeQtz+7l8FboI2qA6lABQVJ+IwD0JsKAxJaE5lm0zxFBiZAg/ymIutgjeq59QxwsktKTrk0bK00MIUWMIUQtZBakYiqAGhZ298LzQu1OeigmPYKORwD6N+0w0KqIkuqPZGwutI7maQADKY2WLoKOKILnOO7azFcEkUL8jWgtbRqLQlAHMc6SzSqLEqzjO4bn/C8B4ummrgGDW1KGr08CVtKdgqqVUVnA6VAmK4Gdfmmfq6xqHh6MfPAruVAAMwAH+Y8IxBWjB4L8tXE/Sm2MtND6a8FEIvAh/mmWGqsMPzKTURAhF9GkGJT7nNP/Ew8ULsORVUhFPMVVqLSQKOIRAa3rCQ1RSKzzFPxi6RIQQoIBEX1WkpRpXxQurLQRmrRCreYoJ7mNs5zk+iKzGa8dZDlABnnU/R3xOz3aorEkC23PHMSVC7aPCuyDFfDxHzjqcD2FYjHWi62sahhVa/cvCqVxLq5yfD5EBr+CrTUrEtiGq6CPGGXzLxPe2pKXBcmvLxpxByNxYyqxdzNzMwPPMw9G33TjN1Pw51gwcWzu1VJuU2rzNftO04RzOVssMRIu0iaK05FxP68zOSOvO71zP9nzP+JzP+rzP/NzP/vzPAB3QAj3QBF3QBn3QCJ3QCr3QDN3QDv3QEB3REj0Y0RRd0RZ90Rid0Rq90Rzd0R790SA9R4EAADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The risk factors for cardiovascular disease found in the transplant recipient include hyperlipidemia, hypertension, diabetes mellitus, hyperhomocystenemia, uremia, and others (shown in blue). Many of these factors are exacerbated by the immunosuppressive drugs (shown in green) in current clinical use to prevent rejection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_8_39054=[""].join("\n");
var outline_f38_8_39054=null;
var title_f38_8_39055="V-Y advancement for anal fissures";
var content_f38_8_39055=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F63328&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F63328&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    V-Y advancement for anal fissures",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 255px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This series of pictures show the incision for creating a V-Y advancement flap for coverage of a chronic anal fissure.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Chambers W, Sajal R, Dixon A. V-Y advancement flap as first-line treatment for all chronic anal fissures. Int J Colorectal Dis 2010; 25:645.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_8_39055=[""].join("\n");
var outline_f38_8_39055=null;
